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Hypoglycaemia in diabetes-related states is caused by relative insulin excess and can 
cause tremor, hunger, sweating, behavioural changes, confusion, fitting and coma. 
The  initial treatment of hypoglycaemia is dietary with recommendations for this 
based on expert opinion or older laboratory-based studies using intravenous insulin 
or older pre-analog insulins. Hypoglycaemia in diabetes-related states is well 
researched but  has tended to focus on mechanisms and prevention, hypoglycaemia-
associated autonomic failure and long-term consequences of hypoglycaemia. There 
are few studies in the area of  diet and treatment of hypoglycaemia. 
The series of published papers presented in this thesis therefore investigates dietary 
practices in the treatment of hypoglycaemia in adults with diabetes and diabetes-
related states along a continuum, from those with increased diabetes risk; to diabetes 
in free-living individuals and then to those dependent on others for their care, 
inpatients with diabetes on nasogastric feeding.  
The first two papers aimed to identify, in free-living individuals in two different 
states of glucose dysmetabolism, effective dietary treatments of hypoglycaemia or 
relative hypoglycaemia. The first paper presents a case study of a woman with 
normal glucose tolerance and elevated 1-h postload glucose. It examines the 
relationship between loss of first phase insulin, 1-h postprandial hyperglycaemia with 
subsequent rapid drop in blood glucose resulting in relative hypoglycaemia, 
carbohydrate intake, GI and weight gain, and assesses the effect of a low 
carbohydrate diet and early intervention with short-acting preprandial insulin on 
glycaemia over 2 h, comparing this to treatment with sitagliptin, or no treatment. 
Results showed a significant difference between the 1-h postload rise for low 
carbohydrate and insulin-treated meals compared with no treatment or sitagliptin. On 
a regime of either low carbohydrate meals or preprandial insulin, glycaemic 
variability, symptoms of relative hypoglycaemia and consequent postprandial hunger 
and weight decreased. It has been suggested that recognition and management of 
those with normal glucose tolerance and 1-h glucose ≥ 8.6mmol/L may reduce 
incidence of diabetes and vascular events. This represents the first published case of 
successful management. The second paper investigated dietary treatment of 
hypoglycaemia in insulin-treated diabetes, aiming to determine if there was a 
significant difference in the need for repeat treatment of hypoglycaemia following 
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initial treatment with 15 or 20 g of fast-acting carbohydrate with wait-time to repeat 
treatment either 5 or 10 min. Results showed that 20 g of fast-acting carbohydrate 
resolved hypoglycaemia within 10 min in 89.3% of free-living individuals on current 
insulin regimes compared with 63.2% for 15 g. Decreasing the wait-time to 
retreatment to 5 min increased repeat treatments. Hyperglycaemia at 30 min post 
hypoglycaemia was not significant. An initial treatment of 20 g carbohydrate with a 
10 min wait-time to repeat treatment was thus judged optimal. 
The next two papers aimed to assess self-reported current practices in dietary 
treatment of hypoglycaemia in adults with insulin-treated diabetes. Paper 3 
investigates self-reported patterns of food selection for self-treatment of 
hypoglycaemia and compares this with recommendations, duration of action of 
carbohydrate, and self-reported efficacy of treatment. Results showed that 78% of 
responders reported initial treatment with recommended foods, but only 40.8% of 
these were quick-acting carbohydrate, with 46.4% using quantities exceeding 
Australian recommendations but within European recommendations. Although non-
adherence is not a reason to review recommendations, in view of the results of paper 
2, the relatively low evidence level on which recommendations are based and the 
variation in world recommendations, this study supports increasing Australian 
recommendations. Only 55.8% of responders reported ingesting follow-up food, 
possibly increasing risk of repeat hypoglycaemic episodes. Therefore in the fourth 
paper repeat hypoglycaemia within 2 h of a primary hypoglycaemic event was 
investigated to identify any association between omission of followup longer-acting 
carbohydrate after an initial hypoglycaemic event and increased frequency of repeat 
hypoglycaemia. Hierarchical logistic regression showed omission of follow-up food 
was not a significant predictor of increased likelihood of repeat hypoglycaemia 
irrespective of method of insulin administration. This study supports judicious, rather 
than routine use of follow-up longer-acting carbohydrate post primary 
hypoglycaemic event. 
The fifth paper aimed to assess knowledge of alcohol-induced hypoglycaemia by 
people with type 1 diabetes and compare this to easily available internet-based 
information. Results showed that 6 national Diabetes Associations provided general 
information on alcohol and hypoglycaemia, eating with, and snacking after alcohol 
and sustained hypoglycaemic effect, but the specified possible duration of 
hypoglycaemia varied from unspecified to 16 - 24 h, and only 2 guidelines provided 
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information on reduction of long-acting insulin. Most  people with type 1 diabetes 
(88.2%) identified the hypoglycaemic effect of alcohol, but only 32.4% postulated 
duration of 4+ h post-consumption for this. The main deficits identified were lack of 
knowledge of duration of alcohol-induced hypoglycaemia and the lack of provided 
information on reduction of long-acting insulin, an important strategy to minimize 
hypoglycaemic risk associated with significant alcohol consumption. 
The next two papers aimed to assess treatment and frequency of hypoglycaemia in 
inpatients in the general ward on total nasogastric feeding. Paper 6 describes a 
retrospective review to determine factors associated with hypoglycaemia. Results 
show frequency of hypoglycaemia as 10.9% patient-days with ≥1 hypoglycaemic 
episode with no association with feed type. There was an association between 
sulphonylurea treatment and extended hypoglycaemia. Kaplan-Meier survival curves 
showed a significantly longer time to a subsequent hypoglycaemic episode in 
patients whose treatment was reduced in response to hypoglycaemia compared to 
those whose treatment remained unchanged. Frequency of hypoglycaemia could not 
be compared with other studies due to variation in reporting methods. Consequent to 
this Paper 7 was a systematic review of the literature that aimed to answer the 
questions: What are the existing summary statistics of frequency of hypoglycaemia 
in insulin-treated adults on established nasogastric feeding in the general ward? To 
what extent does lack of homogeneity in defining, identifying and reporting 
hypoglycaemia affect these statistics? Only 9 studies were judged suitable according 
to inclusion/exclusion criteria and all had the assessment of efficacy of insulin/feed 
regimens as their primary objective. Studies exhibited major heterogeneity; with 
definitions of hypoglycaemia varying and five different methods of reporting 
frequency of hypoglycaemia utilized,  precluding pooled analysis. A descriptive 
synthesis of results was generated. The major conclusions were that reporting 
methods incorporating patients numbers and duration of feeding and multilevel 
documentation of hypoglycaemia are crucial to allow interstudy comparisons. 
The overall aim of this thesis, presented as seven papers has been to increase 
knowledge in the under-researched area of dietary practices in the treatment of 
hypoglycaemia. The study findings have allowed recommendations to be made on 
amendments to the Australian guidelines for treatment of hypoglycaemia in the area 
of optimal quantity of treating carbohydrate, wait-time to retreatment and appropriate 
food selection. They have delineated dietary practices in treatment of hypoglycaemia 
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and their relationship to blood glucose levels, duration of action of carbohydrate and 
repeat episodes of hypoglycaemia, and also highlighted deficits in knowledge and 
available information regarding alcohol-induced sustained hypoglycaemia. In the 
area of hypoglycaemia and nasogastric feeding, they have highlighted factors 
affecting duration and frequency of hypoglycaemia and identified the need for 
specific changes in reporting methods and documentation of hypoglycaemia. 
Findings from all studies will hopefully benefit those who experience  
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CHAPTER 1     INTRODUCTION AND THESIS OVERVIEW 
 The work of science is to substitute facts for appearances, and demonstrations for 
impressions. 
John Ruskin (1819 - 1900) 
                                                 
1.1 Introduction 
This thesis presents a series of published papers investigating dietary practices in the 
treatment of hypoglycaemia in adults with diabetes and diabetes-related states. It 
examines this issue along a continuum, from those who, though classified normal 
under present classification systems, exhibit measurable impaired glucose handling 
and quantified increased diabetes risk; moving past formal prediabetes to diabetes in 
free-living individuals and then to those highly dependent on others for their care, 
inpatients with diabetes on nasogastric feeding.  
The overall aim of this thesis, presented in seven papers, is to quantitatively 
investigate dietary practices associated with the treatment of hypoglycaemia, as far 
as practicable, from the perspective of those experiencing it. Therefore, with the 
exception of paper 7, a systematic review, all projects are practically based and all 
projects (including the systematic review) were designed to obtain measurable results 
that would benefit and to be seen to be of benefit to and by, those experiencing 
hypoglycaemia.  
This chapter gives the overall background and significance of the studies, although 
these are covered in more detail in the studies themselves and, where considered 
necessary, in prefaces to studies. Limitations of the studies are, in the main, dealt 
with in the individual studies and also in the concluding chapter. Publication of the 
research in peer reviewed journals has enhanced the process by providing the 
opportunity to review, discuss and apply research findings and has allowed these  
findings to contribute more directly and immediately to the previously existing 
knowledge in the area of research.  
1.2  General background and significance 
Hypoglycaemia is a state which can impose great discomfit on those experiencing it. 
Its symptomology can include tremor, hunger, sweating, behavioural changes, 
confusion, fitting and coma (Donnelly et al., 2005; Stefanova, Cox, & Hill, 2013). In 
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diabetes and diabetes-related states it is caused by relative insulin excess and in 
diabetes it is an iatrogenic phenomena (Cryer, Stephen N. Davis, & Shamoon, 2003). 
The  initial, and hopefully only, necessary treatment is dietary. The current basis for 
recommendations for dietary treatment are based on expert opinion (American 
Diabetes Association, 2014b)  or  studies carried out before 1995 under laboratory 
conditions and using hospital-based medication regimes (intravenous insulin) or now 
defunct insulins and delivery systems (Brodows, Williams, & Amatruda, 1984; 
Slama et al., 1990; Wiethop & Cryer, 1993). Insulins and delivery systems have 
changed significantly since 1995, the most notable change being the introduction of 
analog insulin in 1998, affecting both patterns of insulin action and hypoglycaemic 
risk (Hirsch, 2005). There is, however, a dearth of studies investigating dietary 
treatment of hypoglycaemia on present regimes. 
Similarly self-treatment for hypoglycaemia in the free-living person is carried out in 
widely diverse situations; while driving, at work, in bed in the middle of the night, 
while surfing, in the supermarket while wheeling a baby and holding a toddler by the 
hand, in short, wherever hypoglycaemia occurs. Conditions may well not be ideal for 
a well-reasoned treatment of hypoglycaemia, and indeed, stressful situations have  
been nominated as causative for severe hypoglycaemia in 6 - 25% of events (Kedia, 
2011). In addition, hypoglycaemia itself does not necessarily foster clear thinking 
(Choudhary & Amiel, 2011). Under real-life conditions, what do people with 
diabetes use to self-treat their hypoglycaemia? With information on this, we, as 
health promoters can, to some extent, ‘walk in their shoes’ and collaborate on food 
treatments that are, hopefully, realistic within the constraints of daily life, and also 
effective. There is however a dearth of information in this area, especially in the 
Australian situation.  
Cryer et al, in the American Diabetes Association’s technical review of 
hypoglycaemia, assert, unscientifically but evocatively, that those with type 1 
diabetes will suffer thousands of episodes of hypoglycaemia and an episode of severe 
hypoglycaemia approximately annually (Cryer, Davis, & Shamoon, 2003). Many of 
these people have, understandably, a significant fear of hypoglycaemia (Wild et al., 
2007) and there is evidence that hypoglycaemia is feared by those who experience it, 
more than the long-term complications of diabetes (which include blindness and 
kidney failure) (American Diabetes Association, 2005). General ratings of health-
related quality of life are significantly reduced by those experiencing hypoglycaemic 
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symptoms, and the reduction is proportional to the severity of those symptoms 
(Alvarez-Guisasola, Yin, Nocea, Qiu, & Mavros, 2010). From the researcher’s 
personal perspective, having interviewed many thousands of people who have 
experienced and are still experiencing hypoglycaemia, what has come across is how 
difficult hypoglycaemia and its treatment are perceived to be, by many who 
experience it. What the researcher has heard countless times is also reflected in the 
literature in studies that include interviews with people experiencing hypoglycaemia: 
 I am terrified of hypoglycaemia, I run my blood sugars high to avoid it, even 
though I know it may do me harm later on (Barnett et al., 2010). 
 When I get hypo, I panic, grab food and just keep eating until I feel better 
(Lawton et al., 2013). 
 When I’ve had a hypo my blood sugars go sky high, I don’t know how much 
is ok to eat (Lawton et al., 2013). 
 When I get hypo my wife has to remind me not to eat too many glucose 
tablets, otherwise I find I eat them like candy  (Mike, 2012). (1 glucose tablet 
= 5 g glucose) 
 I use my hypos as an excuse to eat chocolate (Sumner, Baber, & Williams, 
2000). 
 I’m on insulin. Sometimes I start feeling funny, all shaky and sweaty. I don’t 
know what to do so I have a sleep (Elliott, Abdulhadi, Al-Maniri, Al-Shafaee, 
& Wahlstrom, 2013). 
When, as with inpatients on total nasogastric feeding, the person experiencing 
hypoglycaemia is dependent on others to not only treat their hypoglycaemia but also 
to identify it, the problems of treatment are compounded. Investigating and 
quantifying methods of identification, reporting methods and frequency of 
hypoglycaemic events is an essential first step in its remedy, and again, there is a 
dearth of information in this area.  
So what do people with diabetes who suffer hypoglycaemia want?  
1. They want to be freed from walking a line between, on one hand, 
hypoglycaemia and acute complications, and on the other, ongoing 
hyperglycaemia with its consequent increased risk of long-term 
complications of diabetes  (Rubin & Peyrot, 2001; Shiu & Wong, 2002). 
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2. As this is not possible (with current treatment methods for diabetes) they 
want to self-treat their hypoglycaemia with something that is easily 
available and resolves their hypoglycaemia as quickly as possible without 
contributing to subsequent increased blood glucose levels (Nair, Levine, 
Lohfeld, & Gerstein, 2007; Shiu & Wong, 2002).  
As far as possible, within the current scientific framework, the wishes expressed in 
point 2 have been crystallized into the overall research objectives delineated in the 
next section. 
 
1.3  Research problems and objectives 
The main aim of these seven studies was to investigate dietary practices in the 
treatment of hypoglycaemia with a view to ascertaining and quantifying current 
practices and, where warranted, making recommendations for more effective 
treatment. The general research objectives below summarise and unify the overall 
aims of the investigation. Specific practical research objectives are delineated in 
individual papers. 
Overall objectives aimed: 
1. To practically establish and verify, in free-living individuals, in various states of 
glucose dysmetabolism and on current medication regimes, effective dietary 
treatments of hypoglycaemia or relative hypoglycaemia.  
2. To assess self-reported current practices in dietary treatment of hypoglycaemia 
and their perceived effectiveness by those with insulin-treated diabetes with respect 
to resolution of initial hypoglycaemia, prevention of repeat hypoglycaemia and 
generation of subsequent hyperglycaemia. To compare this to verified scientific 
standards (Glycaemic Index) and currently-used laboratory-generated 
recommendations for dietary treatment of hypoglycaemia. 
3. To assess individual knowledge of self-treatment of hypoglycaemia in a situation 
of high risk for sustained hypoglycaemia (alcohol ingestion) and compare this to 
easily available internet-based information. 
4. To assess frequency and treatment of hypoglycaemia in inpatients on nasogastric 
feeding who are dependent on carers for identification and treatment of 
hypoglycaemia and therefore at putative high risk from that hypoglycaemia. 
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1.4 Outline of papers included in this thesis 
Although a variety of research methods were used, the papers included in this thesis 
form a progression, starting with relative hypoglycaemia in a state of greatly 
increased diabetes risk (elevated 1-h post-load glucose), leading into primary 
hypoglycaemia in free-living people with diabetes (quantities of carbohydrate and 
patterns of food selection for hypoglycaemic treatment), progressing to secondary or 
repeat hypoglycaemia in free-living people with diabetes (dietary practices and 
efficacy of treatment), to the more specialized situations of alcohol-induced sustained 
hypoglycaemia in diabetes and hypoglycaemia in people with diabetes on nasogastric 
feeding in the general ward. 
The first paper (paper 1) is a case report of a woman with increased diabetes risk but 
within the accepted present parameters of normal glucose metabolism as measured 
by series of oral glucose tolerance tests and haemoglobin A1c; that is normal glucose 
tolerance and elevated 1-h post-load glucose.  It examines the relationship between 
loss of first phase insulin, postprandial hyperglycaemia, relative hypoglycaemia, 
carbohydrate intake and glycaemic index, and assesses the effect of low carbohydrate 
diets and early intervention with short-acting preprandial insulin. 
The second paper in this thesis (paper 2) looks at treatment of hypoglycaemia in 
overt diabetes and is a comparative study of the relationship between quantity of 
carbohydrate and efficacy of treatment of hypoglycaemia in insulin-treated diabetes. 
The participants in this study were 92 free-living adults on current insulin regimens 
attending scheduled diabetes clinic appointments and found to have hypoglycaemia 
on routine testing. The study aimed to determine comparative efficacy of different 
quantities of carbohydrate and wait-times to retreatment of primary hypoglycaemia. 
The effect of this on subsequent hyperglycaemia was also assessed. 
The third paper (paper 3) investigates self-reported qualitative and quantitative 
patterns of food selection for self-treatment of hypoglycaemia in 119 free-living 
people with insulin-treated diabetes as compared with international and national 
guidelines, rate of absorption of carbohydrate, self-reported efficacy of treatment and 
subsequent hypoglycaemia.    
In the fourth paper (paper 4) repeat hypoglycaemia within 2 h of a primary 
hypoglycaemic event is investigated in greater depth, with a questionnaire being 
developed, validated and administered to 169 free-living insulin-treated individuals 
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with a view to delineating the association (or lack of) between omission or under-
treatment with carbohydrate after an initial hypoglycaemic event and repeat 
hypoglycaemia. A secondary aim was to investigate the association between repeat 
hypoglycaemia and presence or absence of symptoms and duration of action of 
carbohydrate.  
The fifth paper (paper 5) looks at the more specialized issue of sustained 
hypoglycaemia post-alcohol consumption. Although the mechanism of this is well 
known, knowledge by those with type 1 diabetes of the key aspects of alcohol-
induced sustained hypoglycaemia in the presence of insulin is not well researched, 
nor is the content of freely available information on this topic. Participants were 50 
people with type 1 diabetes. Available information and participant knowledge were 
assessed according to 6 key criteria. 
The last two papers investigate the specialized and under-researched area of 
hypoglycaemia in inpatients with diabetes on nasogastric feeding in the general 
ward. Paper 6 describes a retrospective review of 50 inpatients treated with insulin 
and insulin secretagogues on ≥ 3d nasogastric feeding to determine factors 
influencing hypoglycaemia and uses survival analysis for time to event analysis to 
clarify the issue of the effect of medication change on subsequent hypoglycaemic 
events. Paper 7 is a systematic review of the literature carried out in accordance with 
PRISMA and QUOROM statement guidelines and aimed to answer the questions: 1. 
What are the existing summary statistics of frequency of hypoglycaemia in insulin-
treated adults on established nasogastric feeding in the general ward? 2. To what 
extent does lack of homogeneity in defining, identifying and reporting 
hypoglycaemia affect these statistics? 
The final chapter of this thesis provides a summary of research findings and 
examines their contribution to existing knowledge in the area being researched. It 
looks at the overall limitations of the study. It makes recommendations for action on 
the findings and also directions for further research.  Much of this has been covered 
in the published journal articles, however this chapter brings together the research 
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CHAPTER 2        LITERATURE REVIEW 
Literature review ceased 15/2/2014 
Preamble: This literature review is structured to firstly review glucose 
dysmetabolism (prediabetes and diabetes) and subsequently hypoglycaemia. This is 
intended to elucidate the background within which hypoglycaemia is examined in 
this thesis. 
2.1 Diabetes and diabetes risk  
Diabetes is a group of diseases exhibiting hyperglycaemia resulting from impaired 
insulin secretion and/or action. Prediabetes signals an increased risk of diabetes. 
Prediabetes and diabetes are both diagnosed on abnormal fasting, or 2-h blood 
glucose levels (BGL) on an oral glucose tolerance test (OGTT) (American Diabetes 
Association, 2013c), although following the World Health Organisation (WHO) 
recommendation in 2011, elevated haemoglobin A1c (HbA1c) can also be used for 
diagnosis (d'Emden et al., 2012). One-hour BGL is routinely measured at OGTT but 
not assessed for diagnosis of prediabetes or diabetes (American Diabetes 
Association, 2013c). Where fasting and 2-h levels are within the normal range, 
prediabetes and diabetes are excluded and the OGTT is classified as normal (NGT).  
2.1.1 Prediabetes 
Definition  
Prediabetes is defined by one or more of the following: impaired fasting glucose 
(IFG) diagnosed by increased fasting glucose (≥ 6.1 and < 7 mmol/L)  and/or 
impaired glucose tolerance (IGT), defined by fasting glucose < 6.1mmol/L and 2-
hour OGTT levels (≥ 7.8 and <  11.0 mmol/L), respectively, and/or HbA1c of 5.7 - 
6.4%  (American Diabetes Association, 2013b). In 2003, the expert committee report 
of the American Diabetes Association (ADA) reduced the normal blood glucose cut-
off to < 5.6 mmol/L and thus the IFG cut-off above this figure (American Diabetes 
Association, 2014a),  however the Australian Diabetes Society do not concur with 
this and retain the original definition (Twigg, Kamp, Davis, Neylon, & Flack, 2007). 
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Prevalence 
The prevalence of prediabetes varies widely between ethnic groups. Approximately 
16.4% of Australian adults have been identified with prediabetes (Twigg, Kamp, 
Davis, Neylon, & Flack, 2007) compared to 4.7% in Bangladesh, 4.6% in India, 
19.5% in Nepal (Jayawardena et al., 2012) and 66.3% in a developing population in 
South China (Zhang et al., 2012). In the majority of populations, IGT is more 
prevalent than IFG. Considerably fewer have IFG and less again both combined 
(Unwin, Shaw, Zimmet, & Alberti, 2002b). 
Overweight and obesity increase the prevalence of prediabetes, with a recent UK 
study showing a rate of IGT of 18.1% among overweight and obese young adults 
(Wilmot et al., 2013).  Prediabetes is also more common in those aged ≥ 40 years, 
with IFG more prevalent in men than women, although the reason for this is not 
known (Cowie et al., 2009).  
Mechanism 
Insulin resistance and β-cell dysfunction are present in both IFG and IGT (Bergman, 
2013; Tabak, Herder, Rathmann, Brunner, & Kivimaki, 2012) however those with 
isolated IFG show greater hepatic insulin resistance including increased endogenous 
glucose production. They have a decrease in first phase insulin response (0 - 10 min 
post-consumption) and reduced response over the first 30 min with later phase 
insulin response (60 - 120 min) being normal. By contrast isolated IGT is 
characterized by greater muscle insulin resistance with subsequent hyperinsulinemia 
and both abnormal early and late phase insulin secretion on OGTT (Nathan et al., 
2007; Tabak et al., 2012).  
Prediabetes is often accompanied by obesity, hypertension, dyslipidemia and 
increased subclinical inflammation (Abdul-Ghani & DeFronzo, 2009; Colak et al., 
2013). Adipocyte insulin resistance is present in both individuals with IFG and IGT 
(Abdul-Ghani & DeFronzo, 2009) and lipid accumulation in the liver appears to be 
an important factor in obesity-related insulin resistance (Haus et al., 2010). Body fat 
distribution is an additional factor affecting insulin resistance with adipose tissue 
within the abdominal region increasing insulin resistance (Bergman, 2013). 
Risk of diabetes 
Prediabetes confers a high risk of diabetes, with those exhibiting both IFG and IGT 
being at especially high risk (Bergman, 2013). Diabetes risk has been shown to 
progressively increase with increasing fasting BGL within the normal range (Park et 
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al., 2006; Tirosh et al., 2005). It has been estimated that per year, 4 - 6% of those 
with IGT, 6 - 9% with IFG and 15 - 19% of those with both, progress to diabetes, 
with 60 - 70% eventually being diagnosed with diabetes (Tabak et al., 2012). Similar 
proportions (5 - 10%) will revert to normoglycaemia (Gerstein et al., 2007; Tabak et 
al., 2012) and this is associated with a 56% reduced risk of future diabetes (Bergman, 
2013). In those who develop diabetes, abnormal glucose values are sometimes 
observed up to 13 y before overt diabetes (Tabak et al., 2012) and this accelerates 
markedly 2 - 6 y preceding diagnosis of diabetes (Ferrannini et al., 2004; Mason, 
Hanson, & Knowler, 2007). It was demonstrated in the Insulin Resistance 
Atherosclerosis Study that insulin resistance, β-cell dysfunction and visceral adipose 
tissue were independent predictors of incidence of type 2 diabetes. Visceral adipose 
tissue was a stronger predictor in women than men (Hanley et al., 2009).  
Vascular risk 
Prediabetes is associated  with increased incidence of vascular disease (Tabak et al., 
2012). Increased risk has been variously assessed as 10% (IGT) and 40% (IFG) 
compared to those with normal glucose regulation (Levitzky et al., 2008) and relative 
risk from 0.83 - 1.34 (IGT) and 0.65 - 2.50 (IFG) (Ford, Zhao, & Li, 2010). It has not 
been determined if this increased risk is dependent on development of diabetes 
(Tabak et al., 2012) but in many studies, it remains significant even after controlling 
for other known risk factors, suggesting that hyperglycaemia is the determining 
factor (Milman & Crandall, 2011). The San Antonio Heart Study demonstrated that 
atherogenesis in the prediabetic state was significantly greater in insulin-resistant 
subjects compared to relatively insulin-sensitive subjects (Haffner, Mykkanen, Festa, 
Burke, & Stern, 2000) and the ADA Consensus Statement affirms that prediabetes 
modestly increases the hazard ratio for cardiovascular disease (~1.1 - 1.4) and that 
IGT is a slightly stronger risk predictor than IFG (Nathan et al., 2007). To the 
contrary, a community-based cohort study involving 2157 individuals with 
prediabetes showed that prediabetes is not an independent risk factor for 
cardiovascular events in older adults (Deedwania et al., 2013).  
Microvascular risk 
Typically, the cut-off glucose value defining diabetes versus prediabetes also defines 
the level at which diabetic microvascular complications begin to occur, but in reality 
diabetic retinopathy, nephropathy, and neuropathy do occur at lower levels among 
individuals with prediabetes (Milman & Crandall, 2011) and prediabetes can increase 
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risk of microvascular complications and microalbuminuria (Bahar, Makhlough, 
Yousefi, Kashi, & Abediankenari, 2013; Tabak et al., 2012). 
Intervention 
Some risk factors associated with prediabetes are potentially reversible. The Diabetes 
Prevention Program Research Group targeted excessive fasting and post-prandial 
BSL, excess body weight, and lack of physical activity in a trial involving 3234 
adults with prediabetes. Follow-up was 2.8 y and interventions were lifestyle changes 
or pharmacological intervention with metformin, an oral hypoglycaemic agent. 
Lifestyle changes reduced diabetes incidence by 58% (95% CI 48 - 66%) and 
metformin by 31% (95% CI 17 - 43%), compared to placebo (Knowler et al., 2002). 
Similarly a meta-analysis of 10 randomised trials showed risk ratio for interventions 
versus control of 0.83 (95% CI 0.80 - 0.86) with lifestyle changes being more 
effective than pharmacotherapy (0.52, 0.46 - 0.58 versus 0.70, 0.58 - 0.85, P < 0.05)  
(Hopper, Billah, Skiba, & Krum, 2011). The ADA Consensus statement quotes 
figures of 25 - 60% prevention of diabetes in those with IFG and IGT with lifestyle 
changes and pharmacological intervention, with lifestyle changes by far the most 
effective (Nathan et al., 2007). This meta-analysis also addressed the effect of these 
interventions on vascular events and all-cause mortality and found no significant 
difference in risk of all-cause mortality and cardiovascular infarction and death 
between those with intervention and controls. There was borderline reduction for 
strokes (0.76, 0.58 - 0.99)   with intervention versus control (Hopper et al., 2011).  
2.1.2 Elevated one-hour postload glucose 
One-hour BGL is routinely measured at OGTT but is not a criterion for diagnosis of 
prediabetes or diabetes (American Diabetes Association, 2013c). Where fasting and 
2-h BGL levels are within the normal range a NGT is recorded, irrespective of the 
level at 1 h. It has, however, been shown that individuals with a normal NGT but 
elevated postload 1-h BGL have a greatly increased risk of diabetes (Abdul-Ghani, 
Abdul-Ghani, Ali, & DeFronzo, 2008; Cubeddu & Hoffmann, 2010).  
Definition 
Yen et al used the terminology ‘1-h glucose spikers’, which they defined as 
individuals having a  normal OGTT (WHO/IDF, 2006) (fasting glucose  < 5.5 
mmol/L and 2-hour glucose < 7.8 mmol/L) but a 1-h glucose >11.0 mmol/L (Yen, 
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Williams, & Twigg, 2008). Meisinger et al used different definitional terminology, 
‘elevated1-h postload glucose’  but the same glucose cut-off point, on the grounds 
that as there was no standard criterion for defining asymptomatic hyperglycemia for 
a 75-g challenge at 1 h, they would use a cut-off value of 11.1 mmol/L (the 2-h cut-
off point for diagnosis of diabetes), to define elevated postload plasma glucose 
(Meisinger, Wölke, Brasche, Strube, & Heinrich, 2006). Harada et al defined 
elevated 1-h postload plasma glucose with a cut-off at 10 mmol/L (Harada et al., 
2008) citing a higher risk of developing diabetes for those with a 1-h blood glucose 
above this cut-off than those with a lower level (Kuzuya et al., 2002). Most other 
studies use the terminology ‘elevated 1-h postload glucose’ but use a lower cut-off 
point of 8.6 mmol/L (Abdul-Ghani et al., 2008; Bianchi et al., 2013; Cubeddu & 
Hoffmann, 2010; Kim et al., 2013; Succurro et al., 2009; Taheri, Iraj, Amini, Amini, 
& Aminorroaya, 2010) identifying ≥ 8.6 mmol/L as a cut-off marking increased 
cardiovascular and diabetes risk (Abdul-Ghani et al., 2008; Cubeddu & Hoffmann, 
2010; Succurro et al., 2009).  
Prevalence  
Unlike prediabetes, there are no population-based epidemiological studies assessing 
prevalence of NGT with elevated 1-h BGL in the general population. Several studies 
have assessed prevalence in selected populations. An Australian study involving 
11,925 subjects referred for OGTT aged 47 ± 16 y, using > 11 mmol/L as the cut-off, 
estimated that approximately 5.8% of that population were 1-h spikers (Yen et al., 
2008). A Japanese study in a similar population (those referred for OGTT) showed a 
much higher prevalence (37.2%), possibly because they used a lower cut-off point of  
> 10 mmol/L (Harada et al., 2008). The GENFIEV study followed 926 Italian 
subjects in a cardiovascular risk study and reported 39% had NGT with 1-h postload 
glucose > 8.6 mmol/L (Bianchi et al., 2013) whereas in a study of 490 unselected 
Latino-Hispanics 8.3% exhibited NGT with 1-h postload glucose > 8.6 mmol/L 
(Cubeddu & Hoffmann, 2010).  
Mechanism 
Normal pancreatic beta cell insulin secretion phases 
The effect of blood glucose levels on insulin secretion varies,  so that a given glucose 
concentration does not give rise to a specific rate of insulin secretion. Insulin 
secretion appears to be modified by time-specific mechanisms. It is commonly 
accepted that there are 2 phases, with the first phase being a surge of insulin in 
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response to a fast change in blood glucose levels. This lasts about 10 min. The 
second phase is a sustained insulin release over a more prolonged interval. The 
mechanism is postulated to be a glucose sensing mechanism via the key enzyme 
glucokinase (Vagn Korsgaard & Colding-Jorgensen, 2006). First phase insulin is 
released in the first 5 - 10 min after the β-cell is exposed to a significant increase in 
glucose (Caumo & Luzi, 2004).  It anticipates and minimizes the postprandial insulin 
rise (Hong et al., 2008). Both animal and human studies have shown that the 
mechanism is mainly mediated at the level of the liver, allowing immediate 
inhibition of glucose production by the liver thus restraining the rise over and after 
the meal (Del Prato & Tiengo, 2001), although recent research has shown a role for 
salivary amylase (Mandel & Breslin, 2012). Second phase insulin is released as 
blood glucose levels increase, and is a more sustained release, which is geared to the 
glycaemic load of the meal (Vagn Korsgaard & Colding-Jorgensen, 2006). 
Modification of beta cell insulin secretion phases in elevated post-load glucose 
Those with NGT and elevated 1-h post-load glucose have lost part, or all of their first 
phase insulin release (Harada et al., 2008). When first phase insulin release is lost, 
glucose rises rapidly after a meal which stimulates the second phase insulin release to 
be greater and more prolonged (Caumo & Luzi, 2004; Temelkova-Kurktschiev et al., 
2000). In an older study, when first phase insulin release in people with type 2 
diabetes was simulated by giving a small dose of insulin pre-meal, peak BGL was 
decreased and, in addition, free fatty acid levels fell at a faster rate after the meal 
(Bruce, Chisholm, Storlien, & Kraegen, 1988). 
Risk of prediabetes and diabetes 
All studies show increased risk of progression to prediabetes and diabetes in those 
with NGT and elevated 1-h postload glucose levels. An Australian study of 11,925 
subjects referred for an initial OGTT conducted follow-up OGTTs at 2.8 y for 883 of 
the subjects and showed 35.5% conversion to IGT in those with NGT and elevated 1-
h glucose as compared to 9.8% conversion rate in the population with true NGT (Yen 
et al., 2008). They also generated the ratio of glucose to the natural log (ln) of insulin 
and showed that in those with true NGT this ratio had a concave downward slope 
from 0 - 2 h while those with elevated 1-h postload glucose had an upward sloped 
curve similar to that of combined IFG and IGT, consistent with insulin deficiency 
with a glucose challenge. A positive glucose:ln insulin ratio differential from 0 - 1 h 
in elevated 1-h postload glucose, increased sensitivity in those with elevated 1-h 
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postload glucose who progressed to IGT, to 45.8% (Yen et al., 2008). In a study in 
obese Hispanic youth, a 1-h BGL ≥ 8.6 mmol/L was shown to be an independent 
predictor of β-cell deterioration with a  2.5 times greater likelihood  of developing 
prediabetes during follow-up, independent of body composition (Kim et al., 2013). 
Cubeddu and Hoffman also identified a similar increased risk in an unselected 
population of 490 Latino-Hispanics (Cubeddu & Hoffmann, 2010). Unwin 
commented that although IGT is strongly predictive of diabetes, 40% of those 
diagnosed with diabetes have a NGT at baseline (Unwin et al., 2002b). It has not yet 
been established how many of these individuals have elevated 1-h postload glucose. 
Vascular risk and all-cause mortality 
The CATAMERIS study followed 400 individuals with NGT and elevated 1h 
postload glucose (> 8.6 mmol/L) and showed they had an atherogenic profile similar 
to those with IGT (Succurro et al., 2009). The GENFIEV study also demonstrated 
similar increased cardiovascular risk in those with NGT and increased 1-h postload 
glucose (Bianchi et al., 2013). The Erfurt Male Cohort Study followed 1160 non-
diabetic men over 30 y and showed 1 h postload hyperglycemia (BGL ≥ 11.1 
mmol/L) was a long-term predictor for all-cause mortality (log-rank test, p < 0.0001) 




Diabetes is differentiated from prediabetes as being a state with a significantly 
increased risk of microvascular damage (retinopathy, nephropathy and neuropathy)  
which is associated with significant morbidity and reduced life expectancy (World 
Health Organisation/International Diabetes Federation, 2006.). The most recent 
classification was carried out by the expert committee of the ADA and utilized the 
association between fasting plasma glucose and diagnosed retinopathy as the 
cornerstone in identifying glucose cut-off  levels. Based on this, and data from three 
epidemiological studies, the committee assessed retinopathy against measured fasting 
plasma glucose, 2-h glucose on OGTT and HbA1c and identified cut-off levels of:  
fasting plasma glucose ≥ 7.0 mmol/L; 2-h glucose on OGTT ≥ 11.1 mmol/L; and 
HbA1c ≥ 6.5% as levels above which a marked increase in retinopathy was observed 
(American Diabetes Association, 2014a).  
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Prevalence 
Diabetes is a significant worldwide health problem, with the Atlas of the IDF 
reporting 382 million people with diabetes in 2013, with a projected rise to 592 
million by 2035. The IDF reports that Australia has 1,648,860 diagnosed cases of 
diabetes (20 - 79 y) with a national prevalence of 9.99%   (International Diabetes 
Federation, 2013). The Australian Government Institute of Health and Welfare 
reports that from 1989 - 90 to 2011 - 2012, the age-standardised prevalence of 
diabetes more than doubled, from 1.5% to 4.2%, however, it remained stable 
between 2007 - 2008 (4.1%) and 2011 - 12 (4.2%). This is based on self-reported 
data from the National Health Survey (Australian  Institute of Health and Welfare, 
2013). A systematic review of 24 studies investigating diabetes prevalence and 
determinants in indigenous Australian populations reported a rate of diabetes varying 
from 3.5% to 33.1% (Minges et al., 2011).  
Classification of diabetes 
Based on etiology and pathogenesis, the vast majority of cases of diabetes fall into 
the following two broad categories (American Diabetes Association, 2014a):  
Type 1 diabetes:  Those with type 1 diabetes have an absolute deficiency of insulin 
secretion resulting from autoimmune destruction of the β-cells of the pancreas and 
those at increased risk of developing this type of diabetes are often identifiable by 
genetic markers. The expression of type 1 diabetes is therefore related to genetic 
susceptibility and environmental factors that are still not well understood (American 
Diabetes Association, 2014a). Autoimmune destruction of pancreatic β-cells over 
time eventually result in a complete lack of endogenous insulin which is associated 
with secondary abnormalities in glucagon, and, as the disease progresses defects in 
counterregulatory responses develop (McCall & Farhy, 2013). 
According to the National Health Survey (2011-2012), in Australia in 2011 - 2012  
approximately 119,000 people (or 11.9% of those with diabetes) had diagnosed type 
1 diabetes; approximately 53% males and 47% female. Type 1 diabetes can be 
diagnosed at any age. A Swedish study which assessed all new cases of type 1 
diabetes diagnosed during a 3 y period by antibody testing, reported an incidence of 
type 1diabetes which was highest at ages 0 - 9 y and then again at ages 50 - 80 y. 
Almost 60% of new type 1 cases were diagnosed in people over age 40 y (Thunander 
et al., 2008). In Australia the level of detail on prevalence of type 1 diabetes obtained 
from the National Health Survey is limited due to the low incidence of type 1 
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diabetes but the evidence is that for people aged 45 y or more, 0.6% have type 1 
diabetes, compared with 0.3% among those aged less than 45 y. (Australian  Institute 
of Health and Welfare, 2013). Australia has the highest estimated incidence rate of 
type 1 diabetes in the Pacific region in children, with 22.3 cases per 100,000 children 
(International Diabetes Federation, 2013). The 2011 NHMRC National Evidence-
Based Clinical Care Guidelines in Type 1 Diabetes assert grade A evidence that at 
present there are no recommended interventions to delay or prevent the onset of type 
1 diabetes (Craig et al., 2011).  
Type 2 diabetes: The mechanism of type 2 diabetes varies from insulin resistance, 
with relative rather than absolute insulin deficiency, to a defect in insulin secretion 
with associated insulin resistance. Type 2 diabetes is progressive over time with β-
cell function declining, making control of BGL progressively more difficult over 
time (Corathers, Peavie, & Salehi, 2013). Obesity is associated with insulin 
resistance. Adipose tissue releases increased amounts of non-esterified fatty acids, 
glycerol, hormones and proinflammatory cytokines which potentiates the 
development of insulin resistance (Kahn, Hull, & Utzschneider, 2006) and both 
overall and abdominal adiposity strongly predict risk of type 2 diabetes (Wang, 
Rimm, Stampfer, Willett, & Hu, 2005). However, the evidence shows there are many 
different causes of type 2 diabetes with many specific aetiologies not thoroughly 
elucidated, but, unlike type 1 diabetes, autoimmune destruction of β-cells does not 
occur (American Diabetes Association, 2014a).  
Type 2 diabetes has a much higher prevalence than type 1. In Australia in 2011 - 
2012, 848,000 people (or 84.9% of those with diagnosed diabetes) had type 2 
diabetes. In 2007 - 2008, approximately 3.8% of Australians had been diagnosed 
with type 2 diabetes. Slightly more males than females had type 2 diabetes (4.3% and 
3.3% respectively). Prevalence increased with increasing age, from 0.1% of those 
aged 0 - 34 y to 14.7% of age 65 - 69 y, then decreasing to 12.4% of those ≥  80 y  
(Australian  Institute of Health and Welfare, 2013). 
Treatment of diabetes 
In the absence of some form of endocrine pancreas transplant, diabetes at present has 
no cure and treatment of  both types of diabetes has the aim of controlling glycaemia 
with positive adjunct effects on complications of diabetes. 
Type 1 diabetes: As type 1 diabetes is characterised by insulin deficiency, the 
standard treatment at present, is insulin replacement with dietary modification 
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designed to balance the pattern of insulin action. The main goal of treatment is 
physiological replication of normal insulin secretion (McCall & Farhy, 2013). 
Conventional insulin regimes incorporate both basal and premeal preparations. 
Previously, absorption of regular human insulin was slow, with metabolic effect up 
to 60 min after injection, tending to give postprandial hyperglycaemia  and possible 
later hypoglycaemia. Basal insulin action was not consistent, but peaked and 
exhibited variable absorption affecting glycaemic control (Swinnen, Hoekstra, & 
DeVries, 2009). Research is ongoing in both identifying insulins and insulin regimes 
which more closely approximate the true physiological situation and also 
investigating more effective routes of insulin delivery (McCall & Farhy, 2013). 
Insulin analogs with modified amino acid sequences have been developed allowing 
faster insulin absorption, action and enhanced dissipation (Hirsch, 2005). The 
decreased variability and more physiological action of analog insulins allowed 
improved glycaemic control with lower risk of hypoglycaemia (Hermansen et al., 
2004) and the 2011 NHMRC National Evidence-Based Clinical Care Guidelines in 
Type 1 Diabetes assigns grade 3 evidence to the use of human insulin and insulin 
analogues (Craig et al., 2011). 
 Technological advances in the area of insulin delivery include insulin pens, insulin 
pumps and the ultimate ongoing development of artificial pancreas closed-loop 
technology. Insulin pumps or continuous subcutaneous insulin infusion (CSII) allow 
a more physiological delivery of insulin with, in many cases, reduction in glycaemic 
excursions and improved quality of life (Cummins et al., 2010; McCall & Farhy, 
2013). Pancreatic transplantation, which was first carried out 25 y ago, is the only 
existing therapy allowing normal glucose control without exogenous insulin, 
however it carries with it the risks associated with immuno-suppression and 
rejection. Although 32,000 procedures have been carried out worldwide, it is 
proportionally a little-used therapy at present (Iacovidou & Hakim, 2013). 
Type 2 diabetes: Diet and exercise are the cornerstones of treatment of type 2 
diabetes (Avery, Flynn, van Wersch, Sniehotta, & Trenell, 2012; Vetter, Amaro, & 
Volger, 2014). Weight loss reduces insulin resistance and therefore improves 
glycaemic control, with even 5 - 10% loss of body weight being significant. Surgical 
intervention such as lapbanding is increasingly being used (Inzucchi et al., 2012). 
Maintaining glycaemic control over time becomes progressively more difficult as a 
result of declining β-cell function and additional therapy is required to maintain 
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control (Corathers et al., 2013). As type 2 diabetes is not associated with absolute 
insulin deficiency, oral therapy, in addition to diet and exercise, is normally the next 
stage of treatment. The situation with respect to treatment of type 2 diabetes is 
complex and there are an increasing number of therapies available (Inzucchi et al., 
2012). Metformin, a biguanide, is the usual first-line medication recommended. It 
acts to reduces hepatic glucose output, has some action to improve β-cell function, 
and does not cause hypoglycaemia,  however it is a gastric irritant and is not always 
tolerated (Inzucchi et al., 2012; Lu, Zang, & Li, 2013). Combination therapy, adding 
in one or two oral or non-insulin injectible agents may be a next step (Inzucchi et al., 
2012). Oral agents are sulphonylureas and meglitinides which stimulate insulin 
secretion but also potentiate weight gain and hypoglycaemia; thiazolidinediones, that 
facilitate insulin action, potentiate weight gain but not hypoglycaemia, dipeptidyl 
peptidase-4 inhibitors that increase insulin secretion proportionate to BGL, have 
some effect improving β-cell function and are not associated with hypoglycaemia, 
and alpha-glucosidase inhibitors that delay digestion and absorption of intestinal 
carbohydrate, are not associated with hypoglycaemia but frequently cause flatulence 
(Consoli & Di Fulvio, 2013; Inzucchi et al., 2012; Lu et al., 2013; Plosker, 2014).  
A recently developed group of medications are the sodium-glucose linked transporter 
2 (SGLT2) inhibitors (SGLT-2). These agents inhibit renal glucose reabsorption 
resulting in glucosuria and therefore a reduction of blood glucose. They lower both 
fasting and postprandial blood glucose levels, aid weight loss and do not cause 
hypoglycaemia (Angelopoulos & Doupis, 2014). 
Non-insulin injectible agents are  glucagon-like peptide-1 receptor agonists which 
potentiate insulin action proportional to BGL, increase satiety and potentiate weight 
loss with negligible hypoglycaemia (Inzucchi et al., 2012; McCormack, 2014). Due 
to progressive destruction of β-cells, insulin therapy is often required over time in 
many with type 2 diabetes, although there is disagreement on when this should be 
commenced (Swinnen et al., 2009). Insulin therapy potentiates weight gain and is 
associated with hypoglycaemia but has a positive effect on β-cell function (Rotella, 
Pala, & Mannucci, 2013; Swinnen et al., 2009). All medications have variable effects 
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Methods of assessing diabetes control 
The main methods for assessment of diabetes control are monitoring of blood or 
interstitial glucose, and measurement of HbA1c (American Diabetes Association, 
2014b).  
Capillary blood glucose level: BGL is an assessment of diabetes control in the short 
term. Laboratory assessment of BGL is by venous plasma levels. Measurement of 
BGL by free-living people and at point of care is normally by glucose meter, which 
measures capillary blood and provides an almost immediate result (Tonyushkina & 
Nichols, 2009).WHO  publishes capillary blood equivalence values for venous 
plasma values for glucose, but questions have been raised as to the reliability of 
these. There is evidence that venous results may be higher than capillary in fasting 
and random blood samples but lower in post-prandial samples, with a maximum of 
10% error, depending on the level of glucose measured (Colagiuri et al., 2003). The 
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 
Scientific Division Working Group on Selective Electrodes and Point-of-Care 
Testing have recommended that a factor of 1.11 should be used in converting a 
capillary blood glucose value to plasma glucose. The recommendation from the 
ADA is that blood glucose meters must agree with laboratory results to within ± 
15%, and that this be reduced to ±5% in future (Tirimacco et al., 2013). The 
International Standards Organisation is thus revising its criteria that currently state 
that 95% of the individual glucose results should fall within ± 0.83mmol/L of the 
results of the manufacturer’s measurement procedure at glucose levels <4.2mmol/L  
and within ±20% at glucose levels ≥4.2mmol/L (Kristensen & Sandberg, 2010). 
The performance of  blood glucose meters is important, and the  level of performance 
will be dependent on their intended clinical use. Test principals of blood glucose 
meters are either electrochemical sensor, electrochemical coulometric, optical 
photometric or amperometric. Sample blood volume needed for testing varies from 
0.3 - 4 μL. The range of blood glucose they can accurately test varies from 0.6 - 33.3 
mmol/L with 1.1 - 33.3 mmol/L being the most common range. The time it takes to 
complete the test varies from 4 - 26  sec with 5 and 6 sec being the most common test 
times (Tirimacco et al., 2013).  
The ADA recommends people on multiple daily insulin injections (MDI) or CSII do 
preprandial and occasional postprandial self-monitoring of blood glucose (SMBG), 
also before exercise and driving, post hypoglycaemia and for problem-solving 
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lifestyle changes (American Diabetes Association, 2014b). SMBG in type 2 diabetes 
is less defined, with a fasting and major postprandial measurement often 
recommended. The NHMRC clinical guidelines recommend preprandial blood 
glucose targets of  3.9 - 6.7 mmol/L, postprandial 5 - 10 mmol/L and at 3am 
(measured weekly) > 3.6 mmol/L, although they stress there are individual 
differences (Craig et al., 2011).  
There is conflicting evidence as to whether SMBG benefits glycaemic control in 
those with type 2 diabetes (Davis, Bruce, & Davis, 2006; McAndrew, Schneider, 
Burns, & Leventhal, 2007), however there is also evidence that increased frequency 
of SMBG among new users was associated with improved glycaemic control 
regardless of diabetes treatment (Karter et al., 2006) with efficacy > 1 y decreasing, 
especially in those with type 2 diabetes (Boren & Clarke, 2010). SMBG is the 
cornerstone of diagnosis and management of hypoglycaemia. 
Interstitial blood glucose: The ADA Guidelines For Clinical Practice assert that 
continuous glucose monitoring of interstitial glucose levels (CGM) can be beneficial 
to glycaemic control in adults ≥ 25 y on intensive insulin regimens, although, at 
present CGM is not common practice (American Diabetes Association, 2014b). An 
advantage of CGM is that it can provide semi-continuous information and identify 
changes in glucose levels that may have been missed by SBGM. There are two 
systems of CGM : retrospective and real-time (Langendam et al., 2012). Real-time 
CGM correlates well with plasma glucose, however  calibration with SMBG is 
required and SMBG is still necessary for making acute decisions (American Diabetes 
Association, 2014b). Average error for CGM is approximately 15%, with increased 
error at times of rapid change of glucose levels and with hypoglycaemia. This is 
related to the transference of glucose from the capillary to interstitial fluid by simple 
diffusion, with the lag during times of rapid change of glucose probably due to the 
magnitude of concentration of glucose (Cengiz & Tamborlane, 2009).  
Langendam et al have shown that sensor-augmented insulin pumps improved 
glycaemic control in new pump users (Langendam et al., 2012). A Chinese study of 
the accuracy of a sensor-augmented pump involved 48 patients with type 1 or 2 
diabetes, with comparison of 1,317 paired blood-sensor values and reported  88.3% 
accuracy but concluded that although there was high accuracy in monitoring real-
time continuous changes and predicting blood glucose trends, it lacked accuracy with 
respect to diagnosis of hypoglycaemia and that clinical symptoms should be taken 
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into account for this (J. Zhou et al., 2012). A recent short-term study comparing 
newer generation sensors showed improved accuracy and consistency with respect to 
hypoglycaemia, with the variation coefficient being 7% versus 11%, but the 
conclusion was that although CGS can provide an alert for hypoglycaemia, or 
developing hypoglycaemia, at present it lacks the point accuracy of current blood 
glucose monitors for diagnoses and management of hypoglycaemia (Christiansen et 
al., 2013). 
HaemoglobinA1c:  Measurement of HbA1c is a longer term measure of glycaemic 
control (American Diabetes Association, 2014b). HbA1c consists of a number of 
stable haemoglobin components which are generated non-enzymatically from 
haemoglobin and glucose. The rate of formation of HbA1c is directly proportional to 
the concentration of glucose in the blood. Erythrocytes are permeable to glucose, 
therefore erythrocyte level of HbA1c is an indicator of the glucose level over the 
previous 120 days, which is the average lifespan of an erythrocyte (Goldstein et al., 
2004). Varied analytic aspects are used for measurement of HbA1c. High-
performance liquid chromatography is used to measure the difference in charge 
between HbA1c and other haemoglobin fractions, and affinity chromatography and 
immunochemical methods measure the difference in molecular structure. Affinity 
chromatography is considered to have the least problems with interference and 
abnormal haemoglobin variants. This has resulted in different results in different 
laboratories generating the need for standardization (Weykamp, John, & Mosca, 
2009). The International Federation of Clinical Chemistry (IFCC) Working Group on 
Standardisation of HbA1c has been establishing International Reference Methods for 
HbA1c (Goodall, 2005). The 2007 Consensus Statement On The Worldwide 
Standardisation Of The Hba1c Measurement by the ADA, European Association for 
the Study of Diabetes (EASD), IFCC and Laboratory Medicine, and the IDF has 
recommended that results from this new reference method be compared with results 
from current methodologies. The IFCC recommends that test results be provided in 
scientifically correct S1 units, mmol/mol, so an HbA1c value of 5% would become 
approximately 33 mmol/mol (American Diabetes Association, International 
Federation of Clinical Chemistry and Laboratory Medicine, & and the International 
Diabetes Federation, 2007). A more recent consensus statement (2010) by the ADA, 
the EASD, the IDF, the IFCC and Laboratory Medicine and the International Society 
for Paediatric and Adolescent Diabetes concurred that the IFCC reference system for 
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HbA1c should be the standard measurement, and that HbA1c results be reported 
worldwide in SI units (mmol/mol) and derived National Glycohemoglobin 
Standardization Program units (%), using an IFCC-National Glycohemoglobin 
Standardization Program master equation (Hanas & John, 2010). 
Mathematical modelling and in vivo studies have shown that a large change in mean 
blood glucose is accompanied by a large change in HbA1c within a matter of 1.2 
weeks, however large variations in blood glucose levels will show an 
unrepresentative HbA1c and therefore frequent hypoglycaemia skews HbA1c 
(Goodall, 2005). The ADA recommends that HbA1c be measured twice a year in 
those with good glycaemic control, and every three months in those with fluctuating 
control (American Diabetes Association, 2014b). As stated previously, HbA1c is 
strongly predictive for diabetes complications, however it does not have a role in 
diagnosing or managing hypoglycaemia. 
Complications of diabetes 
In 2010, nearly 7,750 Australians died from diabetes and diabetes- related causes,  
5.4% of all deaths in Australia (Australian Institute of Health and Welfare, 2012). 
Long-term complications of diabetes are the major cause of morbidity and mortality 
in those with diabetes and are the result of ongoing damage to small and large blood 
vessels and nerves throughout the body. These complications include retinopathy, 
potentially leading to blindness; nephropathy potentially leading to chronic renal 
failure; peripheral neuropathy, which can lead to foot ulcers and amputations, and 
autonomic neuropathy which can cause gastrointestinal symptoms and sexual 
dysfunction. Those with diabetes have increased incidence of cardiovascular and 
cerebrovascular disease, hypertension and abnormal lipid metabolism (American 
Diabetes Association, 2013b). Diabetes is an independent risk factor for 
cardiovascular disease (CVD), which is the major cause of morbidity and mortality 
for people with diabetes (American Diabetes Association, 2013b). In Australia, in 
2007 - 2008, based on self-reported data from the National Health Survey, 58% of 
people with diabetes had cardiovascular disease (Australian Institute of Health and 
Welfare, 2013). 
The causes of the complications of diabetes are the subject of ongoing research. 
Whole body glucose metabolism uses a variety of metabolic pathways, therefore 
chronic hyperglycaemia can induce diverse cellular changes. Genes also play a role 
in processes leading to complications of diabetes, as does duration of diabetes, and 
  - 22 - 
 
there is evidence too that increased oxidative stress has a role in the pathogenesis of 
these complications (Sheetz & King, 2002). Prevention or minimization of 
complications of diabetes mainly involves strategies to optimize glycaemic control, 
blood pressure and lipid levels (American Diabetes Association, 2014a) with the 
2011 NHMRC National Evidence-Based Clinical Care Guidelines in Type 1 
Diabetes assigning grade B evidence to the implementation of intensive glycaemic 
control to reduce the risk of onset or progression of diabetes complications (Craig et 
al., 2011). The first (glycaemic control) impinges directly on the topic of 
hypoglycaemia and will be examined in more detail.  
Because complications of diabetes are occur in both type 1 and type 2 diabetes, 
which have hyperglycaemia as their common feature, it was historically suspected 
that hyperglycaemia played a major role in the pathogenesis of those complications 
(DCCT Research Group, 1990). The Diabetes Control and Complications Trial 
(DCCT) carried out between 1982-1993, was set up to test this hypothesis and to 
determine whether diabetes complications in those with type 1 diabetes could be 
prevented or delayed. It was a controlled clinical trial with 1,441 subjects with type 1 
diabetes, which compared intensive therapy, aimed at achieving BGL as close to the 
normal range as possible, with conventional therapy aimed at safe asymptomatic 
diabetes control. The results showed that those on intensive therapy had a median 
HbA1c of 7%, compared to 9% in the conventional group and had a reduction of a 
35-76% in the early stage microvascular disease. A follow-up observational study, 
The Epidemiology of Diabetes Interventions and Complications Study, investigated 
the effects on the more advanced stages of diabetes complications, including CVD 
and found similar results. The major adverse effect of intensive therapy was an 
increased risk of severe hypoglycaemia  (Nathan, 2014).  
A similar study was carried out in those with type 2 diabetes, The UK Prospective 
Diabetes Study (UKPDS). In the study, 3,867 newly diagnosed patients with type 2 
diabetes were randomly assigned to intensive treatment with a sulphonylurea  or 
insulin, or conventional treatment with diet. In the conventional group, medication 
was added only if there were symptoms of  hyperglycaemia  or BGL ≥ 15 mmol/L. 
Over 10 years, HbA1c was 7.0%  in the intensive group compared with 7.9% in the 
conventional group and the risks of microvascular complications were reduced 25% 
in the intensive group compared to the conventional group. Rates of hypoglycaemia 
per year were 0.7% with conventional treatment and 1.0 - 1.8% with intensive 
  - 23 - 
 
treatment, depending on the treatment agent used (Genuth, 2008; UKPDS Group, 
1998). 
2.2  Hypoglycaemia 
Introduction 
Hypoglycaemia is a blood glucose level below the normal range which may be 
asymptomatic or have associated adrenergic or neuroglycopenic symptoms. It is not 
possible to identify a single plasma glucose level that defines hypoglycaemia, 
therefore it is recommended that, in the absence of diabetes, under clinical conditions 
of investigation, it is confirmed by documentation of Whipple’s triad which consists 
of: symptoms and signs consistent with hypoglycaemia, a low plasma glucose level 
and resolution of those symptoms or signs after the plasma glucose concentration is 
raised (Cryer et al., 2009; Guettier & Gorden, 2006).  
2.2.1  Physiology and symptoms 
Normal physiology 
In the healthy individual, hypoglycaemia of magnitude sufficient to impair cognition 
is prevented by counterregulation (Amiel, 2009). The central nervous system 
processes and coordinates the response to an acute drop in BGL, which  triggers a 
sequence of counterregulatory responses involving hormones, the autonomic nervous 
system and the level of glucose itself. This involves a decrease in insulin secretion 
followed by a rise in systemic glucagon, a rise in adrenaline, growth hormone, and 
cortisol. There is increasing evidence that β-cell insulin secretion inhibits glucagon 
secretion and a decrease in insulin secretion potentiates an increase in glucagon 
secretion during hypoglycaemia. Increased glycogenolysis is potentiated by the 
decrease in insulin secretion, the rise in systemic glucagon and the rise in 
epinephrine. Decreased glucose uptake by insulin-dependent tissue is potentiated by 
the drop in insulin secretion and increased epinephrine. Increased epinephrine also 
potentiates increased gluconeogenesis and decreased insulin secretion. Overall, these 
counterregulatory responses limit glucose use by peripheral tissues and increase 
endogenous glucose production with a resulting rise in glucose. Subjectively, the 
individual becomes aware of the symptoms and signs of hypoglycaemia, and 
generally responds to these by seeking food. These very effective mechanisms ensure 
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that clinical hypoglycaemia is rare in the healthy individual (Cryer, 2011; Guettier & 
Gorden, 2006; McCrimmon, 2009). 
Oxidation of glucose provides more than 90% of the energy needed for the brain. 
The brain is unable to synthesize glucose and has glucose stores sufficient for only a 
few minutes. Therefore it is almost totally dependent on a continuous supply of 
glucose from the bloodstream (Bolli & Fanelli, 1999). Glucose sensors, neurons 
shown to be regulated by glucose, have been found in a number of brain areas 
(McCrimmon, 2009). In an in vivo study using fura-2 calcium imaging to assess 
neuronal response to glucose levels Zhou et al have identified the medial amygdalar 
nucleus area of the brain as one of the glucose-sensing regions. They also suggested 
that urocortin 3 receptor  may provide feedback to inhibit counterregulatory 
responses (Zhou et al., 2010). Paranjape et al  have shown, in animal studies, that in 
addition to insulin acting locally in regulating secretion of glucagon from the 
pancreas, the ventromedial hypothalamus may be a mediating agent in both 
euglycaemia and hypoglycaemia (Paranjape et al., 2010) and McCrimmon et al  have 
identified AMP-activated protein kinase in the ventromedial hypothalamus as 
playing a key role in detecting  hypoglycaemia and initiating counterregulatory 
responses to raise glucose levels (McCrimmon et al., 2008). Tong et al, in similar 
animal studies have shown that release of glutamate from the ventromedial 
hypothalamus is also a key factor in counterregulatory mechanisms (Tong et al., 
2007), with Zhu et al similarly suggesting that during hypoglycaemia a decreased 
glucose within the ventromedial hypothalamus rapidly inactivates gamma-
aminobutyric acid activated (GABAergic) neurons, which decreases inhibitory 
GABAergic tone, which potentiates glucose counterregulation (Zhu et al., 2010).  
There are several origins of typical symptoms experienced with hypoglycaemia. 
Firstly, an acute fall in blood glucose level is associated with increased autonomic 
nervous system activity which gives adrenergic and cholinergic symptoms such as 
anxiety, tremulousness, palpitation, sweating, nausea and hunger. When 
hypoglycaemia was induced experimentally by an insulin infusion of different 
concentrations, feelings of hunger were significantly less intense with a high 
concentration insulin infusion than during moderate insulin infusion with the 
investigators concluding that peripheral insulin levels seemed to be associated with 
the intensity of feelings of hunger (Hermanns et al., 2008).  Secondly, brain glucose 
deprivation compromises the functioning of the central nervous system giving 
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neuroglycopenic symptoms such as confusion, sensation of warmth, weakness or 
fatigue, severe cognitive failure, seizure and coma (Cryer, 1999; Guettier & Gorden, 
2006).  
Adrenergic symptoms of hypoglycaemia following consumption of a meal with a 
large glycaemic load have been reported to be present in some normals who do not 
exhibit the complete Whipple’s triad and this has been termed idiopathic reactive 
hypoglycaemia (Sorensen & Johansen, 2010). In a review of this condition, Scheen 
et al assert that a diagnosis of hypoglycaemia is rarely confirmed (Scheen & 
Lefebvre, 2004), whereas Sorensen et al in a study of 362 healthy subjects with 
normal glucose metabolism identified 12.4% as having idiopathic reactive 
hypoglycaemia based on documented 1-h- or 2-h postprandial glucose levels  < 3.9 
mmol/L  (Sorensen & Johansen, 2010). As the Endocrine Society Clinical Practice 
Guidelines recommend evaluation and management of hypoglycaemia only in 
patients in whom Whipple's triad is documented (Cryer et al., 2009), the level of 
glycaemia defining hypoglycaemia is pivotal to this diagnosis, and this is discussed 
in section 2.2.2.  
 
Diabetes 
General: Because normal counterregulatory responses to falling plasma glucose 
levels are so effective, hypoglycaemia is rare in the general population, however this 
is not the case in diabetes when insulin or insulin secretagogues are used to lower 
blood glucose levels (Cryer et al., 2009). In diabetes, hypoglycaemia results from an 
absolute or relative insulin excess and is a byproduct of treatment with exogenous 
insulin and/or oral hypoglycaemic agents and also compromised glucose 
counterregulation in type 1 and advanced type 2 diabetes. (American Diabetes 
Association, 2005; Cryer et al., 2003). Physiological responses are compromised 
with the loss of the normal decrease in insulin and increase in glucagon and 
epinephrine in response to falling blood glucose levels. The loss of the glucagon and 
insulin responses are due to progressive failure of the beta-cells. This develops early 
in type 1 diabetes but later in those with type 2 diabetes (Cryer, 2011). In type 1 
diabetes, insulin is delivered exogenously and therefore insulin levels cannot 
decrease in response to falling glucose levels, as would happen in the normal 
situation, and the combination of this fact with compromised glucagon and 
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epinephrine responses contributes to defective glucose counterregulation (American 
Diabetes Association, 2005).  
Hypoglycaemic unawareness: The main factor determining how the brain responds 
to hypoglycaemia seems to be previous exposure to a specific level of blood glucose 
(Amiel, 2009; McCrimmon, 2009). So in diabetes, where control has been tight and 
blood glucose levels have been maintained at the low end of the normal range, the 
counterregulatory response is only activated at a level of blood glucose well below 
normal physiological levels and thus the person with diabetes has unawareness of 
their hypoglycaemia  (Amiel, 2009). The resulting neurogenic responses to lower 
plasma glucose levels and a shift in the glycaemic threshold for the sympathoadrenal 
system, which includes epinephrine, means  antecedent hypoglycaemia potentiates 
further hypoglycaemia and further impairment of glucose counterregulation termed 
hypoglycaemia-associated autonomic failure in diabetes (HAAF) (Cryer, 2013). A 
recent study has investigated the effects of antecedent hypoglycaemia using a sensor 
augmented insulin pump which allows insulin suspension at a designated level, the 
threshold suspend (TS) feature. Hypoglycaemia was induced by exercise, and  
subjects were randomly assigned to one of two groups, with group one having TS in 
Period 1 and control  in Period 2 and group 2 the reverse. Hypoglycaemia was 
63.7 min shorter when TS preceded control, indicating that the TS feature's ability to 
mitigate hypoglycaemia was decreased by an episode or episodes of prolonged 
antecedent hypoglycaemia (Garg et al., 2014). 
When hypoglycaemia is prolonged, the brain in unable to maintain glucose levels, 
and as the level of cerebral glucose falls, there are changes in EEG, increased 
oxidative stress, and death of neurons (Jensen, Bogh, & Lykkesfeldt, 2014).  
Compromised counterregulatory responses are attributed partly to failure of β-cells 
resulting in a failure of the normal mechanism whereby β-cell insulin secretion 
inhibits glucagon secretion and a decrease in insulin secretion potentiates an increase 
in glucagon secretion during hypoglycaemia. Loss of both insulin and glucagon 
responses develop early in type 1 diabetes but only in advanced type 2 diabetes 
(Cryer, 2011) and the pathophysiology of HAAF explains why the incidence of 
hypoglycaemia increases as absolute endogenous insulin secretion decreases (Cryer, 
2013). In type 1 diabetes, insulin is delivered exogenously and therefore insulin 
levels cannot decrease in response to falling glucose levels, as would happen in the 
normal situation, and the combination of this fact with compromised glucagon and 
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epinephrine responses contributes to defective glucose counterregulation. This results 
in the clinical syndrome of hypoglycaemia unawareness, that is a loss of the warning 
symptoms that previously alerted the person with diabetes to recognize the onset of 
hypoglycaemia and take action to raise blood glucose levels (American Diabetes 
Association, 2005). A study of 518 people with type 1 diabetes over a 2-year period 
showed that 19.5% had impaired awareness of hypoglycaemia. Compared to those 
with normal awareness they were significantly older, had longer duration of diabetes, 
and had a six-fold higher frequency of severe hypoglycaemia in the previous year  
(Geddes, Schopman, Zammitt, & Frier, 2008). Avoidance of hypoglycaemia for 2 - 3 
weeks restores hypoglycaemic awareness in most affected people (Cryer, 2013; de 
Galan, Schouwenberg, Tack, & Smits, 2006; Vignesh & Mohan, 2004).  
2.2.2 What level defines hypoglycaemia? 
The ADA Working Group on hypoglycaemia defined hypoglycaemia in diabetes as 
being: episodes of abnormally low blood glucose that expose the individual to 
potential harm (American Diabetes Association, 2005). This must include episodes 
of hypoglycaemia without symptoms, as these will predispose the individual to 
further hypoglycaemic episodes. It is not possible to state a level of  blood glucose 
that uniquely defines hypoglycaemia, because the level of glucose where symptoms 
occur is variable, as are other manifestations of hypoglycaemia (Cryer, 2010). The 
ADA Working Group on defining and reporting hypoglycaemia in diabetes 
recommended that people with diabetes should be aware of the possibility of 
developing hypoglycaemia at a SBGM level of BGL ≤ 3.9 mmol/L. The rationale 
given for this was that 3.9 mmol/L is the level at which a hormonal glucose 
counterregulatory response is triggered in those without diabetes and therefore a 
BGL lower than this would be physiologically identified as antecedent 
hypoglycaemia, with consequent reduction of counterregulatory hormone response  
to a subsequent episode of hypoglycaemia (Seaquist et al., 2013).   This has often 
been extrapolated in patient education material  to the slogan ‘4’s the floor’, with the 
implication that 4 mmol/L defines the specific onset of hypoglycaemia requiring 
treatment (Diabetes Co UK, 2013; Medical Update Co. UK, 2013), rather than a 
level which alerts the person with diabetes of the need for self-awareness of the 
putative risk of hypoglycaemia (Clarke & Foster, 2012). Cryer asserts that the 
working group recommendation is not for mandatory treatment of a BGL ≤ 3.9 
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mmol/l but it does mean considering a variety of actions (including self-treatment) 
such as repeating the BGL measurement, avoiding exercise, avoiding driving and 
adjustments to treatment regimens (Cryer, 2009). Frier, although agreeing with much 
of the ADA Working Group’s other conclusions on hypoglycaemia, has a major 
disagreement with the ≤ 3.9 mmol/L cut-off, asserting that this level would be 
observed by many clinicians in fasting adults without diabetes. He also comments on 
what he terms ‘biochemical hypoglycaemia’, a BGL below the normal level with no 
symptoms of hypoglycaemia, commenting on the difficulty of ascertaining at what 
level this commenced. He argues that the studies on which the ADA 
recommendation was based used the ‘unphysiological’ glucose clamp technique, not 
comparable with the normal situation. He posits that in those without diabetes and 
those with type 1 diabetes who retain  normal hypoglycaemic awareness and 
maintain reasonable diabetes control, symptoms  of hypoglycaemia and cognitive 
dysfunction commence only when BGL approaches 3.2 mmol/L and thus suggests an 
arbitrary cut-off of 3.5 mmol/L (Frier, 2009). Amiel et al also disagree with a cut-off 
of ≤ 3.9 mmol/L as overestimating frequency of hypoglycaemia. They point out that 
many surgeons and forensic pathologists use glucose cut-off levels < 2.2 mmol/L, to 
avoid defining healthy people as hypoglycaemic. They support the recommendation 
by the European Medicines Agency, an EU regulatory agency for the evaluation of 
medicinal products, that < 3.0 mmol/L be the cut-off when assessing the 
hypoglycaemic risk of different medications, asserting it is the level defining 
impaired cognitive function and is a level of clinical significance. In addition, 
avoidance of BGL < 3.0 mmol/L has been shown to restore hypoglycaemic 
awareness (Amiel, Dixon, Mann, & Jameson, 2008).  
Swinnen et al, using data from two trials examining insulin glargine use in 12,837 
people with type 2 diabetes, quantified the effect of an alteration of cut-off point for 
the definition of hypoglycaemia. They reported that a change in cut-off from  < 3.1 to 
< 3.9 mmol/L more than doubled the recorded frequency of hypoglycaemia and the 
proportion of participants with asymptomatic hypoglycaemia increased from 30.7% 
to 61.7% at < 3.9 mmol/L compared to < 3.1 mmol/L. They concluded that the cut-
off should be lower than the < 3.9 mmol/L recommended by the ADA (Swinnen, 
Mullins, Miller, Hoekstra, & Holleman, 2009). Contrary to this, Cryer has heatedly 
defended the level of 3.9 mmol/L as the only safe definitional level for 
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hypoglycaemia, on the grounds that the issue is not documenting frequency of 
clinical hypoglycaemia but rather preventing clinical hypoglycaemia (Cryer, 2009).  
At present, therefore, there is no consensus on the blood glucose level defining 
hypoglycaemia, and no prospect of agreement. Until these divisions are resolved, a 
comprehensive benchmarking process that would allow institutions to compare 
inpatient diabetes control to accepted guidelines cannot be developed (Cook, Wellik, 
Kongable, & Shu, 2012) and, from a research perspective, mitigates against valid 
interstudy comparisons quantifying hypoglycaemia.  
2.2.3 Classification of hypoglycaemia 
The ADA Working Group on hypoglycaemia has suggested classification of 
hypoglycaemia in diabetes in adults. The suggested categories are as follows:  
Severe hypoglycaemia: defined by the working group as a hypoglycaemic event 
where the assistance of another person is needed to actively administer treatment. In 
the absence of a documented BGL, neurological recovery following normalization of 
BGL is considered confirmation of the cause being a low BGL (Seaquist et al., 
2013). No level of BGL was assigned by the working group but they cited two 
studies which used definitional levels for severe hypoglycaemia of <  2.8 mmol/L 
and  < 2.2 mmol/L respectively (Krinsley & Grover, 2007; Turchin et al., 2009). 
Documented symptomatic hypoglycaemia: defined by the working group as a 
hypoglycaemic event with typical hypoglycaemic symptoms and a measured BGL < 
3.9 mmol/L. 
Asymptomatic hypoglycaemia: defined by the working group as a hypoglycaemic 
event without typical hypoglycaemic symptoms and a measured BGL < 3.9 mmol/L. 
Probable symptomatic hypoglycaemia: defined by the working group as a 
hypoglycaemic event with typical hypoglycaemic symptoms but no measured BGL < 
3.9 mmol/L (Seaquist et al., 2013). 
Pseudo-hypoglycaemia or relative hypoglycaemia (American Diabetes Association, 
2005; Seaquist et al., 2013):  defined by the working group as an event with typical 
hypoglycaemic symptoms with a measured BGL > 3.9 mmol/L. This reflects the fact 
that those with persistently high BGL levels can experience hypoglycaemic 
symptoms at > 3.9 mmol/L as BGL declines toward that level (American Diabetes 
Association, 2005). This event is associated with the release of counterregulatory 
hormones and is most likely to happen when treatment is revised and glycaemic 
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control improves. It usually takes 2 - 4 weeks for the brain to readjust to the 
relatively reduced glucose levels (Briscoe & Davis, 2006). This is because the main 
determinant of the glucose levels at which the brain responds actively to 
hypoglycaemia appears to be recent antecedent glucose levels, thus those accustomed 
to chronic high glucose levels may trigger symptomatic stress responses as the blood 
glucose falls, even though it is still within the normal range. This can make 
improvement in glycaemic control difficult (Amiel, 2009; McCrimmon, 2009). The 
latter four classifications are obviously dependent on definitional level of 
hypoglycaemia (see section 2.2.2). 
The ADA Working Group investigating Defining and Reporting Hypoglycaemia in 
Diabetes has suggested a further classification as follows: 
Nocturnal hypoglycaemia - hypoglycaemia in type 1 diabetes occurs most frequently 
during sleep and can range in severity from asymptomatic mild hypoglycaemia to 
severe, potentially fatal hypoglycaemia. Even asymptomatic nocturnal 
hypoglycaemia exacerbates defective glucose counterregulation thus increasing 
hypoglycaemic risk. The working party therefore recommends that hypoglycaemic 
events be defined  as daytime or nocturnal events (American Diabetes Association, 
2005). Night-time is the longest post-absorptive state with people with diabetes 
having variable insulin needs throughout the night, with less need for insulin between 
0 h and 3h and increased needs between 4h and 7h, mainly due to decreased hepatic 
insulin sensitivity (Bolli, 2001). Wentholdt et al in a study of 57 people with type 1 
diabetes using a glucose sensor showed 33% incidence between 22h and 7h with 
bedtime glucose being the strongest predictor. There was no difference between 
those treated with CSII or MDI (Wentholt et al., 2007). 
2.2.4 Self-treatment of hypoglycaemia 
Many reviews of hypoglycaemia do not discuss, or merely touch on, the topic of self-
treatment of hypoglycaemia; often simply recommending that people with diabetes 
carry or ingest readily accessible carbohydrate (American Diabetes Association, 
2005; Amiel et al., 2008; Amiel, 2009; Seaquist et al., 2013). There is a lack of 
consensus from sources giving more detailed recommendations, and rationales for 
these recommendations are often poor (American Diabetes Association, 2008, 
2014b; Asian-Pacific Type 2 Diabetes Policy Group, 2002; Bantle et al., 2008; Boyle 
  - 31 - 
 
& Zrebiec, 2007; Briscoe & Davis, 2006; Cryer et al., 2003; Diabetes Australia, 
2009; Diabetes Education Study Group of the European Association for the Study of 
Diabetes, 1998; Diabetes New Zealand, 2008; Diabetes UK, 2011). There would 
seem to be a need to provide additional/alternative guidelines. For more discussion 
on this, see section 4.1.1. Similarly, there is little published information on whether 
people with diabetes follow these guidelines, what they actually ingest to self-treat 
their hypoglycaemia, and the efficacy of this self-treatment. Studies available are 
often dated and report responses to now-outdated insulin regimes and pre-analog 
insulins (Brodows et al., 1984; Cryer, Fisher, & Shamoon, 1994; Gaston, 1992; 
Gunning & Garber, 1978). Recent studies are few and some investigate specialized 
populations. Lawton et al investigated self-treatment practices over 1 y among 30 
adults with type 1 diabetes who had attended a Dose Adjustment for Normal Eating 
(DAFNE) course. The study design of individual in depth interviews did not allow 
for quantification of results. Investigators concluded that people with established 
type 1 diabetes may have difficulty with recommendations for fixed amounts of 
carbohydrate and flexible advice may be beneficial (Lawton et al., 2013) and the 
NHMRC clinical guidelines support use of this program for increased flexibilty in  
dovetailing insulin and food (Craig et al., 2011).  Sommerfield et al, in a survey of 
101 insulin-treated individuals, compared their self-treatment of hypoglycaemia to 
Diabetes UK Treatment Guidelines For Hypoglycaemia (Diabetes UK, 2011) which 
recommends initial treatment with 10 - 15 g of ‘refined’ carbohydrate and follow-up 
with ‘unrefined’ carbohydrate. They reported that the guidelines were followed by 
39.6% of participants, with 47.5% undertreating and 12.9% overtreating their 
hypoglycaemia (Sommerfield et al., 2003).  Sumner et al surveyed 125 individuals 
with type 1 diabetes attending routine clinic appointments, reporting that only 24% 
correctly treated hypoglycaemia with short and long acting carbohydrate, with 6% 
making inappropriate food choices. Actual foods used for self-treatment of 
hypoglycaemia were not specified, but sources of information regarding self-
treatment were, with more than 50% of participants nominating hospital clinics and 
GP practices as information providers and approximately 4%  reporting having been 
given no information (Sumner et al., 2000). Elliott et al, in a survey of 309 people 
with type 2 diabetes attending primary health care centres in Oman reported that 27% 
of those surveyed were unable to recognize hypoglycaemia and 26% were unable to 
respond to it, with 4% giving ‘actively dangerous’ responses to hypoglycaemia, such 
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as increasing dosages of oral hypoglycaemic agents and insulin, or going to sleep. 
Again, no specific food choices or quantities were reported (Elliott et al., 2013). 
When hypoglycaemic unawareness or undertreatment of severe hypoglycaemia allow 
progression of hypoglycaemia to the point where the sufferer becomes unable to self-
treat,  glucagon, provided as an emergency kit, can be given by injection in a non-
medical setting by someone other than the sufferer. Glucagon is a major counter-
regulatory hormone that acts to maintain glucose production by glycogenolysis and 
gluconeogenesis in the liver (Kedia, 2011). It is ineffective in later sustained alcohol-
induced hypoglycaemia as in this situation the liver is depleted of glycogen and 
gluconeogenesis is inhibited by alcohol (Carroll, Burge, & Schade, 2003; Siler, 
Neese, Christiansen, & Hellerstein, 1998).  
 2.2.5 Prevalence of hypoglycaemia  
Elevated one-hour postload glucose 
Neither hypoglycaemia nor relative hypoglycaemia have been documented in the 
literature in those with NGT and elevated 1-h postload glucose. 
Prediabetes 
Hypoglycaemia in prediabetes is not documented, except under conditions of trauma  
or experimental trials. The presence of hypoglycaemia is documented with the 
stressor of burns (prevalence not quantified) (Somerset, Coffey, Jones, & Murphy, 
2014) and cardiac surgery (2 asymptomatic hypoglycaemic events in 43 patients)  
(Hagelberg, Ivert, Efendic, Ohrvik, & Anderson, 2008). It is also documented in 
some research trials of early treatment of those at risk of diabetes. Hypoglycaemia 
was documented to have occurred with insulin glargine treatment  in prediabetes, in 
the Outcome Reduction with Initial Glargine Intervention (ORIGIN) study  
(Hanefeld & Bramlage, 2013; Rusavy, Lacigova, & Kvapil, 2013) with 
hypoglycaemia and severe hypoglycaemia recorded in 6% and 7.6% respectively of 
those with prediabetes over median 6.2 y  (Mellbin et al., 2013), and in a similar 
study where 5/18 subjects receiving glargine experienced 16 mild symptomatic 
hypoglycaemic events  (Marbury et al., 2008). Finally, Saloranta et al in a study 
investigating the use of nateglinide in prediabetes, reported hypoglycaemic events in 
26.7% subjects receiving nateglinide and 2.3% receiving placebo (Saloranta et al., 
2002).   
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Diabetes  
There are increasing numbers of studies quantifying hypoglycaemia in diabetes. 
Interstudy comparison of rates of hypoglycaemia are difficult due to variation in 
reporting methods; for more discussion of this see section 8.3 (paper 7). 
Type 1 diabetes: Cryer et al in the ADA’s technical review of hypoglycaemia in 
2003 estimated rates of symptomatic hypoglycaemia in type 1 diabetes as an average 
2/wk and severe hypoglycaemia approximately 1/y, and reported  rates of severe 
hypoglycaemia during aggressive insulin therapy of 62 - 170 episodes per 100 
patient-years (Cryer et al., 2003). Donnelly et al in 2005, in a population-based study 
of 267 adults in Scotland over 1 month  documented rates of hypoglycaemia of 42.89 
mild and 1.15 severe events per patient per year in 94 people with type 1 diabetes. 
Episodes of hypoglycaemia were prospectively self-documented and cross-checked 
with blood glucose records. They found that the predictors of hypoglycaemia in these 
people with type 1 diabetes were a history of previous hypoglycaemia and co-
prescribing of any oral drug. The UK Hypoglycaemia Study Group, in an 
observational study of 107 type 1 subjects over 9 - 12 m in 6 UK secondary care 
diabetes centres in  2007 documented mean rates of 35.5 and 29.0 mild and 1.1 and 
3.2 severe self-reported hypoglycaemic episodes per subject-year (< 5 y and > 15 y 
duration of diabetes respectively). A longer diabetes duration was associated with 
loss of endogenous insulin secretion, increased counterregulatory failure and thus 
increased hypoglycaemia (UK Hypoglycaemia Study Group, 2007). Finally McCoy 
et al in 2013, in a postal survey of 92 adults with type 1 diabetes reported that 28.3% 
had self-reported at least one episode of severe hypoglycaemia within the last 6 m 
(McCoy et al., 2013). All reports show substantial rates of hypoglycaemia amongst 
those with type 1 diabetes, and where assessed against duration of diabetes, show, 
not surprisingly, increased rates with increasing duration of diabetes coincident with 
increasing counterregulatory impairment and thus hypoglycaemic unawareness. 
Type 2 Diabetes: The ADA 2003 technical review merely asserts that rates of 
hypoglycaemia in type 2 diabetes are substantially less than in type 1 diabetes, and 
gives figures for severe hypoglycaemia during aggressive insulin therapy in type 2 
diabetes of 3 - 73 episodes per 100 patient-years (Cryer et al., 2003). Donnelly et al 
report rates of hypoglycaemia in insulin-treated type 2 diabetes of 16.37 events per 
patient per year with 5 of these being severe hypoglycaemic events, that is 0.35 
severe episodes per patient per year. Predictors of hypoglycaemia in these people 
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with type 2 diabetes were a history of previous hypoglycaemia and duration of 
insulin treatment (Donnelly et al., 2005). The UK Hypoglycaemia Study Group  
showed self-reported rates of mild hypoglycaemia of 1.92, 4.08, 10.2, and severe 
hypoglycaemia of  0.1, 0.1, 0.7 episodes per person year for type 2 diabetes on OHA, 
insulin treatment < 2 y duration and insulin treatment > 5 y duration, respectively. In 
this study rates of hypoglycaemia in type 2 diabetes was equivalent in OHA and 
early insulin use and considerably less than in type 1 diabetes (UK Hypoglycaemia 
Study Group, 2007). In type 2 diabetes, longer duration of diabetes is associated with 
increasing age and  increased loss of endogenous insulin secretion giving a higher 
propensity for hypoglycaemia, and in addition, there is evidence that symptoms of 
hypoglycaemia  may become less and cognitive dysfunction more with increasing 
age (Amiel et al., 2008). Finally McCoy et al, in a postal survey of 326 adults with 
type 2 diabetes, reported that 16.9% reported at least one episode of severe 
hypoglycaemia within the last 6 m (McCoy et al., 2013).  
As with those with type 1 diabetes, interstudy comparisons are difficult due to 
different study groupings and reporting methods, however all studies show rates of 
hypoglycaemia in early type 2 diabetes which are substantially lower than amongst 
those with type 1 diabetes but rising rates with longer duration. This is not 
unexpected as the mechanism of type 2 diabetes varies, but includes insulin 
resistance and relative insulin deficiency with progressive loss of β-cell function over 
time. Therefore those with early type 2 diabetes are less likely to be on, or on smaller 
doses of, insulin or potent OHA which make hypoglycaemia less likely (Amiel et al., 
2008; Corathers et al., 2013). 
 
2.2.6 Risk of hypoglycaemia  
 
Treatments - types, regimes and delivery methods  
The DCCT and UKPDS showed that intensive insulin regimes, while reducing 
diabetes complications, markedly increased rates of hypoglycaemia, with the DCCT 
showing a threefold increased risk of hypoglycaemia with intensive treatment and the 
UKPDS showing rates of major hypoglycaemic episodes per year as 0.7% with 
conventional treatment and  1.0 - 1.8% with intensive treatment, depending on 
treatment given (Nathan, 2014; UKPDS Group, 1998). Ongoing developments in 
both treatments types and regimes and insulin delivery methods since these two trials 
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have aimed to maintain and improve treatment quality and minimize hypoglycaemic 
risk.  
Development of treatments and regimes with lower hypoglycaemic risk: Schopman 
et al in a systematic review of hypoglycaemia in patients with type 2 diabetes treated 
with sulfonylureas extracted data from 22 papers and reported that hypoglycaemia 
was experienced by 5.9 - 10.1% of sulphonylurea-treated people and severe 
hypoglycaemia by 0.8%. Hypoglycaemia and severe hypoglycaemia occurred less 
with newer shorter acting sulphonylurea agents (Schopman et al., 2014).  Similarly, 
analog insulins, which both dissociate more quickly and exhibit less variability and 
more physiological action profiles, have been shown to decrease hypoglycaemia 
(Heller, 2002; S. R. Heller, Amiel, & Mansell, 1999; Hermansen et al., 2004). 
Changing insulin regimes from premixed insulins twice daily to basal-bolus, or MDI 
regimes theoretically decrease hypoglycaemic risk by eliminating premeal medium 
acting insulins and increasing flexibility, allowing a more physiological pattern of 
insulin action and thus less hypoglycaemia. Some evidence suggests that premixed 
insulin analogues are cost effective and associated with only minor hypoglycaemic 
risk for the treatment of type 2 diabetes (Garber, Ligthelm, Christiansen, & Liebl, 
2007) and those with newly diagnosed type 1 diabetes (Idris, Pillai, Fernando, 
Thomson, & Tate, 2013) (that is, those with some endogenous insulin production), 
however other studies strongly indicate that premixed insulin regimes increase 
hypoglycaemic risk (Riddle, Rosenstock, Vlajnic, & Gao, 2013). Testa et al showed 
equal rates of symptomatic hypoglycaemia in both type 1 and type 2 diabetes using  
premixed insulin compared to a basal-bolus regime; however glycaemic control was 
reduced on the premixed regime (Testa et al., 2012).   
Changes in insulin delivery methods to minimize hypoglycaemia: CSII or insulin 
pumps give greater flexibility of insulin delivery and as they utilize only short-acting 
insulin, allow interruption of insulin delivery when BGL falls excessively, more 
closely mimicking the physiological situation. Theoretically this should aid 
minimization of hypoglycaemic risk, however, in reality, there is mixed evidence 
regarding the effect of CSII versus MDI on rates of hypoglycaemia A systematic 
review by Yeh et al of 33 randomized controlled trials showed both have similar 
rates of hypoglycaemia (Yeh et al., 2012). Contrary to this, another systematic 
review of 76 studies making similar comparisons, reported that CSII benefitted 
glycaemic control by less variability in BGL and lower rates of hypoglycaemia 
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(Cummins et al., 2010). Papargyri et al in a 7 y follow-up of 112 people with type 1 
diabetes on CSII showed that hypoglycaemia decreased over time with use of CSII 
which improved glycaemic control compared to MDI treatment. However it was 
necessary to implement specific patient training and fine adjustment of insulin 
infusion doses to minimize hypoglycaemia (Papargyri et al., 2013) All evidence 
shows that the relatively newly developed sensor-augmented insulin pumps decrease 
risk of hypoglycaemia (Bergenstal et al., 2013; Yeh et al., 2012). A study by Ly et al 
followed 95 people with type 1 diabetes randomized to a conventional or sensor-
augmented pump over 6 months. After 6 months the adjusted incidence rate per 100 
patient-months was 34.2 and 9.5 for the pump-only and sensor-augmented pump 
groups respectively (Ly et al., 2013). 
Hypoglycaemia in diabetes is a result of absolute or relative insulin excess caused by 
insulin or insulin secretagogues (Cryer, 2011). Matching medication and lifestyle is 
an imperfect science, however, as can be seen above, improvements in treatments 
and delivery methods are slowly decreasing hypoglycaemic risk.  
Exercise and hypoglycaemic risk  
Exercise is generally recommended for individuals with type 1 diabetes as it 
improves physical fitness, reduces cardiovascular risk and improves well-being 
(Chimen et al., 2012), however as it increases glucose utilization, it also increases the 
risk of hypoglycaemia, especially when exercise is prolonged (Seaquist et al., 2013). 
Exercise-induced hypoglycaemia in type 1 diabetes is a result of the inability to 
endogenously decrease exogenously delivered insulin in response to exercise, as 
would happen in the healthy individual. The result of this is a relative insulin excess 
and a reduction in blood glucose levels. Exercise may also increase absorption of 
insulin from the administration site (Guelfi, Jones, & Fournier, 2007). Exercise-
induced hypoglycaemic risk in those with type 1 diabetes can be sustained, as 
glucose uptake by muscle continues to be increased post-exercise, and this glucose is 
utilized to rebuild muscle and glycogen stores. Hypoglycaemic risk has been 
reported to persist for up to 31 hours post-exercise (Guelfi, Jones, et al., 2007). 
Antecedent episodes of exercise can blunt counterregulatory responses during 
subsequent hypoglycaemia (Briscoe, Tate, & Davis, 2007). Galessetti et al, studied 
22 individuals with type 1 diabetes during 90 m of cycling exercise after two 2-h 
periods of previous day euglycaemia or hypoglycaemia. After day 1 euglycaemia, 
participants demonstrated normal counterregulatory responses to exercise, but after 
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previous day hypoglycaemia, reduction of glucagon, catecholamine, cortisol and 
endogenous glucose production was observed (Galassetti et al., 2006).  
Hypoglycaemic risk varies with the duration and intensity of exercise and it is 
recognised that moderate and high-intensity exercise have differing effects on blood 
glucose levels (Guelfi, Jones, et al., 2007). In moderate-intensity exercise the 
muscles increase uptake of glucose and hepatic glucose production increases to 
compensate for this, but this increase is inhibited by the failure to reduce circulating 
insulin levels with resulting increased hypoglycaemic risk. In contrast, short bursts of 
high-intensity exercise are fuelled by creatine phosphate and anaerobic glycolysis, 
resulting in a rise in blood glucose levels  rather than hypoglycaemia (Guelfi, Jones, 
et al., 2007; Guelfi, Ratnam, Smythe, Jones, & Fournier, 2007). Iscoe et al, 
compared the effect of continuous moderate-intensity exercise with continuous 
moderate-intensity alternating with intermittent high-intensity exercise on blood 
glucose levels in trained athletes with type 1 diabetes and showed both increased 
hypoglycaemic risk to a similar degree (Iscoe & Riddell, 2011).  
The risk of exercise-induced hypoglycaemia can be minimized by careful glucose 
monitoring before and after exercise and the appropriate adjustment of medication 
and ingestion of carbohydrate-rich snacks (Seaquist et al., 2013). Campbell et al in a 
study of 11 individuals with type 1 diabetes exercising on a treadmill showed that a 
reduction of 75% in the dose of rapid acting insulin pre-exercise and 50% post-
exercise protected participants from early-onset hypoglycaemia (≤ 8 h) but not late-
onset post-exercise hypoglycaemia (Campbell et al., 2013). Yardley et al, in an 
observational study of physically active people with type 1 diabetes have shown a 
reduction in post-exercise hypoglycaemia by the judicious use of CSII (Yardley et 
al., 2013). 
In type 2 diabetes, exercise is generally beneficial, with potential to improve glucose 
and lipid levels, reduce weight and improve insulin resistance (Chimen et al., 2012). 
Those with type 2 diabetes treated with insulin and/or insulin secretagogues are at 
risk of exercise-induced  hypoglycaemia, if medication dose is not reduced or 
carbohydrate consumption increased. The risk of hypoglycaemia is greater when 
exogenous insulin levels are higher and if exercise is prolonged (Sigal, Kenny, 
Wasserman, Castaneda-Sceppa, & White, 2006). A meta-analysis conducted by 
MacLeod et al in individuals with type 2 diabetes treated by glucose lowering 
medication, insulin, or diet investigated the effect of exercise on blood glucose levels 
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by means of continuous glucose monitoring. Most studies showed that short-term 
exercise significantly decreased average glucose concentrations, with an acute 
glucose lowering via insulin sensitization being generally short-lived, but sometimes 
persisting up to 48-h post-exercise. They reported little effect on either fasting 
glucose levels or hypoglycaemic frequency (MacLeod, Terada, Chahal, & Boule, 
2013). As in type 1 diabetes, the risk of exercise-induced hypoglycaemia can be 
minimized by careful glucose monitoring before and after exercise and the 
appropriate adjustment of medication and ingestion of carbohydrate-rich snacks 
(Seaquist et al., 2013). 
Diet, education and risk of severe hypoglycaemia 
Severe hypoglycaemia is defined as a hypoglycaemic event where the assistance of 
another person is needed to actively administer treatment (Seaquist et al., 2013). 
Donnelly et al in 2005, in a population-based study of 267 adults in Scotland over 1 
m documented rates of severe hypoglycaemia of 1.15 events per patient per year,  
with the  main predictors being a history of previous hypoglycaemia and 
coprescribing of any oral drug (Donnelly et al., 2005). Similarly, the UK 
Hypoglycaemia Study Group, in an observational study of 107 type 1 subjects over 9 
- 12 m documented mean rates of 3.2 severe self-reported hypoglycaemic episodes 
per subject-year with a longer diabetes duration associated with loss of endogenous 
insulin secretion, increased counterregulatory failure and increased severe 
hypoglycaemia (UK Hypoglycaemia Study Group, 2007).  Both reports show 
substantial rates of severe hypoglycaemia amongst those with type 1 diabetes, and 
increased rates with increasing duration of diabetes coincident with increased 
counterregulatory impairment and therefore hypoglycaemic unawareness. A study by 
Geddes et al of 518 people with type 1 diabetes over a 2-year period showed that 
insulin-treated people with hypoglycaemic unawareness had a six-fold higher 
frequency of severe hypoglycaemia in the previous year than those with normal 
awareness (Geddes, Schopman, Zammitt, & Frier, 2008).  
When hypoglycaemic unawareness or undertreatment of severe hypoglycaemia allow 
progression of hypoglycaemia to the point where the sufferer becomes unable to self-
treat, glucagon, can be given by injection in a non-medical setting by someone other 
than the sufferer. (Kedia, 2011).  
The main preventative strategies for severe hypoglycaemia are patient education 
programs which aim to increase the competency of those with type 1 diabetes in 
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dovetailing diet and insulin doses to accommodate a flexible lifestyle. The two most 
well known of these are the HyPOS and the Dafne programs. The HyPOS program 
runs over 5 weeks and specifically targets prevention of hypoglycaemia, by training 
participants in symptom awareness by using diaries and performing blood glucose 
estimation. It has been shown that at 6-m follow-up, hypoglycaemic awareness 
significantly improved (Hermanns, Kulzer, Kubiak, Krichbaum, & Haak, 2007) and 
incidence of severe hypoglycaemia was lower in those who had completed the 
HyPOS program than in an untrained control group (0.1±0.2 vs 0.2±0.4 
episodes/patient-year) (Hermanns, Kulzer, Krichbaum, Kubiak, & Haak, 2010). 
The DAFNE program, similarly, is a 5-day education program which aims to teach 
‘dose adjustment for normal eating’ emphasising (relatively) unrestricted diet with 
carbohydrate counting and using insulin-to-carbohydrate ratios. It has been shown 
variously to, ‘not worsen’ severe hypoglycaemia (Dafne Study Group, 2002), reduce 
severe hypoglycaemia (McIntyre et al., 2010) and also reduce emergency admissions 
for severe hypoglycaemia  (Elliott et al., 2014). 
2.2.7 Consequences of hypoglycaemia 
Physiological consequences 
Short-term: Hypoglycaemia can cause ongoing morbidity and even mortality in those 
with type 1 and advanced type 2 diabetes (Cryer, 2011; Seaquist et al., 2013). In the 
short-term, hypoglycaemia can cause confusion, coma, seizures, and death (Cryer, 
2011). Hypoglycaemia has been reported to cause 4 - 10% of deaths in people with 
diabetes (Patterson et al., 2007; Skrivarhaug et al., 2006).  
Driving-related morbidity: Hypoglycaemia also increases driving-related morbidity 
and mortality. Cox et al, in a study by questionnaire, reported that drivers with type 1 
diabetes had significantly more self-reported car accidents, moving violations, 
episodes of hypoglycaemic stupor, need for assistance, and mild hypoglycaemia 
while driving compared to drivers with type 2 diabetes or spouse control subjects. 
Car accidents were shown to be associated with hypoglycaemia. Drivers with type 2 
diabetes had similar rates to controls (Cox et al., 2003).  
Trauma: Marchesini et al in a retrospective analysis of cases attending 46 Italian 
emergency departments for hypoglycaemia over a year  showed that  injuries 
associated with trauma accounted for 1.3 % of admissions. Diabetes treatment  and 
increasing age were the main determinants (Marchesini et al., 2014). Bloomfield et al 
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in a meta-analysis looking at consequences of severe hypoglycaemia have 
commented that there is limited data on the association between hypoglycaemia and  
falls and traumatic injuries (Bloomfield et al., 2012) however Leckie et al, in a 
prospective 12-month survey of 243 employed people with insulin-treated diabetes, 
showed 0.14 episodes per person per annum of severe hypoglycaemia. This resulted 
in 2% sustaining a head injury, 2% suffering another injury,1% injuring someone 
else, and 1% damaging property (Leckie, Graham, Grant, Ritchie, & Frier, 2005). 
Repeat hypoglycaemia: In the longer term mild symptomatic hypoglycaemia does 
not appear to have significant clinical effects, except for potentiating defects in 
counterregulatory responses and increasing unawareness to subsequent 
hypoglycaemic events (Amiel et al., 2008). However as hypoglycaemia in diabetes 
results from absolute or relative insulin excess as a byproduct of treatment with 
exogenous insulin and/or insulin segretagogues, insulin levels cannot decrease in 
response to falling glucose levels, as would happen in the normal situation 
(American Diabetes Association, 2005; Cryer et al., 2003) and the potential for 
repeat hypoglycaemic episodes exists. The bulk of research concerning repeat 
hypoglycaemia is focussed on the emergency treatment of a primary hypoglycaemic 
event by paramedics and the likelihood of a repeat hypoglycaemic episode 
necessitating a hospital admission within the subsequent  24 - 72 h (Cain, Ackroyd-
Stolarz, Alexiadis, & Murray, 2003; Roberts & Smith, 2003; Socransky, Pirrallo, & 
Rubin, 1998; Strote, Simons, & Eisenberg, 2008). In the short-term situation, 
guidelines for food treatment of hypoglycaemia recommend follow-up with longer 
lasting carbohydrate after initial treatment of primary hypoglycaemia (American 
Diabetes Association, 2013c; Asian-Pacific Type 2 Diabetes Policy Group, 2002; 
Canadian Diabetes Association, 2012; Diabetes Education Study Group of the 
European Association for the Study of Diabetes, 1998; Diabetes New Zealand, 2008; 
Diabetes UK, 2011; Singapore Diabetes Society, 2010), and theoretically this would 
minimize the risk of repeat hypoglycaemia within several hours of a primary event, 
however the efficacy of this  is poorly covered in the literature.  
Nocturnal hypoglycaemia and ‘dead in bed syndrome’: Nocturnal hypoglycaemia - 
hypoglycaemia in type 1 diabetes occurs most frequently during sleep and can range 
in severity from asymptomatic mild hypoglycaemia to severe hypoglycaemia 
(American Diabetes Association, 2005).  Wentholdt et al in a study using a glucose 
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sensor showed 33% incidence between 22h and 7h, with bedtime glucose levels as a 
predictor (Wentholt et al., 2007).  
Nocturnal hypoglycaemia has been shown to be associated with ‘dead in bed’ 
syndrome, with ECG QT prolongation with subsequent ventricular tachyarrhythmia 
being a response to nocturnal hypoglycaemia. Gill et al, in a study using CGM and 
ECG in 25 people with type 1 diabetes, showed corrected QT interval was longer 
during nocturnal hypoglycaemia compared with normoglycaemia and that cardiac 
rate and rhythm disturbances were seen in 62% of nocturnal hypoglycaemic 
episodes. They concluded that this may support an arrhythmic basis for the ‘dead in 
bed’ syndrome (Gill, Woodward, Casson, & Weston, 2009). Hsieh and Twigg, in a 
recent review of ‘dead in bed’ syndrome, asserted that  there was growing evidence 
implicating autonomic neuropathy and nocturnal hypoglycaemia as causative factors. 
They asserted that normally during sleep there is less sympathetic activity and 
relatively increased parasympathetic activity, and in diabetes this can combine with 
autonomic neuropathy induced  impaired parasympathetic activity which may be 
associated with arrhythmias and subsequent death (Hsieh & Twigg, 2014).   
Increased risk of cardiovascular disease: Severe hypoglycaemia has been associated 
with increased all-cause mortality and vascular risk. The Veterans Affairs Diabetes 
Trial randomised participants to very intensive or standard treatment and showed a 
large increase in the rate of sudden death in the intensive group, of whom 21% 
experienced severe hypoglycaemia compared to 10% of the conventional group 
(Duckworth et al., 2009). Similarly the ACCORD study randomised participants to 
an even stricter intensive treatment trial and showed rates of severe hypoglycaemia 
of 16.2% in the intensive compared to 5.1% in the conventional group, and a 22% 
increase in relative risk for all-cause mortality in the intensive group (Bonds et al., 
2010). Severe hypoglycaemia imparts a two - fourfold increased risk of CVD. A 
specific mechanism for this increased risk has not been identified (Skyler et al., 
2009). The follow-up to the DCCT, The Epidemiology of Diabetes Interventions and 
Complications study, found a decrease in CVD in association with intensive 
treatment (Nathan, 2014), however a study by Zoungas et al of 11,140 patients with 
type 2 diabetes over 5 y showed severe hypoglycaemia was associated with a 
significant increase in major macrovascular events, major microvascular events, 
death from cardiovascular causes, and all-cause mortality (Zoungas et al., 2010) and 
consistent with this  Stahn et al in a study of 30 people with type 2 diabetes and CVD 
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showed that severe hypoglycaemic events were associated with increased risk of 
severe ventricular arrhythmias (Stahn et al., 2014). Similar results were obtained by 
Zhao et al in a retrospective cohort study over 2 y using the electronic medical 
records of  veterans with type 2 diabetes. They identified 63,003 controls without 
documented hypoglycaemia and  2,187 veterans who had experienced at least one 
hypoglycaemic episode within the targetted period. The hypoglycaemic group had 
significantly higher risks of both cardiovascular events (HR 2.00 [95% CI 1.63–
2.44]) and microvascular complications (1.76 [1.46–2.11]), but no statistical 
difference in mortality. Two or more hypoglycaemic episodes conferred increased 
risk (Zhao, Campbell, Fonseca, & Shi, 2012). Rana et al have suggested 
hypoglycaemia be viewed as another cardiac risk factor (Rana, Byrne, & Greaves, 
2014). 
Neurological risk: Neurologic syndromes are frequent during severe hypoglycaemia 
but usually reversible. Major irreversible brain damage is rare (Halimi, 2010) 
however  cognitive decline and dementia appear to show an association with severe 
hypoglycaemia, at least in type 2 diabetes. Barrou et al are of the opinion that 
cognitive decline is largely related to poor metabolic control rather than 
hypoglycaemia (Barrou, Lemaire, Boddaert, & Verny, 2008). To the contrary, 
Feinkohl et al in a study of 4 y duration on cognition in 831 adults with diabetes aged 
65 - 70 y concluded that there is a complex relationship between cognitive 
impairment and hypoglycaemia with severe hypoglycaemia associated with both 
poorer initial cognitive ability and accelerated cognitive decline (Feinkohl et al., 
2014). Similarly, the Edinburgh study, which investigated 1066 people with type 2 
diabetes, showed that self-reported history of severe hypoglycaemia was associated 
with reduced cognitive ability in later life (Aung et al., 2012).  
Psychological consequences – fear of hypoglycaemia 
Hypoglycaemia is the most common acute complication in type 1 diabetes and is also 
relatively common in advanced type 2 diabetes (Cryer et al., 2003). It can cause 
unpleasant symptoms such as shaking, sweating, drowsiness, nausea, poor 
coordination, confusion, unconsciousness and fitting. Severe hypoglycaemia can 
cause death. It is, therefore, unsurprising that many people with type 1 and advanced   
type 2 diabetes have a significant fear of hypoglycaemia (Wild et al., 2007).  
Fear of hypoglycaemia is an accepted clinical syndrome. It can be measured by the 
use of a specific scale, the Hypoglycaemic Fear Scale (Cox, Irvine, Gonder-
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Frederick, Nowacek, & Butterfield, 1987). Fear of hypoglycaemia has been shown to 
be associated with an individual’s history of hypoglycaemia, duration of insulin 
treatment, and variability of BGL (Wild et al., 2007). Anderbro et al in a study of 
1387 people with type 1 diabetes in Sweden showed the likelihood of an individual 
developing fear of hypoglycaemia was associated with frequency of severe 
hypoglycaemia, hypoglycaemic symptoms during mild hyperglycaemia, also higher 
number of symptoms, female gender, and hypoglycaemic unawareness (Anderbro et 
al., 2010). 
McCoy et al in a cross-sectional analysis via a postal survey of 875 free-living adults 
with type 1 or 2 diabetes in Rochester reported a prevalence of fear of 
hypoglycaemia of  28.3% (type 1) and 16.9% (type 2). A limitation of this study was 
the low response rate (47.8%), however it does give an idea of the extent of the 
problem, especially among those with type 1 diabetes (McCoy et al., 2013). Myers et 
al in a study of 90 people with type 1 diabetes on intensive MDI and CSII  (85.5%) 
reported that 30% of the sample reported fear of death from hypoglycaemia, with 
25.5% of the total sample meeting the criteria for current posttraumatic stress 
disorder (PDS) (Myers, Boyer, Herbert, Barakat, & Scheiner, 2007). This prevalence 
of fear of hypoglycaemia induced PDS is slightly higher than identified PDS in 
Veterans of the Vietnam war (24.7%) (O'Toole, Catts, Outram, Pierse, & Cockburn, 
2009).  
The extent of the impact of fear of hypoglycaemia can be measured by a newly 
developed subscale of the Hypoglycaemic Fear Survey (Gonder-Frederick et al., 
2013). It has been shown that the consequences of fear of hypoglycaemia can impact 
on diabetes control, self-treatment and lifestyle (Leiter, 2005). There is also evidence 
that fear of hypoglycaemia increases the risk of an individual keeping BGL high to 
avoid hypoglycaemic episodes, which then contributes to impaired diabetes control 
(Bohme, Bertin, Cosson, & Chevalier, 2013; Wild et al., 2007).  
Bohme et al in an observational cross-sectional study of 485 people with type 1 
diabetes showed that fear of hypoglycaemia had a major impact on quality of life 
(Bohme et al., 2013) and as such further research is needed, especially in the area of 
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2.2.8 Alcohol and hypoglycaemia 
 
Alcohol acts to inhibit gluconeogenesis and glyconeogenesis. Post alcohol 
consumption, the dehydrogenation of alcohol by means of alcohol dehydrogenase 
using NAD
+
 generates increased quantities of NADH which leads to reduced liver 
gluconeogenesis which decreases glucose 6-phosphate. Despite reduced liver 
gluconeogenesis, glucose output from the liver does not decrease significantly due to 
compensation which converts glycogen to glucose by glycogen phosphorylase. This 
depletes glycogen stores in the liver. Decreasing glucose 6-phosphate activates the 
glycogen phosphorylase. Some hours post alcohol metabolism gluconeogenesis in 
the liver returns to normal which restores glycogen stores. In the healthy person 
insulin secretion will decrease to prevent BGL falling, but in the insulin-treated 
individual insulin level is not able to respond by decreasing so there is a drop in BGL 
with resulting putative hypoglycaemia, the magnitude of the drop being dependent 
on the amount of alcohol consumed. By this mechanism the drop in BGL and 
hypoglycaemia are necessarily some hours after alcohol consumption (Evans, Kerr, 
& Flanagan, 2006; Plougmann, Hejlesen, Turner, Kerr, & Cavan, 2003; van de Wiel, 
2004; Verlohren, 1981). This process does not occur in diet-treated people with type 
2 diabetes but does occur with treatment by insulin secretagogues which potentiate 
insulin release (Pietraszek, Gregersen, & Hermansen, 2010; Rasmussen, Orskov, 
Schmitz, & Hermansen, 2001; van de Wiel, 2004). 
Confirming this in the practical arena, a study involving 16 free-living people with 
type 1 diabetes given vodka (0.85 g/kg) or placebo and monitored with CGM for 36 
h on 2 occasions reported twice as many hypoglycaemic episodes for the 24-h post-
consumption in those who had drunk vodka compared to placebo (Richardson, 
Weiss, Thomas, & Kerr, 2005). In a similar smaller shorter-term study, 6 men with 
type 1 diabetes were admitted as inpatients on 2 different occasions, given basal and 
preprandial insulin, a standard meal and either white wine (0.75 g/kg alcohol) or 
mineral water. Evening and overnight BGL were the same in both groups but 
significantly lower in the morning in the wine group as compared to the mineral 
water group, although no subject suffered hypoglycaemia (Turner, Jenkins, Kerr, 
Sherwin, & Cavan, 2001). 
Moderate and high doses of alcohol impair cognitive function. A study by Magrys et 
al investigating cognitive skills mediated by frontal and temporal brain regions in 
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healthy subjects showed that alcohol impaired sustained attention in males and verbal 
memory in both genders, exhibiting a U-shaped pattern, with those drinking 
moderate amounts of alcohol exhibiting the greatest impairment (Magrys & 
Olmstead, 2014). There is a complex relationship between cognitive impairment and 
hypoglycaemia with severe hypoglycaemia being shown to be associated with poorer 
cognitive ability older people with diabetes (Feinkohl et al., 2014). Alcohol has been 
shown to be a major contributor in the occurrence of severe hypoglycaemia in 
insulin-treated diabetes (Krnacova et al., 2012). So what is the effect on cognitive 
function when alcohol and hypoglycaemia are combined? Cheyne et al in an insulin 
clamp study investigated alcohol, hypoglycaemia and cognitive performance in 17 
subjects with insulin-dependent diabetes. Cognitive function assessment was for 
reaction time, general intellectual skills, digit symbol substitution and visual 
information processing. They also tested hazard perception with respect to driving 
performance. The results showed that alcohol and hypoglycaemia independently 
impair cognitive function and their effect together is additive. With respect to driving 
ability, participants had blood alcohol levels below the UK legal driving limit, yet 
there was impaired reaction time (Cheyne et al., 2004). 
Alcohol has been shown to be a major contributor in the occurrence of severe 
hypoglycaemia and also death. A study investigating the incidence of severe 
hypoglycaemia requiring admission for Emergency Services over a 1 y period in the 
Czech Republic identified alcohol as one of the major causes (Krnacova et al., 2012) 
and a study in Finland investigating trends in mortality showed that in people with 
type 1 diabetes diagnosed aged 15-29 y, 39% of deaths during the first 20 y of 
diabetes were from alcohol and drug-related causes (Harjutsalo & Forsblom, 2011). 
Finally, a retrospective audit of presentations with severe hypoglycaemia over a year, 
to a major hospital in the UK showed 10.2% causation by alcohol ingestion (Parfitt 
& Bhake, 2012). 
2.2.9  Hypoglycaemia in inpatients in the general ward 
General ward inpatients 
Those with diabetes have a greater frequency of hospitalization and greater length of 
stay in hospital than people without diabetes (Moghissi et al., 2009). Hypoglycaemia 
is not uncommon in general ward inpatients with diabetes treated with insulin or 
insulin secretagogues. An accurate assessment of the extent of hypoglycaemia in 
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these inpatients is difficult to make due to lack of consensus on the definition of 
hypoglycaemia (see section 8.3) and differing methods of data collection between 
hospitals (Eiland, Goldner, Drincic, & Desouza, 2014), however it seems clear that 
inpatient hypoglycaemia is associated with both increased mortality, during and post-
admission, and also increased length of hospital stay.  
Turkin et al in a retrospective cohort study audited 4,368 admissions of 2,582 
patients with diabetes hospitalized in the general ward over an 18-m period and 
documented hypoglycaemia in 7.7% of those admitted. They showed an association 
between each additional day with a hypoglycaemic event and an increase of 85.3% 
and 65.8% in the odds of inpatient death and death within 1 y post-discharge, 
respectively  (Turchin et al., 2009). Similarly Brodovicz et al retrospectively 
investigated 107,312 admissions of insulin-treated patients, hospital stay  ≥ 24 h and 
≤ 30 d over 2 y and reported hypoglycaemia/severe hypoglycaemia in 20%/7%, 
respectively. The rate of inpatient mortality was 6.5%/7.6% in those with 
hypoglycaemia/severe hypoglycaemia and 3.8% in those without. Length of hospital 
stay was 8.2 d with hypoglycaemia compared to 5.2 d without (Brodovicz et al., 
2013). Kim et al carried out a retrospective review of 1276 admissions where insulin 
was administered, 35% of patients experienced hypoglycaemia and they showed that 
hypoglycaemia was strongly associated with increased length of hospital stay and 
other adverse outcomes, more so than glycaemic variability (Kim, Rajan, Sims, 
Wroblewski, & Reutrakul, 2014). However Mendez et al, in a retrospective audit of 
4,262 admissions over 2 y, showed that increased glycaemic variability was 
independently associated with longer length of hospital stay and increased mortality 
(Mendez et al., 2013).  A case control study of 130 patients identified higher rates of 
hypoglycaemia with 65 (50 %) experiencing at least one episode of hypoglycaemia 
and 17% of severe hypoglycaemia (Maynard, Huynh, & Renvall, 2008). Kerry et al, 
in a bedside audit of BGL of 164 patients on insulin or sulphoylurea agents, 
identified an even higher proportion experiencing hypoglycaemia (74%), and also 
reported that 70% of hypoglycaemic events had occurred between 9pm and 9am 
(Kerry, Mitchell, Sharma, Scott, & Rayman, 2013) while Deusenberry et al in a case-
control study involving 234 cases and controls treated with sulphonylurea agents 
reported 19% of patients experiencing hypoglycaemia (Deusenberry, Coley, 
Korytkowski, & Donihi, 2012). Boucai et al retrospectively studied 31,970 patients 
admitted to general wards over 1 y and reported similar rates of hypoglycaemia as 
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Turchin et al (10.5%) but on stratification into subgroups of spontaneous or drug-
associated hypoglycaemia, reported that, after adjustment for comorbidities, neither 
drug-associated nor spontaneous hypoglycaemia were associated with increased 
mortality. They concluded that the hypoglycaemia might be a marker of disease 
burden rather than the direct cause of death (Boucai, Southern, & Zonszein, 2011).  
Rates of hypoglycaemia are demonstrably higher in general inpatients than in free-
living individuals (see section 2.2.5) and Eiland et al reason that illness gives 
variable insulin sensitivity which increases risk of hypoglycaemia in these inpatients 
(Eiland et al., 2014). Maynard et al in their case control study assessed the risk 
factors for general inpatient hypoglycaemia as prior inpatient hypoglycaemia, 
mismatch of insulin and nutrition, nutritional interruption and poor adherence to 
hypoglycaemia management and documentation (Maynard et al., 2008) and 
Anthony, in a retrospective case review of 484 inpatients with hypoglycaemia 
highlighted adherence to practice guidelines and poor documentation as major 
problems (Anthony, 2007). Elliott et al carried out a study to identify risk factors for 
severe hypoglycaemia and based on this developed an algorithm to predict severe 
hypoglycaemia. Risk factors identified were inadequate monitoring of trends in BSL, 
mismatch of diabetes treatment and nutrition, excessive insulin,  nursing errors, and 
insufficient glucose with insulin for the acute treatment of hyperkalemia, many of the 
same factors identified by Maynard et al (M. B. Elliott, Schafers, McGill, & Tobin, 
2012). Kerry et al in their charting of a diurnal pattern of hypoglycaemia theorised 
the risk factor for this was lack of carbohydrate to balance insulin at this time, 
essentially, again, an insulin food mismatch (Kerry et al., 2013). Patients treated with 
sulphonylureas exhibited a different pattern, with all risk factors relating to failure to 
clear sulphonylurea medication through the kidneys (age  ≥ 65 y and reduced GFR) 
and also potentiation of medication effect (longer-acting sulphonylurea and 
concurrent intermediate or long-acting insulin). The authors concluded that 
sulfonylureas should be avoided or used with caution in these situations 
(Deusenberry et al., 2012).   
Patients in the general ward on nasogastric feeding 
It is well documented that hyperglycaemia in inpatients is independently  associated 
with increased morbidity and mortality, increased length of hospital stay and 
increased cost (Lleva & Inzucchi, 2011; Moghissi et al., 2009). Therefore the bulk of 
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the literature on inpatients on nasogastric feeding focusses on factors, mainly feed 
types, designed to reduce hyperglycaemia, especially post-prandial hyperglycaemia 
(Elia et al., 2005), with the emphasis on nasogastric feeding products designed to 
blunt the postprandial blood glucose response (Alish et al., 2010; Vanschoonbeek et 
al., 2009).  
In the general situation, the IDF recommends the consumption of foods with a low 
glycaemic index and preferably a low glycaemic load to improve postprandial 
glycaemia (Ceriello & Colagiuri, 2008). However Wolever et al have cast some 
doubt on the efficacy of this with a long-term study of free-living people with type 2 
diabetes who showed no improvement in HbA1c after 12 m on a low GI diet 
compared to a high GI diet (Wolever et al., 2008). In addition to this, for those on 
bolus nasogastric feeding, it is difficult to retain sufficient feed volume to allow 
adequate energy intake and also reduce glycaemic load (which is partially dependent 
on quantity of carbohydrate), while using standard nasogastric feed products which 
have traditionally been  high in carbohydrate and low in fat (Elia et al., 2005). For 
this and other reasons, diabetes specific-feeds (DSF) for enteral feeding have been 
developed. These products less contain less carbohydrate (35 - 40% of energy), more 
fat (40 - 50% of energy), with a high proportion of monounsaturated fatty acids 
(Vanschoonbeek et al., 2009). This runs contrary to the recommendations from the 
Evidence-Based Nutritional Approaches To The Treatment And Prevention Of 
Diabetes of the EASD, which specifies that in diabetes total fat intake should not 
exceed 35% of total energy (Mann et al., 2004), but not to the Evidence-Based 
Nutrition Principles and Recommendations for the Treatment and Prevention of 
Diabetes and Related Complications of the ADA which specify, more practically, 
that carbohydrate and monounsaturated fat together should provide 60 - 70% of total 
energy (Franz et al., 2003). 
There are many studies comparing the efficacy of standard versus DSF in those with 
diabetes. Elia et al conducted a meta-analysis that included 23 studies of oral 
supplements and nasogastric feeding (7 studies), most of which compared standard 
formulas with DSF. The results showed that the DSF, in the main, reduced 
postprandial glycaemia  and insulin requirements compared to standard feeds (Elia et 
al., 2005). Additional studies since the meta-analysis was published in 2005 have 
shown similar results. Alish et al used CGM to compare two different formula feeds 
in 12 patients with diabetes on enteral feeding. Subjects were fed 5 d of standard feed 
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and 5 d of DSF with assessment endpoints being postprandial glycaemia and 
insulinemia, glycaemic variability and mean glucose. They concluded that relative to 
the standard formula the DSF reduced all endpoints (Alish et al., 2010). 
Vanschoonbeek et al compared two formulas in a randomized, double-blind, 
crossover study involving 15 people with  type 2 diabetes and showed  peak plasma 
glucose was significantly lower and plasma insulin responses were lower without 
increasing the plasma triglyceride response with the DSF when compared with the 
standard formula (Vanschoonbeek et al., 2009) and Ceriello et al conducted a similar 
study in 12 people with type 2 diabetes showing lower individual and mean glucose 
peaks and less hyperglycaemic time over 24 h (Ceriello, Lansink, Rouws, van Laere, 
& Frost, 2009), as did Mori et al using CGM and concluding that a low carbohydrate 
feed improves postprandial and fasting BGL and decreases glucose variability (Mori 
et al., 2011) and Vaisman et al who showed over 12 weeks that postprandial glucose 
response and HbA1c were lower on a DSF compared to a standard enteral feed 
(Vaisman et al., 2009). Hofman et al compared three enteral feed products in a 
similar situation to Ceriello et al and showed both lower carbohydrate feeds  gave 
lower glucose peaks and triglyceride levels (Hofman, Lansink, Rouws, van Drunen, 
& Kuipers, 2007) and in a similar study, Voss et al concluded that two lower 
carbohydrate DSF’s resulted in a lower postprandial BGL compared to a standard 
feed (Voss et al., 2008). As can be seen, major endpoints in all these studies were 
measures of hypergycaemia, glucose variability and lipid levels.  
In addition, many of these studies were of short duration, for example, 4 h 
(Vanschoonbeek et al., 2009; Voss et al., 2008), 6 h (Hofman et al., 2007) and 24 h 
(Ceriello et al., 2009; Mori et al., 2011). Short-term comparative studies of enteral 
feed products can give robust evidence of the hyperglycaemic effect of products but  
are not of sufficient duration to accuractly identify the hypoglycaemic effect, which 
has a more complex etiology (Eiland et al., 2014; Elliott et al., 2012; Maynard et al., 
2008).    
Stagnaro-Green et al investigated the mortality associated with both hyper and 
hypoglycaemia in a prospective audit of inpatient charts over 49 d and showed that 
compared with the mortality rate for general hospital patients of 2.3%, the mortality 
rate of hyperglycaemic patients was 11.1% and the mortality rate for hypoglycaemic 
patients was double this (22.2%) (Stagnaro-Green et al., 1995). There are many 
studies addressing hyperglycaemia in people with diabetes on nasogastric feeding in 
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the general ward but although hypoglycaemia is associated with a higher mortality 
rate, there is a dearth of information on this topic.  
2.3     Summary 
This chapter has reviewed ongoing research in the area of hypoglycaemia in diabetes 
and diabetes-related states and identified key areas where information is lacking in 
with respect to dietary treatment of hypoglycaemia.  
NGT with elevated 1-h glucose is not formally recognized as prediabetes, but 
research has shown it to be associated with a high risk of progression to diabetes with 
associated increased  risk of both vascular disease and all-cause mortality. Fasting 
and 2-h glucose levels are normal in this condition but BGL exceeds normal 
physiological levels at 1-h postload,  subsequently dropping rapidly within 30 min, 
yet despite this, identification and dietary treatment of  hypoglycaemia or relative 
hypoglycaemia in NGT and elevated 1-h postload glucose has not been documented.   
 The normal  physiology of hypoglycaemia is well documented, as are the 
mechanisms of iatrogenic hypoglycaemia in diabetes, with much current research 
focussing on hypoglycaemia associated autonomic failure. Similarly, the level of 
BGL defining hypoglycaemia is well-researched but a consensus on a definitional 
level is yet to eventuate. Literature reports have highlighted the longer-term 
consequences of hypoglycaemia, both physical and psychological, with 
hypoglycaemia being shown to be associated with increased risk of ongoing 
hypoglycaemia and also cardiovascular disease. Severe hypoglycaemia has been 
shown to be associated with all-cause mortality and a complex relationship with 
cognitive impairment is slowly being unravelled. The psychological effects of 
hypoglycaemia are the subject of continuing research, with the development of the 
Hypoglycaemic Fear Scale allowing better assessment of its severity. 
Ongoing research has enabled the development of more physiological insulin-types, 
analog insulins, and insulin-delivery systems that allow delivery of insulin in patterns 
that better mimic the normal situation. However, although these research-driven 
innovations can decrease the incidence of hypoglycaemia, they cannot eliminate it 
and dietary treatment remains the cornerstone of successful resolution of a 
hypoglycaemic event. The evidence base for dietary treatment of hypoglycaemia is 
not, however, well-researched, relying on expert opinion and laboratory based 
assessments using pre-analog or intravenous insulin. There is a dearth of studies 
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investigating optimum recommendations for dietary treatment and current dietary 
patterns in treatment of hypoglycaemia with the effect of this treatment on repeat 
hypoglycaemia also poorly researched.  
Situational factors can increase hypoglycaemic risk for the person with diabetes. 
Alcohol ingestion in the presence of exogenous insulin has been shown to increase 
the risk of sustained hypoglycaemia. The mechanism and consequences of this are 
both well-researched, with several recent studies utilizing CGM demonstrating an 
increase in risk lasting 24 h post-alcohol consumption. This is crucial information for 
those with type 1 diabetes, however there is little published  information  assessing 
the extent of their knowledge in this area, or assessing the content of relevant easily 
accessed educational material on this topic.  
Being hospitalized also increases hypoglycaemic risk, with numerous studies 
showing that hypoglycaemia is common among inpatients with diabetes and is 
significantly associated with both increased length of hospital stay and mortality. 
Those on nasogastric feeding in the general ward situation are potentially particularly 
vulnerable to this, and despite many studies identifying beneficial feed products and 
insulin regimes, there is a dearth of studies investigating hypoglycaemia in this 
population. 
Optimal dietary treatment is crucial to the swift and effective resolution of 
hypoglycaemia, and research findings that increase knowledge of current dietary 
practices highlight areas where interventions may be beneficial. The gaps in the 
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CHAPTER 3:   RELATIVE HYPOGLYCAEMIA, DIET AND ELEVATED 
ONE-HOUR POSTLOAD GLUCOSE.   
3.1 Significance of study 
3.1.1 Identification of relative hypoglycaemia in elevated 1-h postload glucose  
Individuals with NGT and elevated 1-h BGL do not fit the criteria for pre-diabetes; 
their fasting blood glucose is < 6.1 mmol/L, their 2-h glucose is < 7.8 mmol/L  and 
their HbA1c < 5.7% (American Diabetes Association, 2013c). However because of 
their normal fasting and 2-h value in conjunction with their elevated 1-h level (> 8.6 
mmol/L, > 10 mmol/L or > 11.0 mmol/L according to the different criteria), they 
exhibit enhanced glycaemic variability, with a spike in glucose at 1 h and then a 
rapid fall to normal levels by 90 min (Yen et al., 2008). A study by Yen et al  
recorded a fall from 1 h to 2 h of mean amplitude of the order of 6 mmol/L (Yen et 
al., 2008). Similarly, a study by Harada et al observed a mean amplitude of a similar 
order (5.3 mmol/L) (Harada et al., 2008). Kang et al  in a study of 81 individuals 
with different subtypes of impaired glucose intolerance undergoing an OGTT 
showed a mean amplitude in those with IGT of (3.2 ± 1.2) mmol/L, which was 
significantly higher than in those with NGT (1.6 ± 0.5) mmol/L, and significantly 
lower than those with type 2 diabetes (5.2 ± 1.9) mmol/L (Kang et al., 2009). The 
amplitude and timescale of the fall in blood glucose observed over 30 minutes by 
those with 1-h elevated post-load glucose is similar in magnitude and timing to those 
with type 2 diabetes and also to falls in blood glucose recorded in those experiencing  
hypoglycaemia. For example, a recent study by Bergenstal et al investigating insulin-
pump interruption for reduction of hypoglycaemia in people with type 1 diabetes, 
recorded mean nocturnal hypoglycaemic amplitudes of  4.8 ± 0.65 mmol/L in control 
subjects (± 13.6% error as values obtained from continuous glucose monitoring 
system (CGMS)) with mean duration of 39.4 min (Bergenstal et al., 2013). Similarly 
Fanelli et al, in a study of 11 subjects with type 1 diabetes observed a mean 
hypoglycaemic fall in blood glucose of approximately 4 mmol/L over approximately 
40 minutes (Fanelli et al., 2003). In those with NGT and 1-h elevated glucose, this 
fall in BGL is not classifiable as hypoglycaemia (defined as an event during which 
typical symptoms of hypoglycaemia are accompanied by measured glucose ≤ 3.9 
mmol/L (Seaquist et al., 2013)) but is consistent with relative or pseudo 
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hypoglycaemia (defined as an event with typical symptoms of hypoglycaemia with a 
measured glucose > 3.9 mmol/L, but approaching this level (Seaquist et al., 2013)).  
Do those with NGT and elevated 1-h glucose experience hypoglycaemic symptoms?  
Fanelli et al showed a significant increase in counterregulatory response and thus 
symptoms, with a fast fall in blood glucose level (0.1 ± 0.003 mmol/L/min) as versus 
a slow fall (0.03 ± 0.003 mmol/L/min) (Fanelli et al., 2003) . Those with NGT and 1-
h elevated postload glucose demonstrate this fast fall in blood glucose, for example, 
Yen et al observed a fall of 6 mmol/L in 60 minutes (Yen et al., 2008). It would 
therefore be a reasonable expectation that they would exhibit symptoms. The 
following paper is a (partly retrospective and partly prospective) case study. It 
reports relative hypoglycaemia in an individual with NGT and elevated 1-h glucose. 
Relative hypoglycaemia in this context has not been previously reported in the 
literature. 
3.1.2 Normalisation of glucose variability in elevated 1-h postload glucose 
Glycaemic variability in elevated 1-h postload glucose 
Cubeddu et al showed that NGT with 1-h elevated glucose was associated with 
greater postload glycaemia and hyperinsulinaemia than in those with ‘true’ NGT, 
thus potentially creating a state of enhanced glucose variability (Cubeddu & 
Hoffmann, 2010). Glycaemic variability in those with elevated postload glucose was 
investigated by Su et al in a study comparing 29 subjects with NGT and 1-h postload 
glucose ≥ 8.6 mmol/L and 29 age and sex matched controls with NGT and 1-h 
glucose < 8.6 mmol/L. They showed that those with NGT and 1-h glucose ≥ 8.6 
mmol/L had increased glycaemic variability compared to those with NGT and 1-h 
glucose < 8.6 mmol/L (Su et al., 2013). Madhu et al using CGMS demonstrated 
progressively increasing glucose variability in evolving pre-diabetes (Madhu, 
Muduli, & Avasthi, 2013) and Kang et al, similarly using CGMS showed the 
amplitude of glycaemic excursion was lower in those with NGT than in those with 
type 2 diabetes  but the frequency of glycaemic excursion was greater, and concluded 
that the deterioration in postprandial blood glucose levels preceded deterioration in 
fasting blood glucose levels (Kang et al., 2009).  
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Consequences of increased glycaemic variability 
In those with NGT and elevated 1-h glucose, increased glycaemic variability has 
been shown to be consistently associated with indicators of declining β-cell function 
(Su et al., 2013). Similarly, glucose variability per se has been shown to affect β - 
cell function with Luo et al showing that fluctuating glucose inhibited β-cell function 
more than sustained hyperglycaemia (Luo et al., 2013). In those with diabetes, 
increased glucose variability has been shown to be associated with increased free 
radical production which was not associated with 24-h mean glucose, fasting plasma 
glucose levels, or HbA1c (Devaraj, Hirany, Burk, & Jialal, 2001). Glucose variability 
in those with type 2 diabetes has also been associated with vascular endothelial 
dysfunction (Torimoto, Okada, Mori, & Tanaka, 2013), severity of coronary artery 
disease (Su et al., 2011) and increased activation of oxidative stress (Zheng et al., 
2010). Similar effects have been shown in IGT (Chen et al., 2013; Zheng et al., 
2010). A study by Meynaar et al in critical care patients showed glucose variability 
was related to all-cause mortality irrespective of diabetic state.  
Treatment of glucose variability in 1-h elevated postload glucose 
Lifestyle and dietary changes have long been recommended in the official pre-
diabetic states (IFG and IGT) with a view to prevention of progression to diabetes 
and minimisation of vascular complications recognised as being associated with pre-
diabetes (Unwin, Shaw, Zimmet, & Alberti, 2002a). There have, however, been no 
such consensus recommendations for NGT with elevated postload glucose. Wang et 
al, in a recent study of glucose fluctuations in NGT (1-h level unspecified), IGT and 
type 2 diabetes, identified glucose fluctuations present in all three states gradually 
increasing from NGT to type 2 diabetes. Although not specifying NGT with elevated 
1-h glucose, per se, they recommended early diet and lifestyle interventions with a 
view to minimizing glucose variability  (Wang et al., 2012). Zhou et al in a study of 
glucose variability in healthy Chinese adults identified the 95th percentiles of the  
mean amplitude of glycaemic excursions  as 3.86 ± 1.40 mmol/L and, based on this, 
suggested a normal reference range for glycaemic variability of < 3.9 mmol/L be 
adopted (Zhou et al., 2011). There is no documented evidence yet of application of 
lifestyle or dietary interventions in NGT with elevated 1-h postload glucose. 
 The following paper demonstrates the success over 4 years of interventions to 
normalise glucose variability in a woman with 1-h elevated postload glucose. 
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3.1.3 Relative hypoglycaemia, hunger and weight gain  
It is well documented that hunger is associated with hypoglycaemia in diabetes 
(Lawton et al., 2013) and induced hypoglycaemia in healthy subjects has been shown 
to increase subjective reports of hunger (Rodin, Wack, Ferrannini, & DeFronzo, 
1985). Schmid et al, in a study of induced hypoglycaemia in 16 healthy subjects, 
showed that a linear drop in blood glucose level over 60 min to 2.2 mmol/L 
stimulated spontaneous food intake 4+ h later, with carbohydrate intake being 
especially affected (Schmid et al., 2008). It has also been shown that spontaneous 
meal initiations were triggered by a transient decline in blood glucose level within 
the normal range in healthy adults (Melanson, Westerterp-Plantenga, Saris, Smith, & 
Campfield, 1999). In NGT with elevated 1-h postload glucose there is a spike in 
glucose at 1h and then a rapid fall to normal levels by 120 min (Yen et al., 2008).  
Although not documented in the literature, it is postulated that this would lead to 
increased hunger due to the rapid fall in glucose, and further that this would involve 
putative increased energy intake resulting in weight gain, thus increasing the risk of 
progression to diabetes in these individuals who are already at high risk. 
Normalization of this fall in blood glucose should decrease hunger and putative 
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3.2 Expanded results 
The figure below presents expanded results from published Paper 1, which presented 
data on meal composition and relative change in blood glucose from time 0 
(preprandial level) to1h post-meal consumption under different treatment and dietary 
regimens. The treatments were not provided in randomised order. The graphs below 
present absolute blood glucose levels measured at 0, 1h and 2h, with 3 
measurements/meal/regimen, which visually illustrates the marked  1h ‘spike’. 
Analysis was performed using SPSS Statistics, v22,IBM Corporation, NY, USA. 
 
 
Figure 3.1a)   Blood glucose profiles for standard meal 1 (42 g carbohydrate) for 
 four different treatments: 1 - untreated; 2 - sitagliptin; 3 - short-acting insulin; 




                                  
 




Figure 3.1b)   Blood glucose profiles for standard meal 2 (28 g carbohydrate) for 
 four different treatments: 1 - untreated; 2 - sitagliptin; 3 - short-acting insulin; 
4 - low carbohydrate. 
 




Figure 3.1c)   Blood glucose profiles for standard meal 3 (35 g carbohydrate) for 
 four different treatments: 1 - untreated; 2 - sitagliptin; 3 - short-acting insulin; 








Figure 3.1d)   Blood glucose profiles for standard meal 4 (25 g carbohydrate) for 
 four different treatments: 1 - untreated; 2 - sitagliptin; 3 - short-acting insulin; 











  - 60 - 
 
3.3  Paper 1  
Vindedzis SA, Marsh B, Sherriff JL, Dhaliwal SS, Stanton KG. Low carbohydrate 
meals or a small dose of insulin normalises one-hour blood glucose in a woman with 
normal glucose tolerance and elevated one-hour postload glucose: a case report. The 
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Diabetes is diagnosed by 2-hour BGL ≥ 11.1 mmol/L on 
OGTT, fasting BGL ≥ 7.0 mmol/L or HbA1C ≥ 6.5%.1 IFG 
and IGT are similarly diagnosed by elevated fasting and 
2-hour BGLs.1 Although 1-hour BGL is routinely mea-
sured, results are classified as NGT if fasting and 2-hour 
levels are normal, irrespective of elevation at 1 hour. It 
has, however, been shown that 1-hour postload BGL is a 
strong predictor of future risk for type 2 diabetes and 
vascular disease, even in those with NGT.2,3 Additionally 
Meisinger et al. identified 1-hour postload glycaemia as a 
long-term predictor for all-cause mortality in men with-
out diabetes.4 There is no normal range for 1-hour glu-
cose, but ≥ 8.6 mmol/L has been identified as a cut-off 
marking increased cardiovascular and diabetes risk.2,3,5 It 
has been suggested that recognition and management of 
those with NGT and 1-hour glucose ≥ 8.6mmol/L may 
reduce incidence of diabetes and vascular events.3,4
This case report has been approved by Curtin University 
Human Research Ethics Committee, an institutional eth-
ics committee, and a consent form has been signed.
Case report
A.J., a 59-year-old Caucasian woman, had noted ele-
vated BGLs soon after eating for about 10 years. In 2005 
her OGTT showed a 1-hour level of 8.0 mmol/L with 
normal fasting and 2-hour levels (4.5 and 4.7 mmol/L 
respectively). When repeated in 2008 her BGL reached 
11.7 mmol/L at 1 hour and was down to 7.2 mmol/L by 
2 hours. Concurrent assessment of serum insulin 
showed a 1-hour level of 73 mU/L, remaining elevated at 
2 hours (27 mU/L). SBGM had shown normal fasting 
levels on most occasions, but had risen to 6–8 mmol/L 
with acute illness. One-hour postprandial levels were 
often above 10 mmol/L when she ate a carbohydrate-
containing meal. Apart from postprandial hyperglycae-
mia A.J. had no other vascular risk factors and did not 
fit criteria for metabolic syndrome. She had a raised 
LDL which responded to Lipitor but no evidence of a 
metabolic dyslipidaemia. Her blood pressure was 
100/70. Until 2008 A.J. had noted increased postpran-
dial hunger resulting in slow weight gain, although her 
BMI remained well within the normal range (2001, 60 
kg, 20.5; 2008, 64.3 kg, 22.3).
Repeat SBGM over four standard meals showed a 
1-hour postload rise significantly associated with meal 
carbohydrate quantity (p=0.024) but not glycaemic index 
(p=0.51) (Table 1). Mean 2-hour postload drop was 
5.6±2.6 mmol/L.
A.J. commenced sitagliptin but after 4 months of 
treatment felt there was insufficient change in her 1-hour 
levels to warrant continuing. She elected to limit carbo-
hydrate intake in most meals (5-10 g/meal) and use a 
small dose of short-acting insulin (½−1½units) before 
those meals when she elected to have more carbohydrate. 
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BGL  blood glucose level
BMI  body mass index
HbA1C  glycated haemoglobin A1C
IFG  impaired fasting glucose
IGT  impaired glucose tolerance
NGT  normal glucose tolerance
OGTT  oral glucose tolerance test
SBGM  self blood glucose monitoring
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Mean repeat SBGM results are shown in Figure 1. 
Repeated measures ANOVA showed a significant differ-
ence between 1-hour postload rise for low carbohydrate 
and insulin-treated meals compared with no treatment 
or sitagliptin (p<0.001); there was no significant differ-
ence between no treatment and sitagliptin (p=0.26). On 
her current regime postprandial hunger has diminished 
with 3.6 kg weight loss over 4 years.
Discussion
The significance of elevated postload 1-hour BGL is cur-
rently being debated. Whereas a diagnosis of IFG/IGT 
elicits advice on diabetes risk, diet, exercise and, more 
recently, metformin,7 NGT with 1-hour BGL ≥ 8.6 
mmol/L is classified normal and no preventative mea-
sures taken, despite evidence that these individuals have 
Table 1. Standard meals: content, carbohydrate load, glycaemic index and mean 1-hour postload rise in blood glucose.
Stndard meal Foods CHO (g) GI 1-h BGL mmol/L
Meal 1 1½ slice mixed grain toast 41.8 47.8 8.2±1.8
 1 dsp dairy soft  
 1 dsp apricot jam  
 70 mL orange juice  
 Coffee + 50 mL soy milk  
Meal 2 Long wheat roll 28.2 59 7.7±0.9
 Mixed green salad  
 45 g cheese  
Meal 3 Cannellini vegetable casserole 34.9 48.3 6.8±2.9
 2 tbsp basmati rice  
 Green salad  
 Naan bread – palm sized  
 80 mL dry wine  
Meal 4 1 mixed grain toast 25.1 46.1 3.9±0.9
 1 dsp dairy soft  
 2 tsp vegemite  
 80 mL orange juice  
 ¼ apple  
Key: CHO: carbohydrate; dsp: dessert spoon; GI: glycaemic index; 1-h BGL: mean rise blood glucose
1-hour postload.
Carbohydrate content from Foodworks 7, Xyris Software (Aust) Pty Ltd 2012, Qld, Australia.
GI from Atkinson FS et al.6
Figure 1. Mean rise in 1-hour postload blood glucose level (BGL) following four standard meals.
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an atherogenic profile similar to those with IGT5 and a 
similarly increased risk of type 2 diabetes.2
We have described a case where two relatively straight-
forward interventions resulted in normalisation of ele-
vated 1-hour postload BGL. Surprisingly sitagliptin, 
which has demonstrated positive effects on first phase 
insulin secretion,8 had relatively little effect, although 
there was a trend to decreased 1-hour BGL with increased 
carbohydrate load. Our subject therefore chose a combi-
nation of mainly low carbohydrate meals combined with 
a small insulin dose before meals with > 10 g carbohy-
drate. One possible pitfall of low carbohydrate diets is 
increased saturated fat intake, but with proper design, 
this can be avoided. Such diets generally have good sati-
ety and acceptance, although there is some evidence that 
adherence decreases over time.9 Insulin treatment is 
more intrusive. A small dose before carbohydrate-con-
taining meals only, minimises the risk of hypoglycaemic 
episodes, but still entails the necessity of SBGM. Our 
subject additionally noted that treatment appeared to 
reduce her postprandial hunger, thus facilitating weight 
loss. Her insulin profile at OGTT was consistent with 
Harada’s thesis of decreased early phase insulin secretion 
giving rapid postprandial rise in BGL thus exaggerated 
second phase insulin response resulting in a rapid fall in 
BGL to normal levels by 90 minutes.10 Her resulting 
postload drop at 2 hours is consistent with relative hypo-
glycaemia11 and could well result in hunger and putative 
weight gain.
Cubeddu et al. showed that 8.3% of those with NGT 
have1-hour BGL ≥ 8.6 mmol/L,3 so this condition is not 
unusual, but treatment of it is. This case demonstrates a 
practical intervention effective over 4 years. A case series 
is now needed to further investigate this.
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CHAPTER 4: GUIDELINES FOR FOOD TREATMENT OF 
HYPOGLYCAEMIA IN INSULIN-REQUIRING DIABETES     
4.1 Background to study  
4.1.1 The present guidelines  
First-line treatment for hypoglycaemia in the conscious person is dietary. 
Recommendations for self-treatment of hypoglycaemia are primarily made by 
national diabetes associations. General recommendations are fairly consistent 
worldwide: initial treatment with carbohydrate, preferably quickly absorbed, and 
eventual follow-up with longer lasting carbohydrate (American Diabetes 
Association, 2013c; Asian-Pacific Type 2 Diabetes Policy Group, 2002; Canadian 
Diabetes Association, 2012; Diabetes Education Study Group of the European 
Association for the Study of Diabetes, 1998; Diabetes New Zealand, 2008; Diabetes 
UK, 2011; Singapore Diabetes Society, 2010). 
There is, however, less consensus on quantitative dietary treatment of 
hypoglycaemia, with recommendations for quantity of carbohydrate for initial 
treatment varying from 15 - 30 g (see Table 4.1) and recommendations for wait-time 
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Table 4.1 Recommendations for initial treatment of hypoglycaemia  
 
Amount Carbohydrate (g) Recommended By: 
15  Diabetes Australia (Diabetes Australia, 2009)  
 Singapore Diabetes Association (Singapore 
Diabetes Society, 2010) 
 Diabetes New Zealand (Diabetes New Zealand, 
2008) 
15 - 20  Diabetes UK (Diabetes UK, 2011) 
 American Diabetes Association – Standards of 
Medical Care  (2013) (American Diabetes 
Association, 2013) 
 American Diabetes Society  - Nutrition 
Recommendations (2008) (American Diabetes 
Association, 2008) 
20 - 25  National Health and Medical Research Council 
(Craig et al., 2011) 
15 - 30  Diabetes Educators Study Group (European 
Association for the Study of Diabetes) [Diabetes 
Education Study Group of the European 
Association for the Study of Diabetes, 1998 ]  
Quantity unspecified  Asian-Pacific Type 2 Diabetes Policy Group 
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Table 4.2 Recommendation for wait-time to retreatment if hypoglycaemia persists 
 
 
WTR  (min)  Recommended By: 
10  Diabetes New Zealand (Diabetes New Zealand, 2008) 
10 - 15  Diabetes Australia (Diabetes Australia, 2009) 
15  American Diabetes Association – Standards of Medical 
Care  (2013) (American Diabetes Association, 2013) 
 Singapore Diabetes Association (Singapore Diabetes 
Society, 2010) 
10 - 20  American Diabetes Society  - Nutrition Recommendations 
(2008) (Bantle et al., 2008) 
Time 
unspecified 
 Diabetes Educators Study Group (European Association 
for the Study of Diabetes) (Diabetes Education Study 
Group of the European Association for the Study of 
Diabetes, 1998) 
  Diabetes UK (Diabetes UK, 2011) 
 Asian-Pacific Type 2 Diabetes Policy Group (Asian-
Pacific Type 2 Diabetes Policy Group, 2002) 
WTR, Wait-time to retreatment 
4.1.2 Rationale for present guidelines  
What is the scientific basis for these recommendations made by the national diabetes 
associations? Grounds for recommendations are often not referenced (Asian-Pacific 
Type 2 Diabetes Policy Group, 2002; Diabetes Australia, 2009; Diabetes Education 
Study Group of the European Association for the Study of Diabetes, 1998; Diabetes 
New Zealand, 2008) or inter-referenced (Diabetes UK, 2011; Singapore Diabetes 
Society, 2010).  Diabetes UK references a 1990 study by Slama et al (Slama et al., 
1990) and a 1994 review by Cryer et al (Cryer et al., 1994) which in turn references 
Slama et al and two studies published in 1993 and 1984 by Wiethop and Cryer  and 
Brodows et al, respectively (Brodows et al., 1984; Wiethop & Cryer, 1993).  
Singapore Diabetes Association in turn references Diabetes UK (Singapore Diabetes 
Society, 2010). The American Diabetes Association simply cites expert opinion 
(American Diabetes Association, 2013c). 
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4.1.3 Cited studies – laboratory conditions and atypical insulin regimes 
Aside from expert opinion, all referenced recommendations eventually cite three 
studies which were all conducted under laboratory conditions, in the absence of the 
subjects’ normal insulin regimes (Brodows et al., 1984; Slama et al., 1990; Wiethop 
& Cryer, 1993). Two of these (Brodows et al., 1984; Slama et al., 1990) used 
intravenous regular insulin with normal evening insulin (Brodows et al., 1984) or 
medium acting insulin ceased 12 hours previously (Slama et al., 1990). The third 
used intravenous insulin overnight and regular insulin 2 h prior to testing but no 
longer-acting insulin (Wiethop & Cryer, 1993). Intravenous insulin is the most acute 
method of controlling BGL (Magee, 2012), having an onset of several min and a half 
life of 9 min (Mazer & Chen, 2009). Because of this short duration of action, it 
would be expected that hypoglycaemia would resolve quickly with the minimum 
quantity of dietary treatment. It is not possible to extrapolate results from these 
studies to the free-living situation where subject treatment would include medium-
acting insulin with a duration of action of 12 - 18 h (Hirsch, 2005). Longer-lasting 
insulin which continues its action to decrease BGL over a prolonged period can 
cause longer-lasting hypoglycaemia and this may well affect the quantity of 
carbohydrate needed for treatment, and the WTR. An additional complicating factor 
in one study (Slama et al., 1990) was the subjects’ short duration of diabetes (0.9 
±1.2 y). In this situation some subjects may still be producing significant intrinsic 
insulin (Fan et al., 2013) which may modify/enhance normalisation of 
hypoglycaemia. Their response to treatment of hypoglycaemia could not be 
presumed comparable to the general population of people with diabetes.  
In Australia, the NHMRC in the 2011 National Evidence-Based Clinical Care 
Guidelines for Type 1 Diabetes in Children, Adolescents and Adults (Craig et al., 
2011) references a 2009 guideline (Endocrinology Expert Group, 2009) for general 
dietary treatment of hypoglycaemia but cites the 1993 study of Wiethop and Cryer 
(Wiethop & Cryer, 1993) for quantitative recommendations (20‐25g of carbohydrate  
with ‘prompt’ WTR). Diabetes Australia does not concur with this recommendation 
and continues to recommend 15 g and a 10 - 15 min WTR.  
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4.1.4 Current insulin regimes – analog insulins 
A major consideration is that all studies used as a basis for recommendations pre-
date the introduction of analog insulin in 1998. Regular insulin, used in the above 
studies, contains zinc, which causes the molecules to associate and form hexamers 
which diffuse into the circulation and then slowly dissociate by way of dimers and 
then monomers (Hirsch, 2005). Lispro, the first analog insulin introduced, had an 
altered amino acid sequence, with the positions of proline and lysine, adjacent to 
each other in the B-chain, reversed. This resulted in rapid dissociation of the hexamer 
to the monomer,  giving more rapid absorption and shorter duration of action than 
regular insulins. This shorter mode of action has been demonstrated to decrease the 
likelihood of hypoglycaemia (Kucera & Graham, 1998). Other short-acting analogs 
were subsequently developed with different modifications. Insulin aspart has proline 
on its B-chain replaced by aspartic acid. The aspartic acid residue has a negative 
charge which potentiates more rapid dissociation than the original configuration. 
This analog and those subsequently developed gave a similar reduction in 
hypoglycaemia to lispro (Heller et al., 1999; Hirsch, 2005). Other analogues 
produced by different substitutions on the insulin B-chain formed stable long-acting 
insulins suitable for use as basal insulin with a lower incidence of hypoglycaemia 
compared to previously used non-analog medium and longer-acting insulins (Hirsch, 
2005; McKeage & Goa, 2001). Extrapolating data from studies based on regular 
insulins to current regimes using analog insulin has a shaky basis. 
4.1.5 Issues of concern in the determination of food treatment of hypoglycaemia 
Issues of concern in determining quantity of treatment and WTR are the risk of 
progression to severe or extended hypoglycaemia with undertreatment and the 
possibility of subsequent hyperglycaemia with overtreatment (Choudhary & Amiel, 
2011; Sommerfield et al., 2003). It is well documented that failure to identify, or 
undertreatment of mild hypoglycaemic episodes can lead to progression to severe or 
extended hypoglycaemia (Moghissi et al., 2009) which has been associated with 
increased morbidity (Cryer, 2012; Turchin et al., 2009), as has increased duration of 
hypoglycaemia (Braithwaite et al., 2004; Ng et al., 2009). There is abundant 
documentation showing post hypoglycaemic hypoglycaemia due to counter-
regulatory responses (Hejlesen, Andreassen, Cavan, & Hovorka, 1996) but not for 
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subsequent hypoglycaemia resulting from excessive dietary treatment of mild 
hypoglycaemia. 
4.2 Significance of study 
Current recommended insulin therapy is for MDI of analog insulin with long-acting 
basal and short-acting pre-prandial insulin or CSII (continuous short acting analog 
insulin) (American Diabetes Association, 2013c) and it can be reasonably assumed 
that the majority of insulin-requiring individuals are being treated with these 
regimes. Recommendations for quantitative dietary treatment of hypoglycaemia need 
to be based on responses to that treatment by free-living subjects on these current 
regimes. The following paper addresses this issue in the context of current Australian 
recommendations for dietary treatment of hypoglycaemia and, as a secondary aim, 
investigates the poorly documented issue of post-hypoglycaemic hyperglycaemia.  
4.3 Additional limitations of study and extended statistical analysis 
Selection of subjects for the study reported in the following paper (section 4.4) was 
by time sequence, with each of 4 protocols continued for 16 weeks or until 20 
participants had been audited. Study subjects were therefore not randomised for 
study groups. 
The 4 study groups were based on treatment of hypoglycaemia: quantity of 
carbohydrate administered and wait-time to retreatment (15 g/5 min, 15 g/10 min, 20 
g/5 min, 20 g/10 min), (see paper. section 4.4). Results from the paper stated that 
there was a significant association between treatment group and resolution of 
hypoglycaemia with one treatment (
χ2 
P < 0.01), with 89.3% of the 20 g/10 min 
group attaining normoglycaemia with one treatment. A limitation of this result is that 
χ
2 
identifies a significant difference between groups but is unable to distinguish 
between specific groups. Further statistical analysis has therefore been performed to 
identify differences between specific groups as follows:  
Independent samples median test was performed to compare number of treatments 
required to resolve hypoglycaemia with treatment group. This identified a significant 
difference between the 4 treatment groups (p < 0.001). Posthoc testing, pairwise 
multiple comparison, was then carried out. (see Table 4.1).   
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Table 4.3 Post-hoc testing - independent samples median test 
pairwise multiple comparison 
Groups compared pairwise p 
20 g/10 min - 15 g/5 min 0.000 
20 g/5 min - 20 g/10 min 0.017 
15 g/10 min - 20 g/10 min 0.032 
15 g/10 min - 15 g/5 min 0.395 
20 g/5 min - 15 g/5 min 0.663 
15 g/10 min - 20 g/5 min 0.839 
Analysis was performed using SPSS Statistics, v22,IBM Corporation,  USA. 
This identifies a significant difference between the 20 g/10 min group compared to 
all other groups (p =  0.000, 0.017, 0.032). This supports the result in published 
Paper 2. 
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Australian recommendations for treatment of hypoglycaemia are 15 g of carbohydrate
repeated at 10–15 min if hypoglycaemia persists. Cited evidence is expert opinion or
older studies not pertinent to current insulin regimens. This study aimed to determine
the effect of increasing initial treating carbohydrate and decreasing wait-time to retreat-
ment on resolution of hypoglycaemia in 92 free-living adults on current insulin
regimens. The results support an initial treatment of 20-g carbohydrate, with a 10-min
wait to repeat treatment as an optimal recommendation for the insulin-treated indi-
vidual self-treating hypoglycaemia.
Hypoglycaemia in insulin-treated diabetes results from
relative insulin excess.1 The mechanisms of hypoglycae-
mia are well documented,1,2 and programmes such as
BGAT3 and HyPOS4 aid management; but as dovetailing
insulin and lifestyle is an imperfect science, hypoglycae-
mia remains an unfortunate and feared by-product of
insulin treatment.5
Treatment for hypoglycaemia in the conscious person
is dietary and recommendations for this vary worldwide.
All guidelines recommend initial treatment with quick-
acting carbohydrate and follow-up with longer lasting
carbohydrate.6–10 The amount of carbohydrate recom-
mended for initial treatment varies: 15 g (Australia,
Singapore),6,9 10–20 g (UK),7 15–20 g (USA),10 15–30 g
(Europe);8 as does the recommended wait-time to
repeat treatment (WTR) if hypoglycaemia persists:
10–15 min (Australia),6 15 min (Singapore, USA),9,10
unspecified (UK, Europe).7,8 Cited evidence for these rec-
ommendations is clinical opinion7,9–11 or older studies12–14
using intravenous, regular or medium-acting insulin, but
no long-acting insulin. Free-living people treated with
current insulin regimens incorporating short- and
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long-acting insulins or continuous subcutaneous insulin
infusion (CSII) may respond differently to dietary treat-
ment of hypoglycaemia.
It therefore seems of value to determine if there
are optimum recommendations for dietary treatment of
hypoglycaemia in free-living individuals on current
insulin regimens. We chose to assess 15- and 20-g carbo-
hydrate quantities, as they are the most common recom-
mendations. Recommendations for WTR range from 10
to 20 min. We assessed the shortest of these, and also a
5-min WTR, based on a substantial effect of glucose on
blood glucose levels (BGLs) at 5 min.15
This study aimed to determine if there was a signifi-
cant difference in the need for repeat treatment of
hypoglycaemia following initial treatment with 15 or
20 g of fast-acting carbohydrate in free-living people
experiencing spontaneous hypoglycaemia. A secondary
aim was to determine if WTR could be reduced to 5 or
10 min without significantly increasing the need
for repeat dietary treatment. The effect of carbohydrate
quantity and WTR on subsequent hyperglycaemia was
also investigated.
Participants were 92 free-living adults (50 male, 42
female) treated with subcutaneous insulin injection (SII)
or CSII, attending scheduled diabetes clinic appoint-
ments and found to have hypoglycaemia on routine fin-
gerprick blood testing during their clinic visit. As dietary
treatment of hypoglycaemia in insulin-treated diabetes
is a universal recommendation, consent, insulin treat-
ment and hypoglycaemia were the only inclusion crite-
ria. The project was approved by Curtin University
Human Research Ethics Committee and registered as a
clinical audit at Royal Perth Hospital.
Identification of hypoglycaemia was by blood glucose
monitoring with a BGL <3.5 mmol/L defining ‘clinical
hypoglycaemia’.16–18 Treatment was 15 or 20 g of glucose
with WTR either 5 or 10 min, giving four different treat-
ment protocols. Each protocol continued for 16 weeks or
until 20 participants had been audited. Participants iden-
tified as hypoglycaemic were given a fluid containing 15 g
(groups 1 and 2) or 20 g (groups 3 and 4) of glucose. They
were retested in 5 min (groups 1 and 3) or 10 min (groups
2 and 4). If BGL remained <3.5 mmol/L, they were
retreated as per protocol until BGL 3.5 mmol/L.
Hypoglycaemic symptoms were recorded on a checklist
by trained staff concurrent with blood testing. BGL
assessment continued every 30 min while participants
remained in clinic. On leaving, clinic participants were
requested to blood test every 30 min to 4 h post-resolution
of hypoglycaemia using their own blood glucose meter;
record results, food and exercise on a standard form and
return this to clinic. They were advised to follow normal
procedure with meals and insulin. Trained staff measured
clinic BGLs using the same blood glucose meter (Optium
Xceed, Abbott, IL, USA) and measured glucose-containing
fluid (carbotest) in the same premarked measuring
cylinder.
As the study was not based on a hypothesised effect
size, a formal calculation of statistical power was not
applicable. The main objective of the study was to
measure effectiveness of currently recommended dietary
treatments for hypoglycaemia. The rate of incidental
hypoglycaemic events in patients reporting for scheduled
appointments to our clinics varies from 1 to 3 a week;
therefore, we considered a 12-month audit (about 80
participants) that should be enough to answer the study
questions.
Descriptive statistics were used for participant demo-
graphics, Shapiro–Wilk test was used to determine nor-
mality, and between-group differences were analysed
using Kruskal–Wallis test for non-normally distributed
continuous variables. The c2 test was used to compare
categorical variables. Mann–Whitney U-test was used to
determine independent group differences.
Analysis was performed using PASW software (v18,
SPSS Statistics, IBM Corporation, NY, USA).
Participant characteristics are shown in Table 1.
Shapiro–Wilk test was significant for 12/20 continuous
variables, indicating non-normal distribution, so non-
parametric testing was performed. There was no signifi-
cant difference between groups for age, gender, diabetes
duration, haemoglobin A1c (HbA1c), body mass index
(BMI) or presenting BGL. The numbers on CSII versus SII
were too low to allow statistical testing.
Hypoglycaemic symptoms were reported by 35 (38%)
of participants and resolved concurrently with the
resolution of hypoglycaemia except in 10 participants
who remained symptomatic for 10 min after their BGLs
normalised.
The number of dietary treatments (quantity of carbo-
hydrate as per protocol) required to resolve hypoglycae-
mia is shown in Table 2. There was a significant association
between treatment group and resolution of hypoglycae-
mia with one treatment (c2 P < 0.01), with 89.3% of the
20 g/10 min group attaining normoglycaemia with one
treatment.
Short-term:BGLs were recorded for 45 participants
at 30 min postresolution of hypoglycaemia. There was no
significant difference between this group and non-
recorders for age, gender, duration, HbA1c or BMI (P >
0.05). A BGL >10 mmol/L was arbitrarily defined as
hyperglycaemia. Two out of 45 participants were hyper-
glycaemic at 30 min, but results were insufficient to
compare treatment groups.
Longer term: Thirty-four participants returned BGLs
recorded on personal blood glucose metres to 4 h
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post-resolution of hypoglycaemia. There was no signifi-
cant difference between this group and non-recorders for
age, gender, duration, HbA1c or BMI (P > 0.10). Fourteen
recorded at least one BGL >10 mmol/L unrelated to food
intake. To assess association between initial treating
carbohydrate quantity and longer term hyperglycaemia
categorical variables were generated as follows: carbohy-
drate 15g/20g; hyperglycaemia absent/present, present
defined as at least one BGL >10 mmol/L  90 min post-
hypoglycaemia. Association was tested using c2 showing
no significant association (P > 0.10).
Our results indicate that 20 g of fast-acting carbohy-
drate will resolve hypoglycaemia within 10 min
in 89.3% of free-living individuals on current insulin
regimes compared with 15 g that resulted in 63.2%
resolving in 10 min. Decreasing the WTR to 5 min
increased those needing repeat treatments with both 15
and 20 g treatments. Insufficient initial treating quantity
of carbohydrate necessitating repeat treatments markedly
increases the duration of hypoglycaemia. This is often
accompanied by uncomfortable hypoglycaemic symp-
toms that last until clinical hypoglycaemia resolves, and
in a third of symptomatic participants in this study, up to
10 min longer. Even where hypoglycaemic symptoms are
minor or absent, repeated treatments, with the necessar-
ily associated self-blood glucose monitoring, interrupt
work, childcare and daily activities.
There is no consensus in the literature on a bio-
chemical definition of hypoglycaemia. We identified
hypoglycaemia as BGL <3.5 mmol/L, consistent with
recommendations for ‘clinical’ hypoglycaemia.16,17 The
American Diabetes Association recommends 3.9 mmol/L
as a level where individuals should consider the possibil-
ity of hypoglycaemia.19,20 A lower level than this has been
documented to decrease the incidence of hypoglycaemia,
especially symptomless hypoglycaemia.18 Had we used
the 3.9 mmol/L level, we may have increased the
numbers who resolved with one treatment of 15 g
carbohydrate.
The rationale commonly given for restricting treating
carbohydrate is that it causes subsequent hypergly-
caemia. Fast-acting carbohydrate peaks at 30 min,15 and
hyperglycaemia at this time is probably attributable
to treating carbohydrate. In this study, only 2 of 45
participants with BGLs recorded at 30 min post-
hypoglycaemia were hyperglycaemic, but numbers
were too small to relate to quantity of treating
carbohydrate.
Hyperglycaemia after 60 min is unlikely to be related
to initial treating carbohydrate. In this study, 34 partici-
pants returned BGLs recorded to 4 h postresolution of
hypoglycaemia. The characteristics of those with records
did not differ significantly from non-recorders. Fourteen
recorded at least one BGL in the hyperglycaemic range
Table 1 Characteristics of participants by hypoglycaemia treatment group
Variables Treatment group† P-value
15 g/5 min 15 g/10 min 20 g/5 min 20 g/10 min
n 25 19 20 28
Age (years) 47.517.8 50.216.2 45.317.8 52.516.8 0.52‡
Gender (male/female) 13/12 9/10 9/11 19/9 0.36§
Diabetes duration (years) 14.811.5 20.615.8 17.813.5 22.615.5 0.24‡
Diabetes treatment (SII/CSII) 24/1 16/3 18/2 25/3 —
Haemoglobin A1c (%) 8.8 2.0 8.1 1.9 8.8 2.1 8.7 2.2 0.63‡
Body mass index (kg/m2) 28.0 5.8 26.9 4.6 25.4 5.2 26.2 8.1 0.63‡
Presenting BGL (mmol/L) 2.8 0.5 2.7 0.4 2.8 0.5 2.9 0.5 0.59‡
†Treatment group – carbohydrate quantity/wait-time to retreatment. ‡Independent samples Kruskal–Wallis test. §c2 test. BGL, blood glucose level; CSII,
continuous subcutaneous insulin infusion; SII, subcutaneous insulin injection.
Table 2 Number of dietary treatments required to resolve hypoglycaemia
Treatment group† 15 g/5 min 15 g/10 min 20 g/5 min 20 g/10 min
n 25 19 20 28
Resolved with one treatment 32.0% 63.2% 55% 89.3%
Resolved after two treatments 44% 31.6% 30% 10.7%
Required >2 treatments 24% 5.2% 15% 0%
†Treatment group – carbohydrate quantity/wait-time to retreatment.
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90–240 min postresolution of hypoglycaemia. This was,
unsurprisingly, not significantly associated with quantity
of treating carbohydrate and is probably attributable to
counterregulatory mechanisms.1 These results need to be
interpreted with caution because of possible selection
bias in those who returned records and also because BGLs
were from self-blood glucose monitoring records. They
do, however, indicate that subsequent long-term hyper-
glycaemia following hypoglycaemia probably has more to
do with physiology than diet. This warrants investigation
with a cross-over study, which we have in progress.
Wild asserts that anxiety is lessened when an indi-
vidual has a sense of control over their hypoglycaemia.5
To this end, swift effective dietary treatment of hypogly-
caemia is obviously desirable. This study supports an
initial treatment of 20-g carbohydrate with a 10-min wait
to repeat treatment as an optimal recommendation for
the conscious insulin-treated individual self-treating
hypoglycaemia.
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CHAPTER 5:  FOOD SELECTION FOR TREATMENT OF 
HYPOGLYCAEMIA IN INSULIN REQUIRING DIABETES 
5.1 Expanded Methods 
5.1.1 Rationale for use of a self-administered questionnaire 
Methodology for collecting data on health behaviours in free-living individuals can 
be problematic. Observational studies may disrupt the normal behaviour that is the 
target of observation. Self-reported data, while potentially overcoming this problem, 
requires that data acquisition be carried out in a standardized manner from a 
representative sample of a defined population to maximise accuracy (Rattray & 
Jones, 2007). In this type of survey, information is normally collected by interview, 
or self-administered questionnaire. Interview is the least burdensome method on the 
interviewees as they are only required to have basic verbal and listening skills 
(Bowling, 2005), however the presence of the interviewer may influence the 
accuracy of the answers, especially where questions are sensitive (Davis, Couper, 
Janz, Caldwell, & Resnicow, 2010). It has been reported that, compared to self-
administered questionnaires, interviewer-administered questionnaires systematically 
elicited more socially desirable responses to questions relating to personal lifestyle, 
inferring the respondent was trying to please or impress the interviewer (Okamoto et 
al., 2002). It has been asserted that misreporting on sensitive topics is a conscious 
process where respondents edit the information they report to avoid embarrassment 
in the presence of an interviewer (Tourangeau & Yan, 2007). 
A self-administered questionnaire requires more from the respondent, however, it 
allows anonymity and, where information may be sensitive, has been shown to be 
associated with better data quality compared to that obtained from interviewer-
administered questionnaires (Durant, 2002; Ong & Weisse, 2007).  
Can food treatment of hypoglycaemia be considered a sensitive topic? A sensitive 
question is defined as one requiring answers that may not conform to accepted social 
norms or that would be considered socially undesirable (Tourangeau & Yan, 2007).  
In a study involving 30 adults completing a Dose Adjustment for Normal Eating 
(DAFNE) course which includes instruction on food treatment of hypoglycaemia, 
almost all participants expressed a motivation to adhere to instructions on treatment 
of hypoglycaemia, but at interview 12 m post-course, only 50% had consistently 
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done so. Non-adherers gave a variety of rationales for non-adherent behaviour which 
included comments such as “I know that I shouldn’t but ....”, it’s “difficult to avoid 
overtreatment......sweets are simply too nice” and ...... he ‘confessed’ to being unable 
to break a cycle of overmanagement (Lawton et al., 2013); all implying a felt 
betrayal of an accepted social norm. Similarly, it has been shown that fear of 
hypoglycaemia has been associated with non-adherence to treatment and this resulted 
in avoiding involvement with health professionals, presumably because it was 
thought this behaviour would be considered unacceptable (Tan, Chen, Taylor, & 
Hegney, 2012). It would seem that food treatment of hypoglycaemia could be seen, 
at least by some, as a ‘sensitive’ health issue. Thus the accuracy of research data 
obtained on this topic would be maximized by allowing participants to respond 
anonymously, and in the following study we utilized an anonymous self-
administered questionnaire. 
5.1.2  Readability 
Self-administered questionnaires require more from the respondent, with ability to 
respond being contingent on a certain level of literacy. Ability to respond accurately  
requires comprehension of the question, recall of requested information, and 
communication of the response in the manner specified by the question format 
(Bowling, 2005). 
Low literacy is not a well-recognized problem in health care (Davis, Michielutte, 
Askov, Williams, & Weiss, 1998). Results from the 2006 Adult Literacy and Life 
Skills Survey showed that the proportion of Western Australians with literacy skills 
of Level 3 (the minimum literacy level required to deal with the complexities of 
everyday life) or above was about 55%. The lowest rates were in older Western 
Australians, with those aged 65-74 y having the smallest proportion at skill level 3+ 
(Australian Bureau of Statistics, 2011a). It is also well established that lower literacy 
levels are associated with lower socioeconomic status (Perry & McConney, 2010). 
The Australian Health Survey (2011 - 2012) showed that use of medical facilities 
increased with age (Australian Bureau of Statistics, 2011b). There is also a higher 
prevalence of use of general medical services among those who are educationally 
disadvantaged (Wiggers, Sanson-Fisher, & Halpin, 1995). It could, therefore, 
reasonably be expected that the literacy level in those attending a public hospital 
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clinic would be lower than in the community generally, and this may well affect 
health assessments by means of a questionnaire. 
 It has been shown that those with low literacy skills tend to interpret words literally, 
read slowly, and ignore unfamiliar words, which means that they tend to focus on 
details and miss key concepts. The simplification of text is seen as a partial solution 
to this. ‘Readability’ is a measure of the ‘understandability’ of a text (Ley & Florio, 
1996). Readability formulas are quantitative measures of the reading difficulty of 
printed information, and there are numerous readability formulas available to provide 
quantitative estimates of the reading difficulty of printed health information by 
assessing the complexity of the vocabulary used (Friedman & Hoffman-Goetz, 
2006). These formulae are multiple regression equations considering some 
combination of the number of syllables in words, the length of sentences and the 
proportion of common words used (Ley & Florio, 1996). Increasing readability 
usually leads to improvement in understanding (Ley & Florio, 1996) and the 
consensus on optimal level for health leaflets is 6
th
 grade level (Clauson, Zeng-
Treitler, & Kandula, 2010), which is theoretically understandable by 91% of the 
population (Ley & Florio, 1996). There are many different readability formulas. We 
elected to use both Flesch Reading Ease and Flesch-Kincaid Formulae which are 
considered suitable for use in healthcare and require a relatively small amount of text 
for assessment, compared to some other formulae (Ley & Florio, 1996).  
5.1.3 Validity and reliability 
The design of a questionnaire should be such that it accurately measures the health 
issues and behaviours it is designed to survey. The two most important issues in this 
context are the validity and reliability of the questionnaire. Validity is the degree that 
the questionnaire measures what it aims to measure. Reliability is the extent to which 
the questionnaire gives reproducible results, that is, its repeatability  (Rattray & 
Jones, 2007; Saw & Ng, 2001). 
Validity 
Content, or face validity assesses whether the questionnaire is congruent with the 
concepts it is trying to measure. This includes both the relevance and scope of the 
questionnaire items (Scholtes, Terwee, & Poolman, 2011). This is a qualitative 
measure and is normally based on expert opinion (Saw & Ng, 2001). The following 
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paper was concerned with self-reported data on individual frequency and treatment 
of hypoglycaemia in people with insulin-treated diabetes. Item construction was 
carried out with reference to the literature and patient education material and items 
were subsequently reviewed by an experienced diabetes team. They were then 
piloted on a similar patient population (7% sample size of the full study population). 
There are no standards against which content validity can be measured. Its 
assessment is by subjective judgement (Scholtes et al., 2011). 
Criteria validity is the extent to which measures are related to concrete criteria or a 
‘gold standard’ (Manterola, Munoz, Grande, & Bustos, 2002).  As this questionnaire 
was self-reported data on patient behaviour, a gold standard did not exist and criteria 
validity was not assessed. 
Reliability 
 The two most common ways of measuring reliability of a questionnaire are to ask 
the question again in a different way in a different part of the questionnaire, or, 
secondly, to ask the question again to the same group at a different time; the test-
retest method (Roberts, 2008; Saw & Ng, 2001). The results are then compared. 
There are advantages to both methods, but where a short questionnaire is considered 
optimum the second option is the obvious choice.  
Test-retest agreement can be measured by percent agreement, which is calculated as 
the ratio of the number of times the test-retest results agree divided by the total 
number of questions in the questionnaire multiplied by 100. This does not, however, 
take into account the extent of agreement by chance (Stein, Devore, & Wojcik, 2005; 
Viera & Garrett, 2005). Statistical analysis of reliability is contingent on the form of 
information generated by the questionnaire. Zaki et al in a systematic review of 
statistical methods testing reliability in surveys using continuous variables reported 
that the intra-class correlation coefficient was the most popular method with 60% of 
studies utilizing this method. Other methods used were comparison of means (19%), 
Bland-Altman Limits of Agreement (17%) and simple correlation (5%) (Zaki, 
Bulgiba, Nordin, & Azina Ismail, 2013). Where variables are categorical, test-retest 
agreement is most commonly analysed by use of the Kappa coefficient (Roberts, 
2008). The Kappa coefficient is calculated as: κ = {a – e}/{1 – e}, where a is the 
relative observed agreement between test-retest and e is the hypothetical probability 
of agreement by chance. The observed rate of agreement is used to calculate the 
hypothetical probability of test-retest agreement by chance and this is the calculated 
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value of e. The kappa coefficient therefore corrects, to some extent, for the 
proportion of agreement occurring by chance. It can therefore be seen that if the test-
retest results agree completely then κ = 1, and if the converse, κ = 0. It is 
theoretically possible to have kappa values < 0 if there is systematic disagreement 
between the test and retest results. The generally agreed-on interpretation of kappa is: 
κ = 0 - 0.2 indicates slight agreement; 0.21 - 0.4, fair agreement; 0.41 - 0.6, moderate 
agreement; 0.61 – 0.8, substantial agreement; 0.81 – 1.00, almost perfect agreement 
(Saw & Ng, 2001; Viera & Garrett, 2005).  
5.1.4 Response rates 
Bias 
It is critical that the return rate of a self-administered questionnaire is adequate to 
avoid skewed sampling (Sitzia & Wood, 1998).  Bias is introduced by non-response 
if those responding do not reflect the attitudes or behaviours of the whole population 
(Schalm & Kelloway, 2001). Cummings, in a review of physician surveys, asserted 
that similarities between responders and non-responders are almost impossible to 
assess and that non-response bias was one of the most important factors influencing 
validity of a survey (Cummings, Savitz, & Konrad, 2001). 
Researchers cannot calculate the mean score of the non-responders and so cannot 
estimate the extent of the bias introduced by non-response. They can, however, 
calculate non-response and response rates as an indirect indication of the possibility 
of significant bias (Schalm & Kelloway, 2001). Baruch et al, in a study looking at 
response rates in questionnaires assessing organisational issues, commented that 
higher response rates are associated with larger sample sizes and more robust 
statistical conclusions.  They also assert that an assessment of the response rate of a 
survey is a crucial factor in assessing the value of research results (Baruch & 
Holtom, 2008). 
Factors affecting response rates 
There is conflicting evidence on factors affecting response rates. Edwards et al 
reported that response rates were higher for shorter questionnaires and also if an 
incentive was offered for completion (Edwards et al., 2002), whereas Subar et al, 
investigating return rates in dietary questionnaires, showed that return rates were 
independent of length of questionnaire (Subar et al., 2001), as did Stizia et al in an 
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investigation of 210 patient satisfaction surveys. Contrary to the results of Edwards 
et al, Baruch et al showed that incentives did not increase response rates (Baruch & 
Holtom, 2008). It has also been shown that a questionnaire of interest to respondents 
increases response rates and that questionnaires containing sensitive questions are 
less likely to be returned (Edwards et al., 2002).  
Acceptable response rates 
There is no gold standard for an acceptable response rate for questionnaires. Several 
reviews have been published documenting average published response rates. Barush 
et al reviewing surveys used in organizational research looked at the response rate in 
490 studies utilizing questionnaires. The average response rate for studies collecting 
data from individuals was 52.7 ± 20.4% (Baruch & Holtom, 2008). A review of 
results from mailed  physician surveys published over 10 years reported that the 
average response rate was 61 percent (Cummings et al., 2001) and a review of 210 
patient satisfaction surveys showed a response rate of 72.1% (Sitzia & Wood, 1998). 
Kelley et al assert that although it may not be wise to define a minimum acceptable 
response rate, their research indicates that a response rate of 75% for interviews and 
65% for self-completed postal questionnaires should be both achievable and 
acceptable (Kelley, Clark, Brown, & Sitzia, 2003). As these figures are of the order 
of the existing reviews, we have adhered to this recommendation in the following 
paper. 
5.2 Glycaemic index and hypoglycaemia 
In the following paper, Paper 3 (see section 5.4), foods used for initial treatment of 
hypoglycaemia were categorised by two different methods: firstly, recommended/not 
recommended (a food was designated recommended if recommended by any of the 
recommending authorities); and, secondly, rate of action of carbohydrate. For the 
second categorisation, foods were grouped, then ranked by glycaemic index (GI) 
with GI of ≥70 categorised as quick-acting, 56 - 69 medium-acting and ≤55 slow-
acting carbohydrate (Brand-Miller, Stockmann, Atkinson, Petocz, & Denyer, 2009). 
Brand-Miller et al in a study of GI, postprandial glycaemia and the shape of the 
curve in healthy subjects investigated 1126 foods and compared GI and the shape of 
the curve. The average curve was then calculated for low-GI (<55), medium-GI (56 - 
69), and high-GI (>70) foods. GI values correlated strongly with the food’s 
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incremental peak. Differences in peak values between some foods classified as 
quick-acting compared to those classified as medium-acting were, in some instances, 
of the magnitude of 2 - 2.5 mmol/L at both 15 and 30 min post-consumption (Brand-
Miller et al., 2009). This study was carried out using healthy subjects, and it is not 
clear if the results can be extrapolated to those with diabetes, however it has been 
shown that the correlation coefficient for 20 staple foods tested in subjects with and 
without diabetes was r = 0.94 (p <0.001), which seems to indicate a very similar 
response (Atkinson, Foster-Powell, & Brand-Miller, 2008). If this is so, a difference 
of this magnitude 15 min post treatment of hypoglycaemia could be the difference 
between resolution of the event or ongoing hypoglycaemia, and would thus be of 
clinical significance. 
5.3 Expanded results 
The table below presents expanded results from published Paper 3 which were 
excluded from the paper due to the publishing journal’s restrictions on length. It 
shows statistical analysis of test-retest results for items in the questionnaire utilized 
in the study. It can be seen from both the percent agreement and the kappa analysis 
that, in the main there was good agreement. It can be seen that where the CI for 
kappa are wide there is a large discrepancy between percent agreement and the kappa 
coefficient. 
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Table 5.1    Reliability of questions in the hypoglycaemia questionnaire 
Test – Retest by interview 
%† κ‡ 95% CI§ 
Frequency of hypoglycaemia 
(categorical) 
90.3 0.88 0.75 - 1.02 
Hypoglycaemic symptoms yes/no 100 1.00 1.00 -1.00 























0.80 - 1.07 
0.57 - 1.06 
0.80 - 1.06 
0.68 - 1.05 
0.28- 0.88 
0.50 - 0.98 
0.58 - 1.02 
Unique individual symptoms 77.4 0.47 0.14 - 0.80 
Food used for initial treatment 96.8 0.96 0.87 - 1.04 
Quantity of initial treating 
food(categorical) 
77.4 0.73 0.56 - 0.90 
Follow-up with  food   yes/no 93.5 0.80 0.54 - 1.06 
Food used for follow-up 
(categorical) 
93.5 0.92 0.80 - 1.03 
† %, Percent agreement; ‡ κ, Cohen’s kappa;  § CI, confidence interval 
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5.4  Paper 3 
Vindedzis SA, Marsh B, Sherriff JL, Dhaliwal SS, Stanton KG. Food selection for 
treatment of hypoglycaemia in insulin-treated diabetes: what happens in real life? 
Practical Diabetes. 2012;29(7):271-4. 
Introduction
Hypoglycaemia in diabetes is a by-
product of treatment with exogenous
insulin and/or oral hypoglycaemic
agents. It is a common acute compli-
cation of diabetes. Reported rates of
symptomatic hypoglycaemia in type 1
diabetes are one1 to two2,3 episodes
per week with increased frequency of
severe hypoglycaemia with longer
duration of insulin treatment.2,3 The
reported rate in insulin-treated type 2
diabetes is lower,1–3 with the UK
Hypoglycaemia Study Group report-
ing four versus 36 episodes per sub-
ject-year for short duration insulin
treatment in type 2 and type 1 dia-
betes respectively.2
Hypoglycaemia can cause neuro-
genic symptoms such as shaking,
sweating and hunger and also neuro-
glycopenic symptoms, resulting from
brain glucose deprivation, such as
confusion, seizure and coma.3 It has
been estimated that 6–10% of deaths
in people with type 1 diabetes are
caused by hypoglycaemia.4 People
with diabetes are reported to fear
hypoglycaemia more than the long-
term complications of diabetes.5
It has been reported that 90.8% of
people with type 1 and 84.5% of those
with type 2 diabetes self-treat their
hypoglycaemia.6 Recommendations
for this treatment fall into two parts.
Firstly, all recommending authorities
advise ingestion of quick-acting carbo-
hydrate, reassessment of blood glu-
cose levels and repeat treatment until
blood glucose levels normalise.7–13
Specific treatment foods recom-
mended are glucose,7–11,13 sugar,8–13
carbonated beverages,7–9,12,13 jelly
beans, jelly babies etc,8,9,12,13 honey8,9
and fruit juice.7–9,12,13 Subsequent
ingestion of longer-lasting carbohy-
drate is then recommended to aid
continued normalisation of blood glu-
cose levels.7–13 Secondly, there are spe-
cific recommendations for quantity of
primary treating carbohydrate, rang-
ing from 15g (Australia/Singapore/
Canada)8,9,12 to 15–30g (European
Association for the Study of Diabetes
[EASD]).10 For others see Table
1.7,11,13,14 All recommendations for
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Original article
Food selection for treatment of hypoglycaemia in
insulin-treated diabetes: what happens in real life?
Abstract
Hypoglycaemia is a feared complication of insulin-treated diabetes. Treatment
recommendations vary worldwide and their implementation is poorly documented. The
primary study objective was to assess adherence to broad guidelines of hypoglycaemic
treatment; initially with quick-acting carbohydrate and follow up with long-acting
carbohydrate. The secondary objective was to assess if initial treating carbohydrate quantity
complied with current worldwide recommendations. 
Assessment was by questionnaire, which was validated, piloted and administered to all
insulin-treated individuals attending routine outpatient diabetes clinic appointments over four
weeks. The questionnaire response rate, readability and validity were acceptable at 74%,
grade 6 level and 0.61 (Cohen’s kappa), respectively.
Assessment of broad guidelines for treatment of hypoglycaemia showed 78% of
responders reported initial treatment with recommended foods, but only 40.8% of these were
quick-acting carbohydrate. Only 55.8% reported ingesting follow-up food. Assessment of
initial treating carbohydrate quantity showed 20.6% of responders used quantities exceeding
all guidelines. Of the remaining, 46.4% used quantities consistent with the most liberal
recommendations (European Association for the Study of Diabetes).
Most study participants reported treating with recommended foods in quantities
exceeding minimum recommendations, possibly attempting to resolve unpleasant symptoms
of hypoglycaemia quickly. Failure of many to ingest follow-up food is concerning and warrants
investigation. Increased patient education and standardisation of guidelines for treatment of
hypoglycaemia are indicated. Copyright © 2012 John Wiley & Sons.
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quantity of carbohydrate are based on
expert consensus,15 or older studies
based on superseded insulin regi-
mens.16–18 Restriction of initial 
treating carbohydrate is based on 
the rationale that excess may con-
tribute to subsequent hyperglycaemia
although there is a paucity of studies
supporting this.19
There is significant research on
physiology and prevention of hypo-
glycaemia but little on the practical
implementation of treatment recom-
mendations for hypoglycaemia by
people with diabetes.20,21 This study
was initiated to develop and validate
a questionnaire to obtain informa-
tion on self-treatment of hypogly-
caemia in free-living people with
insulin-treated diabetes. It aimed to
assess if broad guidelines of hypo-
glycaemia treatment were being 
followed – i.e. initial treatment with
recommended quick-acting carbohy-
drate and follow up with longer- 
lasting carbohydrate sources; and,




Participants were 119 free-living peo-
ple (81 male, 38 female) over the age
of 18 years with insulin-treated dia-
betes (type 1 and insulin-requiring
type 2) attending routine outpatient
diabetes clinic appointments. The
sample size was determined by feasibil-
ity criteria. Treatment of diabetes was
by subcutaneous insulin injection (SII)
or continuous subcutaneous insulin
infusion (CSII). Ethics approval was
obtained from Curtin University
Human Research Ethics Committee
and the project was registered as a clin-
ical audit at Royal Perth Hospital. 
Procedure 
The questionnaire was given to all
insulin-treated people attending rou-
tine diabetes clinics over a period of
four weeks (n=161). Consent was 
presumed if it was returned to a desig-
nated sealed box. The questionnaire
was short, with readability assessed as
6.2 on Flesch-Kincaid Grade Level
Formula (grade 6 level, thus under-
standable by 85–90% of the popula-
tion).22 It commenced with an 
assurance of anonymity and an expla-
nation of the aim: to investigate indi-
vidual experiences of hypoglycaemia.
Quest ionnaire items were identified
from the literature, clinical experience
and patient education material, and
content validity was assessed qualita-
tively by a team consisting of a dia-
betologist, two diabetes educators and
a dietitian. Test-retest reliability was
assessed by comparing self-reported
data with interview responses to the
same questions by a convenience sam-
ple of 31 insulin-treated people from
the same clinic population. Percent
agreement was high for all questions
(>70%) and Cohen’s kappa, selected
as it measures the amount by which
agreement exceeds that expected by
chance,23 showed values >0.61 (sub-
stantial agreement) for 12 questions
and 0.47–0.58 (acceptable agreement)
for the other two.24 The return rate for
the questionnaire was 74% (n=119),




were used for subject demographics.
The chi-square test (χ2) was used to
compare categorical variables; and
extended Fisher's exact test for age,
diabetes treatment and duration
(>2x2 contingency table with some
cells <5). 
Broad guidelines for treatment of
hypoglycaemia. Initial treating foods
were categorised by two different
methods: firstly, recommended/not
recommended (a food was designated
recommended if recommended by
any of the recommending authori-
ties); and, secondly, rate of action of
carbohydrate. Foods were grouped,
then ranked by glycaemic index (GI).
(GI of ≥70 was categorised as quick-
acting, 56–69 medium-acting and ≤55
slow-acting carbohydrate.)26 GI values
were averaged from the Online
Appendix To The International
Tables of Glycemic Index.26
Quantity of primary treating carbohy-
drate. As most recommendations
specify glucose as optimal treatment
for hypoglycaemia,7–11,13 initial treat-
ing food quantity was standardised by
calculating glucose equivalents (GE).
Glycaemic load (GL) is a stronger pre-
dictor of glycaemia than carbohydrate
content alone27 and was used as the
GE. GL ≡ GE (g) = quantity carbohy-
drate eaten (g) x GI of food 100. 
Statistical analysis. This was per-
formed using PASW, version 18, SPSS
Statistics, IBM Corporation, USA,
and extended Fisher’s exact test by
Gunma online database.28
Results
Participant demographics are shown
in Table 2. Median reported rate of
hypoglycaemia was one per week,
roughly consistent with reported rates
in the literature.1,2 The majority of
responders to the question on symp-
toms of hypoglycaemia (n=118)
reported experiencing symptoms
(89%, 105). The most frequently
reported symptoms were shaking
(78.1% of symptomatic participants,
n=82), sweating (72.4%, 76), behav-
iour change (54.3%, 57) and hunger
(39%, 41).
Broad guidelines for treatment 
of hypoglycaemia
Recommended foods. Of the 103
participants responding to this item,
the majority (78%, n=80) reported
initial treatment of their hypogly-
caemia with recommended foods
(Figure 1); jelly beans, jelly babies etc
(34%, 35) and carbonated beverages
(18.4%, 19) being the most common. 
Rate of action of carbohydrate. Only
40.8% (n=42) of responders reported
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Table 1. Recommended quantity of carbohydrate
for initial treatment of hypoglycaemia
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initial treatment of hypoglycaemia
with foods rated as quick-acting (GI
≥70) with the majority using medium-
acting carbohydrate (50.5%, 52).
(See Figure 1.) 
Follow-up treatment. This question
was answered by 104 participants,
with 55.8% (n=58) of these reporting
ingesting further food for follow up.
Of these, medium-acting carbo hy-
drate was the most commonly
reported category of follow-up food
(46.6%, 27), closely followed by long-
acting carbohydrate (43.1%, 25).
Sandwiches and bread/cereals tied 
as the most common follow-up treat-
ment foods (22.4%, 13).
Quantities of carbohydrate used
for initial treatment
Self-reported quantities of carbohy-
drate used for initial treatment of
hypoglycaemia are shown in Table 3,
with 97 participants responding to
this item. Only 20.6% (n=20) of
responders reported quantities
exceeding all recommendations, 
with a similarly small number (33%,
32) within minimum recommenda-
tions (15g, Australia/Singapore/
Canada). Quantities falling within
the recommendations of the EASD
(15–30g) were reported by 46.4%
(n=45) responders. 
Discussion
The purpose of this study was to inves-
tigate patterns of self-treatment of
hypoglycaemia in people with insulin-
treated diabetes and the extent to
which guidelines for treatment were
implemented. Response rates to 
questionnaire items addressing the
broad guidelines for treatment of
hypoglycaemia were high (≥87%).
Consumption of recommended foods
for initial treatment was reported by
78% of responders; however, only
40.8% were consuming quick-acting
carbohydrate as defined by GI. This is
understandable in that worldwide
guidelines, while recommending
ingestion of quick-acting carbohy-
drate, specify a range of foods, some of
which are actually medium-acting car-
bohydrate. These recommendations
are mirrored in other areas of the 
literature3,29 and also in patient educa-
tion material.8,9,12 GI is now the uni-
versally accepted way of assessing rate
of action of carbohydrate27 but tradi-
tional specification of treatment foods
preceded the advent of GI and some
recommended foods may now be less
than ideal.17,30
The response rate to the question
on follow-up treatment was high, but
only 55.8% of responders reported
ingesting follow-up carbohydrate. The
issue of follow up is important as
quick-acting carbohydrate peaks at
30–45 minutes31 and initial treatment
may be effective for less than an
hour3,29,31,32 giving a subsequent drop
in blood glucose level. A repeat
episode of hypoglycaemia in the
insulin-treated individual will be
largely mitigated by insulin status and
will be more likely where hypogly-
caemia is due to relative excess of
long-acting insulin or exercise, but
lack of long-acting follow-up food
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Figure 1. Foods used for initial treatment of hypoglycaemia ranked by action of carbohydrate: 
(a) numbers in parentheses denote average glycaemic index; (b) blue colour denotes recommended













†(SII) subcutaneous insulin injection; (CSII)
continuous subcutaneous insulin infusion. 
Table 2. Participant demographics (n=119) 
Variable Result
≤15g 32 (33%) Less than or equal to lowest recommendations 
(Australia/Singapore/Canada)
>15–20g 22 (22.7%) Within USA/UK recommendations Within EASD 
>20–30g 23 (23.7%) recommendations 
(i.e. 15–30g; 46.4%)
>30g 20 (20.6%) Greater than all recommendations
Table 3. Self-reported quantities of carbohydrate used for initial treatment of hypoglycaemia
according to recommendations 
Glucose Responders Quantity according to recommendations
equivalents using quantity
Glucose (100)
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Percentage of participants using food
increases the likelihood of repeat
hypoglycaemic episodes.3
The questionnaire item addressing
the second section of the guidelines,
quantities of quick-acting carbohy-
drate used for initial treatment, was
answered by 97 participants. Contrary
to a finding by Sommerfield et al.,21
only 33% of these reported using
quantities consistent with the lowest
recommendations (15g)8,9,12 com-
pared with 46.4% reporting quantities
within the minimally increased EASD
recommendations (15–30g).10 Almost
90% of responders reported suffering
unpleasant symptoms of hypogly-
caemia, mainly shaking, sweating,
behaviour change and hunger, and it
is not surprising if they err towards
larger quantities of initial treating 
carbohydrate with a view to possible
faster resolution. 
There were three main limitations
of this study. As the questionnaire was
anonymous there was no information
available on the 26% of non-respon-
ders; however, the response rate was
74%, well above the 65% considered
acceptable to minimise bias for a self-
completed questionnaire.25 A second
limitation was lack of differentiation
between diabetes types. All respon-
ders were insulin-treated, but self-
reported data on diabetes type were
considered to be of questionable
accuracy. A third limitation was lack
of data on the incidence of repeat
episodes of hypoglycaemia; without
this it is impossible to ascertain the
significance of the large number of
responders reporting lack of follow
up with longer-acting carbohydrate.
Future directions 
This study showed many responders
reporting use of recommended, but
medium-acting carbohydrate for pri-
mary treatment of their hypogly-
caemia. This indicates the need for
increased education on the use of
quick-acting carbohydrate in the treat-
ment of hypoglycaemia. Research on
the efficacy of currently recom-
mended medium-acting foods for
treatment of hypoglycaemia seems
indicated, with a view to their possible
removal from recommendations. 
Many participants in this study
reported quantities of initial treating
carbohydrate within EASD recommen-
dations rather than the lower, country
of origin recommendations. Non-
adherence in itself is not a reason to
review recommendations, but in view
of the relatively low evidence level on
which recommendations are based
and the variation in world recommen-
dations, perhaps standardisation with
more liberal EASD recommendations
is indicated.
Acknowledgements
The authors wish to thank all partici-
pants. Thanks also to Anne Perry,
BeeChoo Lim, Angela Sun and AG
Tan for their help during the study.
Declaration of interests
There are no conflicts of interest
declared.
References
1. Donnelly LA, et al. Frequency and predictors of hypo-
glycaemia in type 1 and insulin-treated type 2 diabetes:
a population-based study. Diabet Med 2005;22:
749–55.
2. UK Hypoglycaemia Study Group. Risk of hypogly-
caemia in types 1 and 2 diabetes: effects of treatment
modalities and their duration. Diabetologia 2007;50:
1140–7.
3. Cryer PE, et al. Hypoglycemia in diabetes. Diabetes
Care 2003;26:1902–12.
4. Cryer PE. Hypoglycemia in type 1 diabetes mellitus.
Endocrinol Metab Clin North Am 2010;39:641–54.
5. American Diabetes Association. Defining and reporting
hypoglycemia in diabetes. Diabetes Care 2005;28:
1245–9.
6. Leiter LYJ, et al. Assessment of the impact of fear of
hypoglycemic episodes on glycemic and hypoglycemia
management. Can J Diabetes 2005;29:186–92.
7. American Diabetes Association. Standards of medical
care in diabetes – 2012. Diabetes Care 2012;35(Suppl
1):S11–S63.
8. Canadian Diabetes Association. Hypoglycemia.
Canada: Canadian Diabetes Association. www.
diabetes.ca/ [accessed June 2012].
9. Diabetes Australia. Hypoglycemia. Canberra: Diabetes
Australia. www.diabetesaustralia.com.au/ [accessed
June 2012].
10. Diabetes Education Study Group of The European
Association for the Study of Diabetes. Teaching Letter
2, Hypoglycemia. www.desg.org/ [accessed June
2012].
11. Asian-Pacific Type 2 Diabetes Policy Group. Type 2
Diabetes Practical Targets and Treatments.
International Diabetes Federation. www.idf.org/idf-
wpr-type-2-diabetes-pratical-targets-and-treatments
[accessed April 2012].
12. Singapore Diabetes Society. Diabetes and
Hypoglycemia. Singapore: Diabetic Society of
Singapore. www.diabetes.org.sg/ [accessed June
2012]. 
13. Treatment of hypoglycaemia. London: Diabetes UK.
www.diabetes.org.uk/ [accessed June 2012].
14. Clinical Guidelines. Belgium: International Diabetes
Federation. www.idf.org/ [accessed June 2012].
15. American Diabetes Association. Introduction. Diabetes
Care 2008;31(Suppl 1):S1–S2.
16. Brodows RG, et al. Treatment of insulin reactions in 
diabetics. JAMA 1984;252:3378–81.
17. Slama G, et al. The search for an optimized treatment
of hypoglycemia: carbohydrates in tablets, solution, or
gel for the correction of insulin reactions. Arch Intern
Med 1990;150:589–93.
18. Wiethop BV, Cryer PE. Alanine and terbutaline in treat-
ment of hypoglycemia in IDDM. Diabetes Care
1993;16:1131–6.
19. Heller SR. Diabetic hypoglycaemia. Baillieres Best Pract
Res Clin Endocrinol Metab 1999;13:279–94.
20. Cox DJ, et al. Self-treatment of hypoglycemia while
driving. Diabetes Res Clin Pract 2001;54:17–26.
21. Sommerfield AJ, et al. Self-treatment of mild sympto-
matic hypoglycaemia by people with insulin-treated
diabetes. Diabet Med 2003;20:686–7.
22. Ley P, Florio T. The use of readability formulas in health
care. Psychol Health Med 1996;1:7–28.
23. Viera AJ, Garrett JM. Understanding interobserver
agreement: the kappa statistic. Fam Med 2005;
37:360–3.
24. Saw SM, Ng TP. The design and assessment of ques-
tionnaires in clinical research. Singapore Med J
2001;42:131–5.
25. Kelley K, et al. Good practice in the conduct and report-
ing of survey research. Int J Qual Health Care
2003;15:261–6.
26. Atkinson FS, et al. International tables of glycemic
index and glycemic load values: 2008. Diabetes Care
2008;31:2281–3.
27. Brand-Miller J, Buyken AE. The glycemic index issue.
Curr Opin Lipidol 2012;23:62–7.
28. Gunma University Faculty of Medicine. Fisher Exact
Test. Japan: Shigenobu AOKI. http://aoki2.si.gunma-u.
ac.jp/exact/exact.html [accessed June 2012].
29. Choudhary P, Amiel SA. Hypoglycaemia: current man-
agement and controversies. Postgrad Med J
2011;87:298–306.
30. Husband AC, et al. The effectiveness of glucose,
sucrose, and fructose in treating hypoglycemia in chil-
dren with type 1 diabetes. Pediatr Diabetes 2010;
11:154–8.
31. Brand-Miller J, et al. Carbohydrates – the good, the bad
and the whole grain. Asia Pac J Clin Nutr 2008;
17(Suppl 1):16–9.
32. ADA. Nutrition Recommendations and Interventions
for Diabetes. Diabetes Care 2008;31(Suppl 1):S61–S78.
274 PRACTICAL DIABETES  VOL. 29 NO. 7 COPYRIGHT © 2012 JOHN WILEY & SONS
Food and hypoglycaemia
Original article
l This study showed many responders reporting use of recommended, but medium-acting,
carbohydrate for initial treatment of their hypoglycaemia. Increased education in the 
use of quick-acting carbohydrate and research on the efficacy of recommended 
medium-acting carbohydrate for treatment of hypoglycaemia seems indicated
l Many study participants reported using quantities of initial treating carbohydrate within EASD
recommendations (15–30g) rather than the lower country of origin recommendation (15g).
Non-adherence is not a reason to review recommendations, but in view of the relatively low
evidence level on which recommendations are based and worldwide variation in
recommendations, standardisation with the more liberal EASD recommendations seems timely
l In spite of recommendations, only 55.8% of responders reported ingesting follow-up food
post initial treatment of hypoglycaemia. Further investigation to assess association between
follow-up food and repeat hypoglycaemia would clarify the significance of this finding
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ABSTRACT
Introduction: Guidelines for self-treatment of
hypoglycaemia specify initial treatment with
quick-acting carbohydrate until blood glucose
levels normalize and then follow-up with
longer-acting carbohydrate. The few studies
investigating follow-up show 29–57% omission
or undertreatment with follow-up carbohydrate
but do not investigate the association of this
with repeat hypoglycaemia. This study aimed
to develop, validate and administer a
questionnaire to delineate this association.
The timeframe targeted was 2 h post primary
hypoglycaemic event (PPHE), the time
influenced by long-acting carbohydrate.
Methods: A questionnaire was generated, test–
retest reliability assessed, and it was piloted on
convenience samples from the target
population. The final version was administered
to all insulin-treated individuals attending an
outpatient diabetes clinic over 4 weeks (169).
Results: Questionnaire development:
readability (69.6—standard/easy), test–retest
reliability (Cohen’s kappa 0.57–0.91) and
return rate (72.2%) were all acceptable.
Questionnaire data: questionnaires were
returned by 122 participants (63 males/59
females). Method of insulin administration
was subcutaneous insulin injections (91%) and
continuous subcutaneous insulin infusion
(CSII) (9%). Repeat hypoglycaemia within 2 h
PPHE was reported by 8.2% of respondents.
There was no significant difference for age,
gender and diabetes duration between those
reporting repeat hypoglycaemia and those
without. Consumption of follow-up longer-
acting carbohydrate was reported by 58.2% of
responders with 48% of these using long-acting
and 52% medium-acting carbohydrate foods.
Method of insulin administration and
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consumption of follow-up food were
significantly associated with repeat
hypoglycaemia (P = 0.015, 0.039) but presence
or absence of symptoms and duration of
action of carbohydrate were not significantly
associated (P = 0.103, 0.629). Hierarchical
logistic regression analysis showed omission of
follow-up food PPHE was not a significant
predictor of increased likelihood of repeat
hypoglycaemia within 2 h PPHE, irrespective
of method of insulin administration
(P = 0.085).
Conclusion: This study supports guidelines that
recommend judicious, rather than routine use
of follow-up longer-acting carbohydrate PPHE.
Keywords: Repeat hypoglycaemia; Insulin-
treated diabetes; Follow-up carbohydrate
INTRODUCTION
Hypoglycaemia is a common complication of
insulin treatment resulting from relative
insulin excess and suboptimal glucose
counterregulation [1]. Mean rates of
hypoglycaemia in insulin-treated diabetes are
reported as 42.89 (type 1) and 16.37 (type 2)
events per person per year (population-based
study) [2] and 29.0 (type 1 [15 years duration)
and 10.2 (type 2 [5 years duration) events per
person-year (secondary health based study) [3].
Hypoglycaemia is cited as the main impediment
to euglycemia [4] and the most feared
complication of insulin-treated diabetes [5].
It has been reported that 90.8% of adults
with type 1 and 84.5% with type 2 diabetes
self-treat their hypoglycaemia [6].
Recommendations for self-treatment advise
ingestion of quick-acting carbohydrate,
reassessment of blood glucose and repeat
treatment until blood glucose levels normalise.
Subsequent ingestion of longer-acting
carbohydrate is then recommended [7–14] as
quick-acting carbohydrate used for initial
treatment peaks at 30 min and may return to
baseline by 90–120 min [15], theoretically
increasing the possibility of a repeat
hypoglycaemic event within this timeframe.
Longer-acting carbohydrate potentially stays
above baseline to 210 min post-ingestion [16].
There are few reports in the literature on
the extent of adherence to recommendations
for follow-up treatment with longer-acting
carbohydrate [17–19]. Sommerfield et al. in a
survey of 101 insulin-treated individuals
reported 29% undertreating with long-acting
follow-up food [17], defining undertreatment as
less than 10–20 g of long-acting carbohydrate
(Diabetes UK Treatment Guidelines For
Hypoglycaemia) [13]. Sumner et al. surveyed
125 individuals with type 1 diabetes reporting
57% omitted long-acting follow-up
carbohydrate [18], and Vindedzis et al.
reported 44.2% omitted follow-up
carbohydrate in a survey of 119 insulin-treated
individuals [19]. The association of omission or
inadequate ingestion of follow-up food with
repeat hypoglycaemia was not investigated in
any of these studies.
Repeat hypoglycaemia per se does not have a
formal definition, and the term is sometimes
used interchangeably with recurrent
hypoglycaemia [20] and multiple episodes of
hypoglycaemia [21]. Current literature on
repeat/recurrent hypoglycaemia examines a
longer timeframe than would be affected
by lack of follow-up food post-primary
hypoglycaemic event (PPHE). Reports on
paramedic treatment of hypoglycaemia
identify repeat hypoglycaemia as occurring
within 24–72 h PPHE [22], and reviews of
mechanisms and prevention of hypoglycaemia
identify repeat hypoglycaemia over 24 h PPHE,
Diabetes Ther
123
or longer [23, 24]. This timescale for recurrence
in the insulin-treated individual will be largely
influenced by insulin status and also defective
counterregulation, clinically indicated by
reduced awareness of hypoglycaemic
symptoms [23]. Method of insulin
administration may be a modifier of
hypoglycaemia within a shorter timeframe;
there is mixed evidence of the association of
continuous subcutaneous insulin infusion
(CSII) with reduction in severe hypoglycaemia
as compared with multiple daily injections
[25, 26].
It could be reasonably assumed that the
effect of follow-up longer-acting carbohydrate
on blood glucose levels would be confined to
2–3 h PPHE depending on the source of the
carbohydrate [16]. We therefore hypothesized
that omission of follow-up longer-acting
carbohydrate would increase the frequency of
repeat hypoglycaemia within 2 h PPHE in free-
living insulin-treated individuals. The aim of
this study was therefore, first, to develop and
validate a questionnaire to obtain data on
treatment of primary hypoglycaemia, the
presence or absence of symptoms of
hypoglycaemia, and the frequency of repeat
hypoglycaemia within 2 h PPHE and second, to
administer this questionnaire to free-living
insulin-treated individuals to assess the
likelihood of repeat hypoglycaemia with and
without follow-up food while controlling for
other significant modifiers of hypoglycaemia.
MATERIALS AND METHODS
Development of the Questionnaire
The one-page questionnaire was couched in
simple language with explanation of technical
terms and aimed at completion within 10 min.
It commenced with a brief preamble assuring
anonymity and explaining the aim was
investigation of individual experience of
hypoglycaemia. Contact and ethics approval
details were provided. Questionnaire items were
generated from the literature, patient education
material and clinical experience and were a
mixture of multichoice and numeric and text
open-ended questions. Readability of the
questionnaire was assessed by the Flesch
Reading Ease Formula and Flesch–Kincaid
Grade Level Formula, which are considered
suitable for use in health care settings [27].
Content validity was assessed qualitatively by a
diabetologist, two diabetes educators and a
dietitian. A convenience sample of 19 insulin-
treated people from the population to be tested
were recruited to assess test–retest reliability of
the questionnaire, which was conducted by
comparing self-administered responses with
interview responses to the same questionnaire
items. Interviews were carried out by one of five
experienced diabetes educators blinded to the
original responses. The questionnaire was then
piloted on a convenience sample of nine people
with insulin-treated diabetes (7% of sample size)
to gain insight into item comprehension; this
resulted in several minor rewordings. The return
rate of the questionnaire was calculated by
number of returned questionnaires against
number distributed.
Administration of the Questionnaire
The questionnaire was distributed to all insulin-
treated adults attending routine outpatient
diabetes clinic appointments over a period of
4 weeks (n = 169). Treatment of diabetes was by
either subcutaneous insulin injection (SII) or
CSII. All procedures followed were in
accordance with the ethical standards of
the responsible committee on human
experimentation (institutional and national)
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and with the Helsinki Declaration of 1975,
as revised in 2000. Study information was
given and consent presumed on return of
questionnaire. Ethics approval was obtained
from Curtin University Human Research Ethics
Committee and the project was registered as a
clinical audit at Royal Perth Hospital. The
questionnaire was designed for self-
administration but was initially given to
insulin-treated individuals, with a brief
explanation, by one of five credentialled
diabetes educators. The questionnaire was
anonymous, filled out while waiting to see the
doctor and consent was presumed on return of
the questionnaire to a designated sealed box.
Statistical Methods
Questionnaire Development
Test–retest reliability of the questionnaire was
evaluated by percent agreement and also using
the kappa statistic (j), which measures the
amount by which agreement exceeds that
expected by chance. Kappa was calculated for
the self administered—interview data with 95%
confidence intervals based on 1,000 bootstraps.
Data from Questionnaire
Descriptive statistics were used for participant
characteristics and hypoglycaemic frequency.
The Chi-square test (v2) was used to compare
categorical variables and extended Fisher’s exact
test for age and duration of diabetes ([2 9 2
contingency table with some cells \5).
Glycaemic index (GI) was used to assess
duration of action of follow-up carbohydrate
with GI of B55 categorized as long-acting and
56–69 as medium-acting carbohydrate [28].
Hierarchical logistic regression analysis was
performed to predict the likelihood of repeat
hypoglycaemia with respect to consumption/
non-consumption of follow-up food while
controlling for other significant variables.
Analysis was performed using SPSS Statistics—
version 21 (IBM Corporation, Somers, NY, USA)




Readability of the questionnaire was assessed
as 69.6 on Flesch Reading Ease Formula
(standard—easy level) and 6.2 on Flesch–
Kincaid Grade Level Formula consistent with a
grade 6 level, thus theoretically understandable
by 85–90% of the population [27]. Test–retest
reliability and response rate for individual items
are shown in Table 1. Response rates and percent
agreement were uniformly high. Values for j
exceeded 0.61, indicating substantial agreement
for six of the seven questions, with moderate
agreement for the other [30].
Data from Questionnaire
Questionnaires were returned by 122 out of 169
participants (63 males, 59 females) giving a
return rate of 72.2%, well above the estimated
acceptable rate of 65% for self-completed postal
questionnaires [31]. Participant characteristics
are shown in Table 2 and self-reported frequency,
symptoms and treatment of hypoglycaemia in
Table 3. Repeat hypoglycaemia was reported by
8.2% (n = 10) of participants and correlated well
with a separate question on self-reported
frequency of repeat hypoglycaemia (P\0.001).
There was no significant difference in the
distribution of age, gender and duration of
diabetes between those reporting repeat
hypoglycaemia and those without (P = 0.343,
1.00, 0.458 respectively). All participants
reported consuming initial treatment food.
Diabetes Ther
123
Follow-up food ingestion was reported by
58.2% of item responders with 48% of these
using long-acting and 52% medium-acting
carbohydrate. Ninety percent of those using
medium-acting carbohydrate chose food
sources in the lower half of this category, i.e.
GI \62 (Fig. 1).
Both method of insulin administration and
consumption/non-consumption of follow-up
food PPHE were significantly associated with
presence/absence of repeat hypoglycaemia (v2:
P = 0.015, 0.039) but presence/absence of
hypoglycaemic symptoms and duration of
action of carbohydrate were not significantly
associated (v2: P = 0.103, 0.629). Hierarchical
logistic regression analysis was then conducted
to predict the likelihood of repeat
hypoglycaemia using consumption/non-
consumption of follow-up food PPHE as a
predictor variable while controlling for
method of insulin administration. A test of the
full model against a constant only model was
statistically significant, indicating that the
predictor variables should distinguish between
those with and without repeat hypoglycaemia
(v2 = 4.445, P = 0.035 with df = 1), the Hosmer–
Lemeshow goodness of fit test was not
significant (P = 0.838) indicating the model
prediction was not significantly different from
Table 1 Test–retest reliability and response rates of questionnaire items
Question topic Test–retest by interview % Item responseb
%a j 95% CI
Frequency of hypoglycaemia 94.7 0.91 0.71–1.00 97.5
Hypoglycaemic symptoms yes/no 78.9 0.69 0.39–0.92 94.3
Repeat hypoglycaemia yes/no 84.2 0.57 0.21–0.84 100
Frequency of repeat hypoglycaemia 94.7 0.89 0.63–1.00 100
Initial treatment food 88.9 0.84 0.60–1.00 100
Follow-up with food yes/no 89.5 0.76 0.53–1.00 98.4
Food used for follow-up 84.6 0.61 0.32–0.84 98.4
a Percent agreement
b Percent of total responders answering item
j Cohen’s kappa, CI confidence interval
Table 2 Participant characteristics
Percent
responders
Gender (m/f) 63/59 100





Treatment (SII/CSII) (N, %) 111/11
(91/9)
100





CSII continuous subcutaneous insulin infusion, m/f male/




the observed values; however, the Wald
criterion demonstrated that consumption/non-
consumption of follow-up food PPHE was not a
significant predictor of repeat hypoglycaemia
(P = 0.085). All standard errors \2 indicated no
multicollinearity between variables.
DISCUSSION
Insulin-treated individuals in the target
population are routinely taught to ingest
follow-up food post-hypoglycaemia; therefore,
it might be presumed they may be reluctant to
admit they do not carry this out. In view of this,
the data collection method considered optimal
for this study was an anonymous self-
administered questionnaire. This mode has
been shown to decrease biased responses and
result in more accurate and less ‘socially
desirable’ responses to sensitive health-related
questions than information obtained by
interview [32]. A negative aspect of self-
administered questionnaires is a possible
decrease in reliability for open and more
complex questions [33], but this was not
demonstrated in this study. Advanced
notification ahead of self-administration of a
questionnaire has been shown to raise response
rates and credibility without affecting
questionnaire response type [33], and the
initial contact by diabetes educators with









































wk week, y yes, n no, N number of responders
Fig. 1 Follow-up carbohydrate—foods ingested and
duration of action. Numbers in brackets in legend
(x) denote average GI. Slice labels denote percent
respondents ingesting specific food. Dotted slices denote
long-acting carbohydrate. Cross-hatched slices denote
medium-acting carbohydrate with GI \62
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potential participants may partly account for
the relatively high response rate.
Potentially many factors influence repeat
hypoglycaemia [23]. We have investigated one
of these (follow-up food) and sought to control
for the other factor (method of insulin
administration) that showed a significant
association within the specified timeframe.
Perhaps surprisingly, lack of symptoms of
hypoglycaemia was not a modifier, possibly a
function of the inclusion of individuals with
insulin-treated type 2 diabetes and the
associated lower rate of compromised
counterregulation [34].
A limitation of this study was the inability to
differentiate between type 1 and insulin-treated
type 2 diabetes. It was considered that self-
reported data on this may be inaccurate.
Similarly, we collected no data on alcohol
consumption, a modifier of hypoglycaemia, as
this requires strategies to obtain accurate
information outside the scope of this study [35].
Hierarchical binary logistic regression was
the statistical test of choice as it assesses the
likelihood of an event occurring given a set of
conditions and does not require the statistical
presumption of normality, which was not
fulfilled in this data as all variables were
categorical. Although only 10 participants
reported repeat hypoglycaemia, the sample
size (122) was considered adequate according
to the rule of thumb N - k - 1 C 50 (N = sample
size, k = number of predictor variables) [36].
The questionnaire item yes/no to experiencing
repeat hypoglycaemia was used as the outcome
variable, but only exhibited moderate
test–retest reliability. It did, however, show
excellent correlation with the separate
questionnaire item on frequency of repeat
hypoglycaemia, which exhibited high
test–retest reliability, and was therefore taken
as robust data.
The high reported rate (40.2%) of omission
of follow-up food in this study is consistent
with two other comparable studies [17, 19]. The
use of medium-acting foods for follow-up is
consistent with some recommendations [9, 13,
14], but notably, in this study, the majority of
respondents selecting medium-acting follow-up
foods tended towards those that were slower-
acting in this category and this may account for
the lack of association of duration of action of
carbohydrate with incidence of repeat
hypoglycaemia.
The relative percentages of reported repeat
hypoglycaemia and omission of follow-up
longer-acting carbohydrate PPHE suggest many
individuals do omit follow-up food with
impunity. The situation is rather complex,
with some guidelines recommending routine
consumption of follow-up food [7, 9, 12] and
others stating follow-up food may be required
[10, 13, 14]. CSII treatment is cited as one
instance where follow-up food may be
unnecessary as short-term insulin status is
more controllable [14]; however, in this study
omission of follow-up food PPHE did not
significantly increase the likelihood of repeat
hypoglycaemia irrespective of method of
insulin administration.
CONCLUSION
The results of this study support guidelines
recommending judicious, rather than routine
use of follow-up longer-acting carbohydrate
PPHE.
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CHAPTER 7: PATIENT KNOWLEDGE OF ALCOHOL AND 
HYPOGLYCAEMIA IN TYPE 1 DIABETES 
7.1  Expanded significance of study 
7.1.1 Alcohol intake in people with type 1 diabetes 
Consumption of alcohol is the norm in Australia and the results from the Australian 
2011-2012 National Health Survey showed that in 2011-12, 82.4% of Australians ≥ 
18 y had consumed alcohol in the past year with 19.5% of adults consuming more 
than two standard drinks per day on average, thus exceeding the drink-safe 
guidelines (Australian Bureau of Statistics, 2012).  
Alcohol consumption in specific groups is difficult to assess as questions about 
‘typical’ quantities of alcohol consumed tend to lead to underestimates (Stockwell et 
al., 2004), and it is well documented that survey questions on alcohol intake are 
‘sensitive’ questions which are answered with less accuracy than other question types 
(Beck & Peretti-Watel, 2002; Tourangeau & Yan, 2007). This may be the reason 
there is a paucity of current information on alcohol intake by those with type 1 
diabetes in Australia.  
A 1991 US study of alcohol consumption in adolescents with type 1 diabetes showed 
approximately 50% had tried alcohol and 25% reported ongoing use, less than for the 
general population (Glasgow et al., 1991). A more recent study from Chile, also in 
adolescents, showed 30.1% of those surveyed had consumed alcohol compared to 
39.2% of those without diabetes (Martínez-Aguayo et al., 2007) although conversely 
an Italian study showed alcohol consumption by 56% of those with type 1 diabetes 
compared to  51% of controls (Scaramuzza et al., 2010). Overall, from the available 
information consumption of alcohol may be less in those with type 1 diabetes than in 
equivalent populations without diabetes. 
7.1.2 Associated risk 
Health risks 
Although the intake of alcohol by those with type 1 diabetes may be less than that in 
the general population, the risk to health is greatly increased and includes reduced 
diabetes self-care, ketoacidosis and hypoglycaemia (Barnard, Sinclair, Lawton, 
Young, & Holt, 2012). Of these, the most common, associated with the greatest acute 
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risk, is hypoglycaemia (Choudhary & Amiel, 2011). In a study in adults with type 1 
diabetes using CGMS, intake of alcohol at dinnertime has been associated with 
increased hypoglycaemic events the following day (Turner et al., 2001) and in a 
larger study using CGMS Richardson et al reported similar results and also showed 
decreased hypoglycaemic awareness (Richardson et al., 2005). Pedersen-Bjergaard et 
al in an analysis of 141 people with type 1 diabetes hospitalized with severe 
hypoglycaemia reported that 17% of these were associated with alcohol which was 
consistent with two other studies (Pedersen-Bjergaard et al., 2005). Cheyne et al, in a 
hyperinsulinaemic glucose clamp study, showed that the combination of alcohol and 
hypoglycaemia caused a marked decrease in cognitive function, and this posed a 
special risk to driving skills  (Cheyne et al., 2004), which is especially concerning, as 
accidents while driving are often preceded by frequent mild symptomatic 
hypoglycemia (Cox et al., 2003). 
Alcohol-related mortality 
In 2003, alcohol consumption accounted for 3.3% of disease and injury in Australia 
and 13 per cent of deaths among Australians of 14 – 17 y (National Health and 
Medical Research Council, 2008) and worldwide, alcohol is reported to have caused 
3.7% of all deaths (National Health and Medical Research Council, 2008).  The 
figures for alcohol-associated mortality in those with type 1 diabetes in Australia are 
not available, however in Finland, where alcohol-related deaths are on a par with the 
world average (3.7%) (Official Statistics of Finland (OSF), 2012), a nationwide 
population-based cohort study examining trends in mortality among patients with 
type 1 diabetes showed that alcohol and drug-related mortality accounted for 39% of 
the deaths during the first 20 years of diabetes, 10 times that of the general 
population (Harjutsalo et al., 2011).  
7.1.3  Education, hypoglycaemia and alcohol 
Richardson et al asserted that there is a lack of consistent advice given to those with 
type 1 diabetes concerning alcohol and hypoglycaemia (Richardson et al., 2005). 
Scaramuzza et al recommend educational intervention (Scaramuzza et al., 2010), 
Jaser et al recommend development and testing of standardized prevention programs 
(Jaser, Yates, Dumser, & Whittemore, 2011) and Engler et al in a review of alcohol 
use by diabetes patients strongly recommend assessment of alcohol intake and 
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intervention (Engler, Ramsey, & Smith, 2013). Cheyne et al state that patients with 
type 1 diabetes should be educated about hypoglycaemia and driving (Cheyne et al., 
2004). The ADA, in a review of driving and diabetes recommend patients should be 
advised to self-monitor their glucose levels more frequently for several hours after 
moderate alcohol intake because of the risk of hypoglycaemia (American Diabetes 
Association, 2013a) and the NHMRC highlighted the need for education in this area 
(Craig et al., 2011).  
How much, then, do people with type 1 diabetes know about alcohol and 
hypoglycaemia? Ahmed et al in a study of 65,996 people with diabetes showed that 
alcohol intake is inversely associated with adherence to diabetes self-care behaviours  
but did not identify the extent of knowledge of alcohol and hypoglycaemia (Ahmed, 
Karter, Warton, Doan, & Weisner, 2008), as did Thomas et al in a similar study on 
3,930 veterans (Thomas et al., 2012). Ramchandani et al in a study on factors 
affecting glycaemic control in 42 college students with type 1 diabetes in the USA 
reported that of those surveyed, 35.7% drank alcohol once or twice a week with 
33.3% drinking 4 - 6 drinks in an evening. Alcohol was rated as 6/16 of factors 
identified by students as causing deterioration in diabetes control but hypoglycaemia 
was not reported in association with this and students’ knowledge of alcohol and 
hypoglycaemia not reported (Ramchandani et al., 2000). Engler et al in a recent 
publication, commented that although brief interventions can change alcohol-related 
behaviour in those with diabetes, there is only one study measuring the efficacy of 
this and this is in type 2 diabetes (Engler et al., 2013; Fleming, Brown, & Brown, 
2004). And finally, looking at online education, Jones et al in a study investigating 
social networking and understanding of alcohol-associated risk for people with type 
1 diabetes, identified 10 web sites with information/opinion/advice on alcohol and 
diabetes. No professional health information sites were identified and inaccurate 
information was common in the existing sites. No assessment or self-assessment of 
knowledge on these sites was reported (Jones, Sinclair, Holt, & Barnard, 2013). The 
only study reporting knowledge of hypoglycaemia and alcohol is a qualitative study 
by Miller-Hagen et al investigating perception and management of alcohol by 
college students in the USA, 11 of whom had type 1 diabetes. This study is reported 
as an unquantified narrative, and describes how some of the sample with type 1 
diabetes developed knowledge/strategies. It recommends further research on how 
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education can improve drinking management in students with diabetes (Miller-Hagan 
& Janas, 2002). 
There is, therefore, a dearth of information on assessment of current knowledge of 
alcohol and hypoglycaemia by those with type 1 diabetes. The following paper 
investigates this topic and compares assessed knowledge with current information 
provided on this topic by a variety of national diabetes associations.  
7.1.4 Hypoglycaemia and alcohol - recommendations 
Recommendations for avoidance of alcohol-induced hypoglycaemia are presented in 
Appendix 4 (with thanks to Royal Perth Hospital Diabetes Clinic).  
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7.2  Paper 5 
Vindedzis SA, Marsh B, Sherriff JL, Stanton KG. Alcohol and type 1 diabetes: 
Patient knowledge of alcohol-induced sustained hypoglycaemia. Diabetes Res Clin 
Pract. 2013 Nov;102(2):e19-20. doi: 10.1016/j.diabres.2013.08.010. Epub 2013 Sep 
26. No abstract available
Letter to the Editor
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 2 ( 2 0 1 3 ) e 1 9 – e 2 0
Contents available at ScienceDirect
Diabetes Research
and Clinical Practice
journal homepage: www.elsevier.com/locate/diabresAlcohol and type 1 diabetes: Patient
knowledge of alcohol-induced
sustained hypoglycaemia
In type 1 diabetes alcohol can significantly reduce blood glucose
6–8 h post-consumption [1] with increased risk lasting 24 h [2].
Risk is dose-related and can be reduced with judicious
carbohydrate consumption and long-acting insulin reduction
where necessary [1]. There are, however, few studies assessing,
firstly, easily available information and secondly, patients’
knowledge in this area. We accessed and assessed National
Diabetes Association guidelines, as typical information retriev-
able from an Internet search for ‘alcohol and type 1 diabetes’
and also assessed knowledge of alcohol and hypoglycaemia in
adults with type 1 diabetes by questionnaire.
Questionnaire items assessed knowledge of the hypogly-
caemic effect of alcohol, duration of hypoglycaemia post-
consumption and number of standard drinks perceived to
cause hypoglycaemia. Standard drink quantity was depicted
for comparison. Risk reduction (dietary or insulin modifica-
tion) was not addressed to minimize prejudicing assessment
of knowledge of hypoglycaemic effect per se. Questionnaire
readability was 7.3 on Flesch–Kincaid Grade-Level score, thus
understandable by a seventh grader. It was distributed to 50









American Diabetes Association y  y
 up to 24 h
Canadian Diabetes Association y  y
 up to 24 h
Diabetes Australia y  y
 up to 24 h
Diabetes New Zealand y  n
 n.s.
Diabetic Society Singapore y  y
 n.s.
Diabetes UK y  y
 up to 16 hroutine outpatient clinics; was anonymous, and consent
was presumed by return to a designated sealed box.
1. Results
Information on alcohol and hypoglycaemia provided by 6
National Diabetes Associations [3–8] is shown in Table 1. All
provided general information on alcohol and hypoglycaemia,
eating with, and snacking after alcohol, and sustained
hypoglycaemic effect, but the possible duration of hypogly-
caemia varied from not specified to 16–24 h. Only 2 guidelines
provided information on reduction of long-acting insulin.
Questionnaires were returned by 37 (74%) participants,
exceeding the acceptable return rate of 65% for self-completed
questionnaires [9]. Diabetes duration was 16.5  11.9 y and
treatment was by basal-bolus (83.8%)/CSII(16.2%). The hypo-
glycaemic effect of alcohol was correctly identified by 88.2% of
responders, but only 32.4% postulated duration of 4 + h post-
consumption. Standard drink quantity perceived to lower
blood glucose level was 1–3 (50%) and 4+ (41.2%). Study
limitations were small sample size (50) and the notorious
difficulty of obtaining accurate information on alcohol
consumption. We aimed to maximize accuracy by the proven
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d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 2 ( 2 0 1 3 ) e 1 9 – e 2 0e202. Conclusions
Knowledge of alcohol and hypoglycaemia was acceptable in
this group, except in the important area of duration of alcohol-
induced hypoglycaemia. This is congruent with accessed
guidelines and may reflect an identified lack of consistency in
information given to patients regarding alcohol-induced
hypoglycaemia [2]. Additionally not all guidelines provided
information on reduction of long-acting insulin, an important
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CHAPTER 8    HYPOGLYCAEMIA IN INPATIENTS WITH INSULIN-
REQUIRING  DIABETES ON NASOGASTRIC FEEDING 
8.1  Expanded significance of studies 
Those with diabetes have a greater frequency of hospitalization and longer length of 
hospital stay than people without diabetes (Moghissi et al., 2009). Prevalence of 
hypoglycaemia is demonstrably higher in general inpatients than in free-living 
individuals, with 3 - 29% of inpatients suffering at least one hypoglycaemic event 
during their hospital admission (Umpierrez et al., 2009; Umpierrez et al., 2011). 
Eiland et al have asserted that illness gives variable insulin sensitivity which 
increases risk of hypoglycaemia in inpatients with diabetes (Eiland et al., 2014). 
Other specific identified risk factors for inpatient hypoglycaemia in those with 
diabetes are mismatch of insulin and nutrition (Elliott et al., 2012; Kerry et al., 2013; 
Maynard et al., 2008), unexpected nutritional interruption (Maynard et al., 2008), 
prior inpatient hypoglycaemia (Maynard et al., 2008; Varghese et al., 2007), 
inadequate monitoring of trends in BSL (Elliott et al., 2012) and poor adherence to 
practice guidelines and documentation (Anthony, 2007; Maynard et al., 2008). 
Arguably, those on established nasogastric feeding in the general ward are a 
vulnerable subgroup of inpatients with an enhanced risk from all of these factors. 
They are on a relatively inflexible nutrition delivery schedule to which it may be 
difficult to match an appropriate insulin regimen within staff time constraints (Ng et 
al., 2009) and interruption of feeds for medical procedures and tests may further 
exacerbate hypoglycaemic risk (Maynard et al., 2008). Decreased nutritional intake 
is an indicator for the introduction of nasogastric feeding (Lloyd & Powell-Tuck, 
2004) and also often a trigger for an initial hypoglycaemic event and thus a risk 
factor for subsequent hypoglycaemic episodes (Maynard et al., 2008). Studies in 
critical care have shown that frequent measurement of blood glucose levels is 
essential to attain good glycaemic control and chart trends in BGL (Harper, 2007), 
yet the recommended frequency of blood glucose monitoring in the general ward for 
those on nasogastric feeding is 4 - 6 hourly testing (American Diabetes Association, 
2014b), and finally there is evidence that, at least in some hospitals, there is less than 
acceptable adherence to practice guidelines and documentation of nasogastric 
feeding practice (Dobson & Scott, 2007; Persenius, Hall-Lord, Baath, & Larsson, 
2008).  
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Aside from critical care and short-term post-operative care, nasogastric feeding is 
most often used to deliver nutrition to patients who have an altered conscious state or 
impaired swallowing ability (Lloyd & Powell-Tuck, 2004). There is little 
information on the prevalence of hypoglycaemia in inpatients with diabetes with 
altered conscious state, however, a parallel could perhaps be drawn with free-living 
individuals with hypoglycaemic unawareness, who are similarly unable to respond to 
symptoms of impending hypoglycaemia and have been shown to have a six-fold 
higher frequency of severe hypoglycaemia than those with normal awareness of 
hypoglycaemia  (Geddes et al., 2008). 
Turchin et al have shown that in patients in the general ward, each additional day 
with hypoglycaemia is associated with an increase of 85.3% in the odds of death 
(Turchin et al., 2009). It could be surmised that inpatients on nasogastric feeding 
may be at even greater risk.  Interventions to decrease hyperglycaemia in people on 
nasogastric feeding are well researched (Alish et al., 2010; Ceriello et al., 2009; Elia 
et al., 2005; Vanschoonbeek et al., 2009), but this is not the case with 
hypoglycaemia. The following papers add information to this crucial yet under-
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8.2  Paper 6 
Vindedzis SA, Marsh B, Sherriff JL, Stanton KG. Hypoglycaemia in inpatients with 
diabetes on nasogastric feeding. Practical Diabetes. 2014; 31(1):29-31.  
DOI:10.1002/pdi.1824. 
Introduction
Hypoglycaemia is a common compli-
cation of treatment with insulin and
sulphonylurea agents.1 Swift identifi-
cation and management of mild
hypoglycaemic episodes prevent
progression to severe hypogly-
caemia2 which has been associated
with increased morbidity,3,4 as has
increased duration of hypogly-
caemia.5,6 The majority of inpatients
with diabetes on nasogastric feeding
have altered conscious state and are
unable to respond to symptoms of
hypoglycaemia, making them reliant
on often busy staff, to identify and
treat their hypoglycaemia. In this
context, even with regular blood glu-
cose monitoring (BGM) there may
be considerable progression of a
hypoglycaemic episode prior to its
identification.5,6 There is extensive
literature on diabetes specific for-
mula feeds, mainly with regard to
post-feed hyperglycaemia,7 but less
quantifying hypoglycaemia.8–10
We carried out a retrospective
case note review to determine the
frequency and timing of hypogly-
caemia in hospitalised patients with
diabetes on established nasogastric
feeding in a tertiary hospital. 
Methods 
Subjects were 50 inpatients with dia-
betes (27 male, 23 female) fed
entirely by nasogastric feeding for ≥3
days as per hospital protocol (Table
1). Patients on insulin infusions or
in ICU were excluded. Subjects were
consecutively flagged by the treating
dietitian. Data were collected from
medical notes, BGM records, and
medication charts. Goals of treat-
ment were blood glucose level
(BGL) ≥4 and <10mmol/L. Initial
treatment of hypoglycaemia was 
liquid carbohydrate as per hospital
protocol. No identifying informa-
tion was collected. The study was
approved by the Human Ethics
Research Committee (Curtin
University, Western Australia) and as
a tertiary hospital clinical audit.
Measures 
Hypoglycaemia was defined as BGL
<3.5mmol/L, as a level having clini-
cal relevance.11,12 Severe hypogly-
caemia is formally defined as ‘an
event requiring assistance of
another person to actively adminis-
ter carbohydrate’;13 but as this was
applicable to all events in this study,
we arbitrarily defined severe hypo-
glycaemia as BGL <2.0mmol/L, and
extended hypoglycaemia as dura-
tion >2 hours or repeat episode
within 2 hours. There is no stan-
dardised reporting method for 
frequency of hypoglycaemia14 so we
have reported it both as percentage
of patient-days with ≥1 hypogly-
caemic episode (PPD) and percent-
age of total blood glucose values
<3.5mmol/L (PTG), to allow for
variable feed duration and consis-
tent with two other studies.8,9
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Abstract
Hypoglycaemia in patients with diabetes on nasogastric feeding is both potentially damaging
and under-researched. We retrospectively reviewed 50 such inpatients to determine factors
influencing hypoglycaemia. Our results showed 10.9% patient-days with ≥1 hypoglycaemic
episode and 3.5% total blood glucose values <3.5mmol/L. There was an association between
sulphonylurea treatment and increased and extended hypoglycaemia. Reducing diabetes
treatment post-hypoglycaemia was associated with reduced subsequent hypoglycaemia but
not increased hyperglycaemia. 
This study supports optimal blood glucose monitoring, insulin treatment and judicious
medication reduction post-hypoglycaemia. Copyright © 2014 John Wiley & Sons.
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Descriptive statistics were used
for subject demographics, χ2 test to
compare categorical variables and
proportions, Shapiro-Wilk test to
determine normality, Spearman
rank-order correlation to determine
strength of association between non-
normally distributed continuous
variables, and log-rank test to com-
pare time to event data. Analysis was
performed using IBM SPSS
Statistics, v21, IBM, NY, USA, and
GraphPad Prism 6, GraphPad
Software Inc, USA.
Results 
Subject characteristics are shown in
Table 2. Frequency of hypogly-
caemia was: PPD 10.9%, PTG 3.5%,
and this was not statistically associ-
ated with gender, age, or feed carbo-
hydrate content (p>0.05). Increased
total hypoglycaemia was associated
with increased duration of nasogas-
tric feeding (p=0.016).
Hypoglycaemia was prevalent
before the next medication dose
and rare between medication
administration and feed bolus:
34.8% and 4.3% of hypoglycaemic
patients respectively. 
It was not possible to assess the
impact of withheld feeds from avail-
able documentation. Frequencies of
hypoglycaemia, severe hypogly-
caemia and extended hypogly-
caemia are shown in Table 3.
Sulphonylurea treatment (SU) was
associated with increased incidence
of hypoglycaemia (p<0.001) and
extended hypoglycaemia (p=0.038).
All hypoglycaemic patients had
increased BGM post-hypoglycaemia
(6.1±1.6/day) and based on this
78% had medication decreased in
response to hypoglycaemia. Survival
analysis showed a significantly
longer time to a subsequent 
hypoglycaemic episode between
patients whose treatment was
reduced in response to hypogly-
caemia and those whose treatment
remained unchanged (p=0.008)
(see Figure 1). There was no associa-
tion with subsequent hypergly-
caemia (p=0.33). 
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Figure 1. Kaplan-Meier survival curves for patients with treatment changed post-hypoglycaemia
(blue line) and unchanged (red line); + denotes censored data
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BGM: blood glucose monitoring; SA: short
acting; LA: long acting. 
BGM (h) Insulin Feed (h)











PPD: percent of patient days with 1+
hypoglycaemic event; PTG: percent of total
blood glucose level <3.5mmol/L; 
SCII: subcutaneous insulin injection; 
SU: sulphonylurea; PTG <2, percent of total
blood glucose level <2.0 mmol/L (severe
hypoglycaemia); PTG >2h, percent of total
blood glucose level >2h (extended
hypoglycaemia).
Variable Percent P-value
Table 3. Frequency of hypoglycaemia
Gender: M/F 27/23
Age: years 67.8±13.9
NG duration: days[range] 13.0±9.2[3–41]










NG: nasogastric feed; CHO: carbohydrate; 
SCII: subcutaneous insulin injection; 
SU: sulphonylurea.
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Discussion 
Hypoglycaemic episodes were not
uncommon in these patients.
Comparison with other nasogastric
studies is difficult due to lack of quan-
tification of hypoglycaemic events.15
Rates of hypoglycaemia in this study
(PPD 10.9%; PTG 3.5%) were higher
than the two comparable studies
(PPD – not reported8 and 1.1–1.3%9;
PTG – 1.4–5.48 and 1.1–1.39), espe-
cially as both defined hypoglycaemia
as <3.9mmol/L; the higher cut-off
point would be expected to identify
more hypoglycaemic episodes.16
Frequency of BGM also varied from
6.1±1.6/day (this study) compared to
4/day,8 and 4/day+ (maximum
6/day).9 However, it has been shown
that increased BGM can increase 
documented inpatient hypogly-
caemia and severe hypoglycaemia.17
Additionally, one study9 included sub-
jects on dual oral and enteral feeding
which may tend to decrease fre-
quency of hypoglycaemia.6,18
Severe and extended hypogly-
caemia are not quantified in the liter-
ature on nasogastric feeding but the
high frequency of BGM in our study
may have increased documentation
of these.17 Hypoglycaemia and
extended hypoglycaemia were statisti-
cally associated with SU, consistent
with other reports documenting
increased frequency of hypogly-
caemia in SU treated individuals,
especially those >65 years of age.19,20
As this was a retrospective obser-
vational study, duration of nasogas-
tric feeding varied. We therefore
used Kaplan-Meier survival curves
for time to event analysis of the
effect of reduction in medication
post-hypoglycaemia on a subsequent
hypoglycaemic episode. This meant
that censored data which arose from
cessation of nasogastric feeding
before a subsequent hypoglycaemic
event was observed, were taken 
into account. As a consequence, we 
have shown a significantly increased
time to a subsequent hypoglycaemic
event in those whose medication was
reduced. There was no association
with subsequent hyperglycaemia. 
Limitations of study
Neither type nor duration of dia-
betes or interruption of feeds are
quantified as they were not consis-
tently recorded in patient notes. 
Conclusions 
This study highlights the prevalence
of hypoglycaemia in patients on
nasogastric feeding. It supports opti-
mal blood glucose monitoring and
treatment with insulin rather than
sulphonylureas, and highlights the
need for appropriate medication
reduction based on blood glucose
monitoring results.
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● This study showed hypoglycaemia was
prevalent in inpatients with diabetes on
established nasogastric feeding in the
general ward, with increased frequency
associated with longer duration of
feeding but not with feed carbohydrate
content
● There was an association between
sulphonylurea treatment and increased
and extended hypoglycaemia. Reducing
diabetes treatment post-hypoglycaemia
was associated with reduced
subsequent hypoglycaemia but not
increased hyperglycaemia
● This study supports insulin treatment,
optimal blood glucose monitoring, and
judicious medication reduction post-
hypoglycaemia
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Purpose
This study aimed to address 2 questions: First, what are 
the existing summary statistics of frequency of hypogly-
cemia in insulin-treated adults on established nasogastric 
feeding in the general ward? Second, to what extent does 
lack of homogeneity in defining, identifying, and report-
ing hypoglycemia affect these statistics?
Methods
A systematic review of the literature documenting hypo-
glycemia in insulin-treated adults on nasogastric feeding 
for ≥ 3 days in the general ward was carried out. Data 
sources were PubMed, Embase, ProQuest, Cochrane, 
Directory of Open Access Journals, and PLoS. Search 
period was 1999 onward, postdating introduction of ana-
log insulin.
Results
Initially, 231 studies were identified, with 9 judged suit-
able for inclusion, according to inclusion/exclusion crite-
ria. All included studies had as their primary objective 
the assessment of efficacy of insulin/feed regimens in the 
target population. Studies exhibited major heterogeneity. 
Definitions of hypoglycemia varied from < 60 mg/dL 
(3.3 mmol/L) to < 80 mg/dL (4.4 mmol/L), and 5 meth-
ods of reporting frequency of hypoglycemia were uti-
lized, precluding pooled analysis. A descriptive synthesis 
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of results was generated with some comparable results 
presented on a modified forest plot, showing 2.1% to 
10.2% of patients with a hypoglycemic event and 1.1% 
to 5.4% blood glucose level < 70 mg/dL (3.9 mmol/L).
Conclusions
Hypoglycemia is not uncommon in this population, but 
further research is needed for quantification. Standardized 
documentation and reporting methods incorporating 
sample size and study duration, such as hypoglycemic 
events per patient-days, would facilitate interstudy com-
parisons, as would documentation of hypoglycemia 
at the 2 most commonly defined levels: < 63 mg/dL 
(3.5 mmol/L) and < 70 mg/dL (3.9 mmol/L).
H
ypoglycemia is common among inpa-
tients with diabetes,1 with a reported 
incidence ranging from 7.7%2 to 20%.3,4 
It has been shown to be significantly 
associated with both increased length of 
hospital stay and mortality.2,3,5 Turchin et al have reported 
that each additional day with hypoglycemia is associated 
with an increase of 85.3% in the odds of inpatient death.2 
Curkendall et al showed similar results with an addi-
tional economic impact of higher hospital charges and 
increased discharge to a skilled nursing facility associ-
ated with documented hypoglycemia.6
Variation in definition and reporting of inpatient hypo-
glycemia affects both strength of association with adverse 
effects and interstudy comparisons. The NICE-SUGAR 
Study showed increased mortality (hazard ratio, 1.41) 
associated with a hypoglycemic level of 41 to 70 mg/dL 
(2.3-3.9 mmol/L). This increased (2.1) with a hypoglyce-
mic level of ≤ 40 mg/dL (2.2 mmol/L).7 Krinsley et al 
used different cutoff points (< 40, 40-54, and 55-69 mg/
dL [2.2, 2.2-3.0, 3.1-3.9 mmol/L]) and showed increased 
relative risk of mortality of 3.55, 2.70, and 2.18, respec-
tively.8 A recent retrospective study by Sechterberger et al 
identified < 63 mg/dL (3.5 mmol/L) as a cutoff for detri-
mental low blood glucose level in critical care patients,9 
while Curkendall et al used different cutoff levels (70 mg/
dL [3.9 mmol/L] and 50 mg/dL [2.8mmol/L]).6
In the critical care situation, intensive blood glucose 
monitoring is in place, allowing swift identification and 
treatment of hypoglycemic episodes,10 but in the general 
ward, staffing and routine monitoring are reduced, and 
there is evidence that reduced staffing has a detrimental 
effect on resolution of hypoglycemic episodes.10,11 
Patients on established nasogastric feeding in a general 
ward situation are particularly vulnerable, often having 
altered conscious state, and are dependent on staff to 
identify and treat their hypoglycemia.
Despite numerous studies assessing the short-term 
glycemic effects of enteral feeding products12-15 and 
similar longer-term assessments of insulin regimens16,17 
and formula feeds,18-20 there are few studies directly 
quantifying hypoglycemia in those on nasogastric feed-
ing outside the critical care unit. This systematic review 
therefore aimed to address 2 questions: First, what are 
the existing summary statistics of frequency of hypogly-
cemia in insulin-treated adults on established nasogastric 
feeding in the general ward? Second, to what extent does 
lack of homogeneity in defining, identifying, and report-
ing hypoglycemia affect these statistics?
Methods
Search Strategy
The review was carried out in accordance with 
PRISMA and QUOROM statement guidelines.21-23 A sys-
tematic search to retrieve potentially relevant articles was 
conducted, from 1999 onward. This time frame was cho-
sen as postdating the introduction of analog insulin, 
whose shorter mode of action has been demonstrated to 
decrease the likelihood of hypoglycemia.24 Databases 
searched were as follows:
PubMed: Accessed April 19, 2013. Search terms—insulin 
AND (diabetes OR diabetic) AND (enteral OR “tube 
feed” OR nasogastric) AND (hypoglycemia OR hypo-
glycemia) NOT children NOT critical NOT “critically 
ill” NOT “intensive care” NOT neonates NOT pediatric 
[All Fields] and accessed again 21/04/2013 using search 
terms (diabetes OR diabetic) AND “tube feeding” AND 
insulin NOT children NOT critical NOT “critically ill” 
NOT “intensive care” NOT neonates NOT pediatric [All 
Fields].
ProQuest: Accessed April 20, 2013. Search terms—insulin 
AND (diabetes OR diabetic) AND (enteral OR “tube 
feed” OR nasogastric) AND (hypoglycemia OR hypo-
glycemia) NOT children NOT critical NOT “critically 
ill” NOT “intensive care” NOT neonates NOT pediatric 
[All Fields].
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Embase and Cochrane Library: Accessed April 21, 2013. 
Same search terms [All Fields]. Cochrane systematic 
reviews were searched April 24, 2013, by topic (diabetes), 
then subtopic (effective practice, general, type 1, type 2).
PLoS clinical trials and Directory Open Access Journals 
were searched April 21 and 22, 2013, respectively, with 
the following search terms: diabetes AND (enteral OR 
nasogastric OR “tube feed”) [All Fields]. Key journals in 
the field of enteral feeding and practical diabetes man-
agement were hand searched—Nutrition in Clinical 
Practice, Clinical Nutrition, Practical Diabetes, Diabetes 
Care, Clinical Diabetes, Diabetic Medicine—as were 
citations from retrieved articles.
Initial Retrieval, Selection Criteria, and 
Study Inclusion
Papers were initially identified from electronic and 
hand searches by screening of titles, abstracts, and 
extracts by one author (S.A.V.). Papers were retrieved if 
they met study inclusion/exclusion criteria. Inclusion cri-
teria were studies referencing hypoglycemia with partici-
pants ≥ 18 years old who had insulin-treated diabetes and 
were on nasogastric feeding. Papers were excluded if par-
ticipants were critically ill or in intensive care, were 
receiving significant oral supplementation (> 25% total 
energy intake orally), or were on nasogastric feeding < 3 
days, PEG feeding, or total parenteral nutrition. The full 
documents were then read by 2 authors (S.A.V. and 
J.L.S.). Papers were excluded if they did not meet inclu-
sion/exclusion criteria, were not original studies, or dem-
onstrated ineligible methodology. Papers were included 
on consensus from both authors.
Data Extraction and Analysis
Data were extracted by one author (S.A.V.) and veri-
fied by another (J.L.S.). Quality was assessed via SIGN 
checklists.25 Qualitative data extracted were study design, 
outcomes, and study mode of reporting hypoglycemia. 
Quantitative variables extracted were duration of data 
collection, level of blood glucose used to define hypogly-
cemia, reporting methodology, frequency of hypoglyce-
mia, and frequency of routine assessment of blood 
glucose. Due to the small number of studies suitable for 
inclusion and the heterogeneity of data, we largely took a 
descriptive approach to combining results; however, 
where data were comparable, they were presented as a 
modified forest plot to give a better picture of variability 
in reported frequency of hypoglycemia. Analysis was 
carried out with GraphPad Prism 6 (GraphPad Software 
Inc, La Jolla, California, USA).
Results
Of the total 231 studies initially identified by the 
search strategy, 185 were excluded after review of the 
title/abstract and a further 37 on the basis of the full paper 
(see Figure 1). The major reasons for exclusion were 
study overlap, inadequate duration of nasogastric feed-
ing, and critical care setting. Studies were listed accord-
ing to evidence level, with 9 papers16,17,19,26-31 that 
referenced hypoglycemia judged suitable for inclusion 
(Table 1). In these studies, hypoglycemia was variously 
referenced as an outcome,16,17,26,27,31 clinical data,28,30 or 
an adverse event,19,29 with the primary study objective 
being the assessment/comparison of insulin regi-
mens16,17,26-28,30,31 or nasogastric feed products.19,29 As the 
stated aim of this review was to assess published sum-
mary statistics of frequency of hypoglycemia in insulin-
treated adults on established nasogastric feeding in the 
general ward irrespective of insulin or feeding regimen, 
groups within studies have been assessed autonomously 
rather than comparatively.
Level of Blood Glucose Defined as 
Hypoglycemia
The level of blood glucose defined as hypoglycemia and 
the referenced rationale for this definition varied greatly 
among studies (see Table 2). It was variously defined as 
follows: < 80 mg/dL (4.4 mmol/L),27,28 referencing Finney 
et al32; < 70 mg/dL (3.9 mmol/L),16,17 referencing Dinardo 
et al33 and the American Association of Clinical 
Endocrinologists and American Diabetes Association con-
sensus statement34; < 60 mg/dL (3.3 mmol/L),19,26,29 2 
unreferenced and 1 referencing Centennial Medical Center 
policies35; and 2 studies30,31 with undefined levels, with one 
of these specifying no hypoglycemic events requiring treat-
ment, presumably referring to symptomatic hypoglycemia 
rather than biochemical definition.
Identification of Hypoglycemia
With the exception of 2 studies, identification of hypo-
glycemia was specified by level of blood glucose. 
Frequency of routine blood glucose monitoring varied 
widely among studies (median, 4 assessments/day; range, 
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2-6), and the rationale for this was, in the main, not speci-
fied. Where specified, frequency was tailored to study 
objectives,19 and it is reasonable to presume that the 2 
retrospective studies16,26 were following hospital proto-
col for frequency of blood glucose monitoring.
Study Methodology for Reporting 
Hypoglycemia
These 9 studies utilized 5 methods for reporting hypo-
glycemia (see Table 2), and 4 studies16,17,19,29 reported 2 
ways. The most common reporting method (6 stud-
ies)16,19,28-31 involved total number of hypoglycemic 
events. Study group sample size varied from 1 to 76 and 
data collection duration, when specified, from 3 to 84 
days; thus, reporting of total number of hypoglycemic 
events equates to a large variation among studies in fre-
quency of hypoglycemic events per patient-day. The sec-
ond-most utilized reporting method was percentage of 
patients with hypoglycemic event (2 studies)19,29 and 
percentage of total blood glucose levels < 70 mg/dL 
(3.9 mmol/L) (2 studies).16,17 One study each reported 
frequency of hypoglycemia as patient-days with 1 or 
more hypoglycemic events17 and percentage of time with 
blood glucose level < 60 mg/dL (3.3 mmol/L).26
Reported Frequency of Hypoglycemia
Reported frequencies of hypoglycemia are shown on 
Table 2. The only reporting methods utilized frequently 
enough to allow interstudy comparison were percentage 
of patients with hypoglycemic event and percentage of 
Figure 1. Flowchart showing search and retrieval of articles
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total blood glucose levels < 70 mg/dL (3.9 mmol/L), and 
these are presented on modified forest plots (Figures 2 
and 3). These plots are intended to give only a visual 
impression of study trends. Confidence intervals were 
calculated from study data using the point estimate (per-
centage) and the sample size—that is, group size (Figure 
2) and total number of blood glucose values (Figure 3) to 
calculate standard error. Total number of blood glucose 
values was estimated by the product of study data collec-
tion duration by number of blood glucose assessments 
per day. Due to small sample sizes, 90% (rather than 
95%) confidence intervals were calculated to minimize 
confidence interval spanning 0. As data are descriptive, 
data points are not weighted for study effect size, and a 
combined effect is not displayed. Both plots give the 
visual impression of moderate variation in hypoglycemic 
frequency among studies, showing a range of 2.1% to 
10.2% of patients with a hypoglycemic event and 1.1% to 
5.4% blood glucose level < 70 mg/dL (3.9 mmol/L).
Discussion
A systematic review of the literature from 1999 
onward was carried out to identify and analyze informa-
tion on the summary statistics of frequency of hypoglyce-
mia in insulin-treated adults on established nasogastric 
feeding in the general ward. Only 9 acceptable articles 
were identified, none with the stated primary objective of 
assessing hypoglycemic frequency in the targeted group. 
In these studies, biochemical definition and identification 
and reporting of hypoglycemia—factors crucial to accu-
rate assessment of frequency of hypoglycemia—exhibited 
great heterogeneity.
Definition of Hypoglycemia
The variations in biochemical definition of hypoglyce-
mia reflect the lack of consensus in the general literature, 
with recommendations varying from < 70 mg/dL 
(3.9 mmol/L)34,36 to < 63 mg/dL (3.5 mmol/L)37,38 and 
< 60 mg/dL (3.3 mmol/L)39 as levels having greater “clin-
ical” significance. Swinnen et al demonstrated that 
changing the glucose cutoff values that define hypogly-
cemia has a major effect on reported frequencies of hypo-
glycemia40; so, valid interstudy comparisons would seem 
to be precluded pending consensus on a definition. Dual 
documentation at the 2 most commonly defined levels 
may be a practical solution: < 63 mg/dL (3.5 mmol/L) 
and < 70 mg/dL (3.9 mmol/L).
Reporting of Hypoglycemia
Heterogeneity of reporting methodology in included 
studies precluded valid comparisons of frequency of 
hypoglycemia, especially the reporting of total number of 
hypoglycemic events in studies of markedly differing 
duration and sample size. Reporting as hypoglycemic 
events per patient-days and/or percentage blood glucose 
level < defined hypoglycemic level would facilitate inter-
study comparison.
Identification of Hypoglycemia
The significance of the interstudy variation in fre-
quency of blood glucose monitoring is difficult to assess. 
Increased frequency of blood glucose monitoring can 
increase and even overestimate documented inpatient 
hypoglycemia,41 but any trend in this direction was 
Figure 2. Modified forest plot showing percentage of patients with hypo-
glycemic events as reported in reviewed studies, with 90% confidence 
intervals calculated from study data. DF, diabetes feed; HC, high carbohy-
drate; HM, high monounsaturated fatty acid; SF, standard feed.
Figure 3. Modified forest plot showing percentage of total blood glucose 
levels < 70 mg/dL (3.9 mmol/L) as reported in reviewed studies, with 90% 
confidence intervals (calculated from study data). B2, biphasic insulin, 2/d; 
B3, biphasic insulin, 3/d; GI, glargine insulin; GL, glargine/lispro; SS, sliding 
scale insulin.
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impossible to identify due to definitional and reporting 
heterogeneity.
Reported Frequency of Hypoglycemia
Due to the small number and heterogeneity of identi-
fied studies, we were unable to calculate a quantitative 
synthesis of frequency of hypoglycemia but instead pres-
ent a descriptive summary. In the few studies where com-
parisons were possible, forest plots give the visual 
impression of moderate variation in hypoglycemic fre-
quency between studies (2.1%-10.2% of patients with an 
event; 1.1%-5.4% blood glucose level < 70 mg/dL [3.9 
mmol/L]). However, given the limited numbers and sec-
ondary calculation of confidence intervals, this should be 
interpreted with caution.
Both the Endocrine Society42 and the Society of 
Hospital Medicine43 have recommended standardized 
documentation and reporting of inpatient hypoglycemia, 
and in this context, it is of concern that there is so little 
comparable information on the frequency of hypoglyce-
mia in this potentially vulnerable population. There is no 
reason to suppose that people on established nasogastric 
feeding are at any less risk of hypoglycemia-associated 
mortality than the general hospital population,2,3,5 and, 
indeed, their risk may well be greater.
Limitations of Study
The major limitation of this study was the small num-
ber and heterogeneity of identified papers and the indi-
rect nature of the data. We were unable to identify any 
trials designed to directly quantify frequency of hypogly-
cemia in insulin-treated adults on established nasogastric 
feeding in the general ward and therefore utilized data 
generated from trials designed to compare the efficacy of 
insulin/feed regimens, including 1 case study.
Implications for Diabetes 
Educators and Conclusions
This systematic review indicates that hypoglycemia is 
not uncommon in insulin-treated adults on established 
nasogastric feeding in the general ward. There is a need 
for further practical research to accurately quantify this. 
Standardized documentation and reporting methods 
incorporating sample size and study duration, such as 
hypoglycemic events per patient-days, would facilitate 
interstudy comparisons, as would documentation of 
hypoglycemia at the 2 most commonly defined levels: 
< 63 mg/dL (3.5 mmol/L) and < 70 mg/dL (3.9 mmol/L).
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CHAPTER 9:   GENERAL DISCUSSION AND CONCLUSION  
 
9.1  Introduction and significance 
Hypoglycaemia in diabetes-related states is well researched, but has tended to focus 
on mechanisms and prevention of hypoglycaemia, hypoglycaemia-associated 
autonomic failure and longer-term physical and psychological consequences of 
hypoglycaemia.   
All evidence shows that hypoglycaemia can be a major stressor for those who 
experience it, with a significant number suffering major anxiety or fear of 
hypoglycaemia syndrome (Amiel et al., 2008; Anderbro et al., 2010; McCoy et al., 
2013; Shiu & Wong, 2002; Shiu & Wong, 2000). There is evidence that anxiety is 
lessened when individuals have a sense of control over their hypoglycaemia (Wild et 
al., 2007), and to this end, swift effective treatment of hypoglycaemia is obviously 
desirable. Dietary treatment of hypoglycaemia, although a crucial element in a swift 
resolution of a hypoglycaemic event, has been presumed to be a ‘given’ determined 
by expert opinion (American Diabetes Association, 2014b) or has relied on findings 
from older laboratory-based investigations (Brodows et al., 1984; Slama et al., 1990; 
Wiethop & Cryer, 1993) with results being extrapolated to present regimes in the 
free-living situation.  
To address these gaps in the literature, the overall aim of this thesis, presented as a 
series of seven published papers, has been to quantitatively and qualitatively 
investigate dietary practices associated with the treatment of hypoglycaemia with a 
view to determining efficacious resolution of hypoglycaemia. All investigations have 
been practically based, and include, where possible the perspective of those 
experiencing hypoglycaemia. When, as with inpatients on total nasogastric feeding, 
the person experiencing hypoglycaemia is dependent on carers to identify, treat and 
document the frequency of their hypoglycaemia, the problems of treatment are 
compounded. Quantifying methods of identification, reporting methods and 
frequency of hypoglycaemic events is essential for instigating efficacious treatment 
without subsequent hypoglycaemic events or hyperglycaemia, and again, there is a 
dearth of information in this area. All projects aimed to obtain measurable results 
that would be of potential benefit to those experiencing hypoglycaemia.  
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The study findings can be found in the included papers, however this chapter 
provides a brief summary of the study results in relation to the overall research 
objectives. The overall significance of the study, limitations of the research and 
recommendations for future research are also discussed. 
9.2 Summary of study findings 
Research objectives are italicized: 
1. To practically establish and verify, in free-living individuals, in various states of 
glucose dysmetabolism and on current medication regimes, effective dietary 
treatments of hypoglycaemia or relative hypoglycaemia.  
The first paper of this thesis (paper 1) presents a case report of a woman with NGT 
and elevated 1-h postload glucose.  It examines the relationship between loss of first 
phase insulin, postprandial hyperglycaemia with a subsequent rapid drop in blood 
glucose resulting in relative hypoglycaemia, carbohydrate intake, glycaemic index 
and weight gain and assesses the effect of a low carbohydrate diet and early 
intervention with short-acting preprandial insulin on glycaemia over 2 h and 
compares this to treatment with the DPP-4 inhibitor, sitagliptin or no treatment. 
Results showed a significant difference between the 1-h postload rise for low 
carbohydrate and insulin-treated meals compared with no treatment or sitagliptin. 
There was no significant difference between no treatment and sitagliptin. On a 
regime of either low carbohydrate meals or preprandial insulin, glycaemic 
variability, symptoms of relative hypoglycaemia and consequent postprandial hunger 
diminished with loss of 3.6 kg over 4 y. Cubeddu et al. showed that 8.3% of those 
with NGT have 1-h BGL ≥ 8.6 mmol/L, so this condition is not unusual, but 
treatment of it is (Cubeddu & Hoffmann, 2010). It has been suggested that 
recognition and management of those with NGT and 1-h glucose ≥ 8.6mmol/L may 
reduce incidence of diabetes and vascular events (Cubeddu & Hoffmann, 2010; 
Meisinger et al., 2006). This represents the first published case of identification and 
treatment of relative hypoglycaemia and glucose variability in an individual with 
NGT and elevated 1-h postload glucose. 
The second paper in this thesis (paper 2) investigated dietary treatment of 
hypoglycaemia in those with insulin-treated diabetes and aimed to determine if there 
was a significant difference in the need for repeat treatment of hypoglycaemia 
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following initial treatment with 15 or 20 g of fast-acting carbohydrate with wait-time 
to repeat treatment either 5 or 10 min. The effect of carbohydrate quantity and wait-
time to repeat treatment on subsequent hyperglycaemia was also investigated. 
Results showed that 20 g of fast-acting carbohydrate will resolve hypoglycaemia 
within 10 min in 89.3% of free-living individuals on current insulin regimes 
compared with 15 g that resulted in 63.2% resolving in 10 min. Decreasing the wait-
time to retreatment to 5 min increased those needing repeat treatments with both 15 
and 20 g treatments. Hyperglycaemia at 30 min post hypoglycaemia was not 
significant but numbers were insufficient to relate to quantity of carbohydrate. 
Insufficient initial treating quantity of carbohydrate necessitating repeat treatments 
markedly increases the duration of hypoglycaemia and often uncomfortable 
hypoglycaemic symptoms that last until clinical hypoglycaemia resolves, and in a 
third of symptomatic participants in this study, up to 10 min longer. Therefore this 
study supports an initial treatment of 20 g carbohydrate with a 10 min wait-time to 
repeat treatment as an optimal recommendation for the conscious insulin-treated 
individual self-treating hypoglycaemia. 
2. To assess self-reported current practices in dietary treatment of hypoglycaemia 
and their perceived effectiveness with respect to resolution of initial hypoglycaemia, 
prevention of repeat hypoglycaemia and generation of subsequent hyperglycaemia. 
To compare this to verified scientific standards (GI) and currently-used laboratory-
generated recommendations for dietary treatment of hypoglycaemia. 
The third paper in this thesis (paper 3) again looks at free-living people with insulin-
treated diabetes and investigates self-reported qualitative and quantitative patterns of 
food selection for self-treatment of hypoglycaemia as compared with international 
and national guidelines, rate of absorption of carbohydrate, self-reported efficacy of 
treatment and subsequent hypoglycaemia. Results showed that 78% of responders 
reported initial treatment with recommended foods, but only 40.8% of these were 
quick-acting carbohydrate, mainly glucose tablets and jellybeans. Initial treating 
carbohydrate quantity showed 20.6% of responders used quantities exceeding all 
guidelines with 46.4% used quantities exceeding Australian recommendations but 
consistent with the most liberal recommendations (EASD). Only 55.8% reported 
ingesting follow-up food. 
Most study participants reported treating with recommended foods in quantities 
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exceeding minimum recommendations, possibly attempting to resolve unpleasant 
symptoms of hypoglycaemia quickly. Non-adherence in itself is not a reason to 
review recommendations, but in view of the results of paper 2, the relatively low 
evidence level on which recommendations are based and the variation in world 
recommendations, it would seem practicable to increase recommended treatment 
quantities.  Failure of many to ingest follow-up food was concerning in view of the 
perceived risk of repeat hypoglycaemic episodes and was deemed to warrant 
investigation (see paper 4) as was various foods recommended for treatment but not 
fitting the criteria of quick-acting carbohydrate (see recommendations, section 9.4 ). 
In the fourth paper (paper 4) repeat hypoglycaemia within 2 h of a primary 
hypoglycaemic event in people with insulin-treated diabetes is investigated in greater 
depth to ascertain if there was an association between omission or under-treatment 
with carbohydrate after an initial hypoglycaemic event and increased frequency of 
repeat hypoglycaemia. A secondary aim was to investigate association between 
repeat hypoglycaemia and presence or absence of symptoms and duration of action 
of carbohydrate. Results showed repeat hypoglycaemia within 2-h post primary 
hypoglycaemic event was reported by 8.2% and consumption of follow-up longer-
acting carbohydrate by 58.2% of responders. Method of insulin administration (MDI/ 
SCII) and consumption of follow-up food were significantly associated with repeat 
hypoglycaemia but presence or absence of symptoms and duration of  action of 
carbohydrate were not. Hierarchical logistic regression analysis showed omission of 
follow-up food was not a significant predictor of increased likelihood of repeat 
hypoglycaemia within 2 h of a primary hypoglycaemic event, irrespective of method 
of insulin administration. This study supports guidelines that recommend judicious, 
rather than routine use of follow-up longer-acting carbohydrate post primary 
hypoglycaemic event. 
3. To assess individual knowledge of self-treatment of hypoglycaemia in a situation 
of high risk for sustained hypoglycaemia (alcohol ingestion) and compare this to 
easily available internet-based information. 
The fifth paper (paper 5) looks at the more specialized issue of knowledge of the key 
aspects of alcohol-induced sustained hypoglycaemia in the presence of insulin in 
those with type 1 diabetes and how it relates to freely available diabetes association 
information on the internet. Available information and participant knowledge were 
assessed according to 6 key criteria. Results showed information on alcohol and 
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hypoglycaemia addressed by 6 national Diabetes Associations provided general 
information on alcohol and hypoglycaemia, eating with, and snacking after alcohol 
and sustained hypoglycaemic effect, but that the specified possible duration of 
hypoglycaemia varied from unspecified to 16 - 24 h, with only 2 guidelines 
providing information on reduction of long-acting insulin to minimize sustained 
hypoglycaemic effect.  
When knowledge of people with type 1 diabetes was assessed, most responders 
(88.2%) identified the hypoglycaemic effect of alcohol but only 32.4% postulated 
duration of 4+ h post-consumption for this. Standard drink quantity perceived to 
lower blood glucose level was 1 - 3 (50%) and 4+ (41.2%). Risk reduction (dietary or 
insulin modification) was not addressed to minimize prejudicing assessment of 
knowledge of hypoglycaemic effect per se. Knowledge of alcohol and 
hypoglycaemia was acceptable, except in the important area of duration of alcohol-
induced hypoglycaemia. This is congruent with accessed guidelines and may reflect 
an identified lack of consistency in information given to patients regarding alcohol-
induced hypoglycaemia. Additionally not all guidelines provided information on 
reduction of long-acting insulin, an important strategy to minimize hypoglycaemic 
risk. 
4. To assess treatment and frequency of hypoglycaemia in inpatients on nasogastric 
feeding and thus dependent on carers for identification and treatment of 
hypoglycaemia and therefore at putative high risk from that hypoglycaemia. 
The last two papers investigate the specialized and under-researched area of 
hypoglycaemia in inpatients with diabetes on nasogastric feeding in the general 
ward. Paper 6 describes a retrospective review of 50 in-patients treated with insulin 
and insulin secretagogues on ≥ 3 d nasogastric feeding to determine factors 
influencing hypoglycaemia. Results show frequency of hypoglycaemia as 10.9% 
patient-days with ≥1 hypoglycaemic episode and 3.5% total blood glucose values < 
3.5mmol/L. There was no association with feed type but there was an association 
between sulphonylurea treatment and increased and extended hypoglycaemia. As this 
was a retrospective observational study, duration of nasogastric feeding varied, 
therefore Kaplan-Meier survival curves were used for time to event analysis of the 
effect of reduction in medication post-hypoglycaemia on a subsequent 
hypoglycaemic episode. It showed a significantly longer time to a subsequent 
hypoglycaemic episode between patients whose treatment was reduced in response to 
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hypoglycaemia and those whose treatment remained unchanged. There was no 
association with subsequent hyperglycaemia. 
This study supports optimal blood glucose monitoring, insulin treatment and 
judicious medication reduction post-hypoglycaemia but frequency of hypoglycaemia 
was not comparable with other studies due to variation in reporting methods (see 
paper 7). 
Paper 7 is a systematic review of the literature that aimed to answer the questions: 1. 
What are the existing summary statistics of frequency of hypoglycaemia in insulin-
treated adults on established nasogastric feeding in the general ward? 2. To what 
extent does lack of homogeneity in defining, identifying and reporting 
hypoglycaemia affect these statistics? Results were sourced from 9 studies (from 231 
identified) judged suitable according to inclusion/exclusion criteria. None had 
assessment of hypoglycaemia as their primary objective but rather the assessment of 
efficacy of insulin/feed regimens in the target population. Studies exhibited major 
heterogeneity with definitions of hypoglycaemia varying from < 3.3 mmol/L to < 4.4 
mmol/L. Five different methods of reporting frequency of hypoglycaemia were 
utilized, which precluded a pooled analysis, however a descriptive synthesis of 
results was generated and some comparable results presented on modified forest 
plots. These showed 2.1 - 10.2% of patients with a hypoglycaemic event and 1.1 - 
5.4% blood glucose level < 3.9 mmol/L. The major conclusions were that 
standardization of documentation, reporting methods incorporating patient-numbers 
and duration of feeding (hypoglycaemic events per patient-days and/or percentage 
blood glucose level < defined hypoglycaemic level) and documentation of 
hypoglycaemia at the two most commonly defined levels: < 3.5 mmol/L and < 3.9 
mmol/L are crucial to allow interstudy comparisons.  
9.3 Limitations  
9.3.1  Classification of diabetes 
Limitations of studies have been outlined within the individual papers. This section 
will merely expand on two reoccurring themes.  
Several of the studies (papers 2,3,4,6) have investigated insulin-treated subjects, that 
is, a mixture of those with type 1 diabetes and insulin-treated type 2 diabetes. There 
are differences between these two groups, which may affect dietary treatment of 
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hypoglycaemia, although obviously the aetiology of the hypoglycaemia is the same, 
being a relative insulin excess causing blood glucose to drop below the definitional 
level for hypoglycaemia. Those with type 1 diabetes have an absolute deficiency of 
insulin secretion while the mechanism of type 2 diabetes varies, but, in the main, 
encompasses relative rather than absolute insulin deficiency, progressive over time 
with β-cell function declining and thus endogenous insulin secretion declining 
(American Diabetes Association, 2005; Cryer et al., 2003).  People with type 2 
diabetes who have been treated with insulin > 10 y are therefore more insulin 
deficient behaving more like those with type 1 diabetes. There is both a higher 
incidence of mild and severe hypoglycaemia in type 1 compared to type 2 diabetes, 
except in advanced type 2 diabetes (Donnelly et al., 2005). In insulin-treated type 2 
diabetes, there is relative insulin deficiency, therefore both endogenous and  
exogenous insulin present, and it could be surmised that response to dietary treatment 
will be different than with total insulin deficiency. Insulin resistance will likely also 
modify the situation (Miller et al., 2001). 
In papers 3 and 4, to maintain anonymity, all data was self-reported and it was 
considered that  self-reported data on diabetes type would be of questionable 
accuracy. There was no reason to think lack of differentiation of diabetes type would 
affect the qualitative data on foods consumed but may have had some effect on the 
quantitative data. Similarly, in paper 6, although information was collected from 
patient medical notes, type of diabetes was often not documented or was documented 
with no accompanying medical rationale. Therefore, in this study, mode of treatment 
of diabetes was recorded, but not diabetes type.  
In paper 2, we aimed to make a new recommendation for optimal quantity of quick-
acting carbohydrate and wait-time to repeat treatment for hypoglycaemia in diabetes. 
The aim was for a universal recommendation (as with presently existing 
recommendations), and therefore differentiation of diabetes type was unnecessary 
and was not considered a limitation in this paper.  
9.3.2 Self-reported data 
The second overall study limitation was the use of indirect self-reported data 
accessed by data collection via a self-administered questionnaire (papers 3,4,5). 
Although direct observation of subject food consumption and hypoglycaemic 
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behaviour would, on the face of it, seem a more accurate method of data collection, it 
is impractical in the free-living situation, with the presence of an observer having the 
potential to change the very behaviour being observed. There is a discussion of the 
strengths and limitations of this type of data collection in section 5.1 of this thesis. 
Collection of self-reported data was chosen judiciously for these three projects which 
had, as their aim, that the investigation be from the subjects’ perspective. Every 
effort was made to maximise accuracy of collected data (see section 5.1). Hawkshead 
et al comment that self-reported data can have reduced accuracy due to recall bias 
and the propensity for the respondent to return socially desirable responses 
(Hawkshead & Krousel-Wood, 2007). The latter has been covered in detail in section 
5.1. Recall bias cannot be eliminated from self-reported retrospective data but has 
been shown to be less where the retrospective time frame is shorter, where recalled 
information is of a repeated behaviour, and where the recalled information is in 
temporal proximity to an event that made an impression on the respondent (Choi & 
Pak, 2005; Evans & Crawford, 1999), all factors likely pertinent to the recall of the 
experience and treatment of hypoglycaemia  
9.4 Recommendations 
Some recommendations arising from the study findings are as follows: 
 The initial steps in the Australian guidelines for dietary treatment of 
hypoglycaemia should be amended to recommend initial consumption of  20 
g of quick-acting carbohydrate with a 10 minute wait-time to retreatment. 
This is based on Paper 2, Level 4 Evidence (NHMRC, 1999), in the absence 
of higher level evidence. A higher level of evidence, namely a prospective 
randomised control trial would give a more definitive result. 
 Increased education on the use of quick-acting carbohydrate for initial 
treatment of hypoglycaemia is recommended, as quick-acting carbohydrate 
has been shown to have an enhanced glucose response 15 min post-
consumption compared to medium-acting carbohydrate (Brand-Miller et al, 
2009). ( Based on results reported in Paper 3 that 50.5% of participants used 
medium-acting carbohydrate for initial self-treatment of their 
hypoglycaemia).  
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 The follow-up step in the Australian guidelines for dietary treatment of 
hypoglycaemia should read: If your next meal is more than 20 minutes away, 
you may need to eat some longer-acting carbohydrate, rather than the present 
wording of: ‘If your next meal is more than 20 minutes away, eat some longer 
acting carbohydrate’ (Diabetes Australia, 2009). Based on Paper 4 (results 
from a well-validated questionnaire), in the absence of higher level evidence. 
A higher level of evidence, namely a prospective randomised control trial 
would give a more definitive result. 
 All guidelines and educational material giving information on alcohol and  
insulin should highlight the fact that sustained alcohol-induced 
hypoglycaemia can have a duration of  24 h and include information on 
reduction of long-acting insulin to minimize hypoglycaemia when the 
quantity of alcohol consumed is significant. 
 Insulin, rather than sulphonylurea agents should be used to treat in-patients 
with diabetes who are receiving ≥ 70% of their nutrition from nasogastric 
feeding, as the use of sulphonylureas in this situation is significantly 
associated with increased hypoglycaemia and extended hypoglycaemia. 
(Based on observational evidence only).  
 There should be increased education for medical and ward staff involved in 
caring for insulin-treated in-patients with diabetes on nasogastric feeding 
regarding the very real possibility of hypoglycaemia in these patients.  
 Research, quality assurance etc assessing hypoglycaemia in insulin-treated in-
patients with diabetes on nasogastric feeding should use standardized 
documentation and reporting methods incorporating sample size and study 
duration, such as hypoglycaemic events per patient-days and report 
hypoglycaemia at the two levels of  < 3.5 mmol/L and < 3.9 mmol/L. 
9.5 Suggestions for future research 
Suggested areas for further research that arise from the study findings are: 
 It has been suggested that recognition and management of those with NGT 
and 1-h glucose ≥ 8.6mmol/L may reduce incidence of diabetes and vascular 
events. The case study in paper 1 in this thesis demonstrates a practical 
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intervention in a woman with NGT and 1-h glucose ≥ 8.6mmol/L  effective 
over 4 years. A case series is now needed to further investigate this. 
 The findings from paper 2 in this thesis have shown that 20 g of fast-acting 
carbohydrate will resolve hypoglycaemia within 10 min in 89.3% of free-
living individuals on current insulin regimes compared with 15 g that resulted 
in 63.2% resolving in 10 min. Hyperglycaemia at 30 min post-hypoglycaemia 
was not significant but numbers were insufficient to relate to quantity of 
treating carbohydrate. In view of the fact that the findings from paper 3 
showed that 46.4% of those surveyed self-treat their hypoglycaemia with 
between 15 and 30 g of quick-acting carbohydrate, investigation with a cross-
over study of the effect on resolution of hypoglycaemia and subsequent 
hyperglycaemia of 20, 25 and 30 g of quick acting carbohydrate is warranted.  
 Arising from the findings of paper 4, a further study of follow-up food and 
repeat hypoglycaemia with a sample size large enough to differentiate more 
accurately the relationship between duration of follow-up carbohydrate action 
and frequency of hypoglycaemia. 
 Findings from paper 6 indicated that frequency of hypoglycaemia appeared to 
rise with increasing duration of nasogastric feeding in insulin-treated 
individuals obtaining > 70% of nutrition from nasogastric feeding in the 
general ward. A follow-up case control study confirming this would add to 
the knowledge of distribution of hypoglycaemic events in these vulnerable 
patients. 
9.6 Conclusion 
Findings from the series of studies presented in this thesis make a significant 
contribution to existing knowledge in the area of dietary practices and treatment of 
hypoglycaemia, with an emphasis on practically-based investigations grounded in 
current dietary practices and treatment regimens. Where possible, studies have been 
based on information collected from, and from the perspective of, those experiencing 
hypoglycaemia or relative hypoglycaemia.  
Study findings are presented in seven published journal articles included within this 
thesis, with expanded information on significance, methods and results preceding 
these where considered necessary. The study findings have allowed 
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recommendations to be made on amendments to the Australian guidelines for 
treatment of hypoglycaemia in the area of optimal quantity of treating carbohydrate, 
wait-time to retreatment and appropriate food selection. They have delineated dietary 
practices in treatment of hypoglycaemia and relative hypoglycaemia and their 
relationship to blood glucose levels, duration of action of carbohydrate and repeat 
episodes of hypoglycaemia, and also highlighted deficits in knowledge and available 
information regarding alcohol-induced sustained hypoglycaemia. In the area of 
hypoglycaemia and nasogastric feeding, findings from an observational study have 
highlighted factors affecting severity, duration and frequency of hypoglycaemia, with 
a follow-up systematic review which identifies the need for specific changes in 
reporting methods and documentation of hypoglycaemia, and for further research in 
this area. Findings from all studies will hopefully benefit those who experience 
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Dear Sally,  
 
Thank you for your request. You can consider this email as permission to use the material as 
detailed below in your upcoming thesis.  Please note that this permission does not cover any 
3rd party material that may be found within the work. We do ask that you properly credit the 










Los Angeles | London | New Delhi 
Singapore | Washington DC 
The natural home for authors, editors & societies 
 
 
From: Sally Vindedzis [mailto:salvindedzis@bigpond.com]  
Sent: Wednesday, February 26, 2014 8:14 PM 
To: permissions (US) 
Subject: Request for permission 
 
Dear Sir/ Madam, 
                            As the author of the article: 
  
.       Vindedzis SA, Sherriff JL, Stanton KG. Hypoglycemia in Insulin-Treated Adults on 
Established Nasogastric Feeding in the General Ward: A Systematic Review. Diabetes 
Educ. 2014. DOI: 10.1177/0145721714523510 
  
I request permission to use in a thesis/dissertation (digital and print) of  about 200 pages to 
be completed in June 2014 entitled: 
  
Dietary Practices In Treatment Of Hypoglycaemia In Elevated One-Hour Postload 
















FORMS: DATA COLLECTION AND INFORMATION 
 
 Information and consent form – case study 
 Instructions to diabetes educators conducting assessment of carbohydrate 
quantity and wait-time 
 Sample participant information assessment of carbohydrate quantity and 
wait-time 
 Sample collection sheet A assessment of carbohydrate quantity and wait-time 
 Sample collection sheet B (30 min +) assessment of carbohydrate quantity 
and wait-time 
 Home testing collection sheet assessment of carbohydrate quantity and wait-
time 
 Questionnaire backing/information sheets 
 Food selection questionnaire 
 Repeat hypoglycaemia questionnaire 
 Alcohol and insulin questionnaire 











Participant Information and Informed Consent 
 
Title:  Low carbohydrate meals or a minidose of insulin normalises one-hour 
postload blood glucose in a one hour glucose spiker. A case report  
Name of Investigators: Sally Vindedzis, Beryl Marsh, Dr Kim Stanton, Associate Professor 
Satvinder Dhaliwhal, Associate Professor Jill Sherriff 
 
General Purpose, Methods and Demands: 
You are being asked to consider allowing the above investigators to use information 
about treatment of your blood glucose levels to write a case report.  A case report is 
written to share information experienced by one patient during their clinical care that 
may be useful to other members of the health care profession.  This may be 
published or presented at a conference.  The purpose of this case report is to inform 
other members of the health care profession how the rise in your blood glucose one 
hour after a meal is affected by low carbohydrate meals, a small dose of insulin 
before the meal, and a medication called sitagliptin.  Your information being used for 
this case report includes results of your self blood glucose monitoring, body weight 
and levels of fat in your blood which will be obtained from your private practice 
medical notes, pathology reports and the memory of your blood glucose monitor, 
which we will ask you to download for us at your regular doctors appointment.  
 
Participation is completely voluntary and you may withdraw at any time for any reason 
without explanation. All data will be kept strictly confidential, such that only research staff 
will have access to the information. The results from this study will be reported in a written 
research report and you will be provided with a copy of this. Information about the project 
will not be made public in any way that identifies you.  
 
 Possible risks, inconvenience and discomforts:  
There are no substantial risks with this study. However, you must be prepared to allow 
access to your medical notes and reports and download the results of your blood glucose 
meter when you attend the doctor. 
 
Consent to Participate: 
After considering this information, if you have decided to participate in this study, please 
understand your participation is voluntary and you have the right to withdraw your consent 
or discontinue participation at any time without discrimination, judgment or penalty. Your 
identity will not be disclosed in any published or written material resulting from the study 
and you will be offered the opportunity to view the results and or any material produced 
from this study, before it is submitted. You will not directly benefit from participating in this 
study.  The information that can be shared with other health care professionals, however, 
may improve the care that is received by others in the future. Allowing your information to 









This study has been approved by the Curtin University Human Research Ethics 
Committee (Approval Number SPH-55-2012). The Committee is comprised of 
members of the public, academics, lawyers, doctors and pastoral carers.  Its main role 
is to protect participants.  If needed, verification of approval can be obtained either 
by writing to the Curtin University Human Research Ethics Committee, c/- Office of 
Research and Development, Curtin University, GPO Box U1987, Perth, 6845 or by 
telephoning 9266 2784 or by emailing hrec@curtin.edu.au. If you request any further 
information, or have any queries you wish to be answered, please don’t hesitate to 
contact Sally Vindedzis on 64775213 or sally.vindedzis@postgrad.curtin.edu.au. 
Please direct any ethical complaints to the Human Research Ethics Committee 
(Secretary) on phone: 9266 2784 or hrec@curtin.edu.au or in writing C/- Office of 
Research and Development, Curtin University of Technology, GPO Box U1987, 
Perth WA 6845. 
 





I have read the information on the attached letter. Any questions I have asked have been 
answered to my satisfaction. I agree to participate in this research but understand that I can 
change my mind or stop at any time. I understand that all information provided is treated as 
confidential. I agree that research gathered for this study may be published provided names 
or any other Information that may identify me is not used. 
o I understand the purpose and procedures of the study. 
o I have been provided with the participant information sheet. 
o I understand that the procedure itself may not benefit me. 
o I understand that my involvement is voluntary and I can withdraw at any time 
without problem. 
o I understand that no personal identifying information like my name and address will 
be used and that all information will be securely stored for 5 years before being 
destroyed. 
o I have been given the opportunity to ask questions. 
o I agree to participate in the study outlined to me. 
 





______________________________________     ____________ 
Participant       Date 
 
 
________________________________________       ______________ 







Hypo Audit – Instructions to Diabetes Educators 
Procedure:  
When a patient has a  blood glucose (sugar) less than 3.5 

























1. Blood test immediately and record on Blood test form A. 
 
2. Give __ mls carbotest. 
 
3. Record patients symptoms on checklist provided. 
 
4. Blood test again after __ minutes and record. If blood sugar is less 
than 3.5 mmol/L repeat steps 1, 2, 3 and 4 and record until blood 
sugar is above 3.5 mmol/L, then go to step 5. 
 
5. Obtain verbal consent for further blood testing. If consent, go to 
step 6, if no consent offer complex carbohydrate and usual 
information. 
 
6. Blood test every 30 minutes while patient is in clinic and record on 
Blood test form B. 
 
7. Give patient Home blood test form C and stamped self addressed 
envelope. Ask patient to blood test every 30 minutes to 4 hours 
post hypo on their own blood glucose meter at home,  record on 
form C and  post form back to clinic in provided stamped 





Study Title: Audit of Hypoglycaemia in a Tertiary Centre Diabetic Clinic   
    
STUDY SUMMARY 
 
You are being asked to participate in this study because  you have insulin treated diabetes and 
you have had a routine clinic blood test that is below the normal range (less than 3.5mmol/L), 
that is you are suffering from hypoglycemia, or are having a  ‘hypo’. Your participation in 
this study is voluntary.  
Hypoglycemia (‘hypos’) or low blood glucose (sugar) in insulin treated diabetes is the result 
of the insulin you have injected being too much for your needs at a particular time. As you 
will have noticed, a hypo is often followed by rebound hyperglycemia, or high blood sugars. 
The present current recommended treatment for hypoglycemia is 15g carbohydrate in 
Australia, and 20 g glucose in the USA. This is repeated 5 or 10 minutes later if low blood 
sugars persist. In this study we will treat your hypoglycemia with: 
 
60 mls of carbotest (which provides 15 g glucose) repeated at 10 minute intervals until blood 
testing shows your blood glucose is normal. 
 
To enable us to assess how effective this treatment is we will ask you to blood glucose/sugar 
test on your own meter every 30 minutes over the next 4 hours, record on the provided sheet 
and send it back to us in the provided stamped envelopes. This information will be compared 
with similar results from other people with insulin treated diabetes. If you do not wish to do 
further blood testing you will be offered a snack and information on hypoglycemia. 
There will be no other involvement by you, and no cost.  
 
DO I HAVE TO TAKE PART? 
 
You do not have to take part in this study if you do not want to.  
This study has been approved by the Curtin University Human Research Ethics Committee 
(Approval Number HR 86/2010). The Committee is comprised of members of the public, 
academics, lawyers, doctors and pastoral carers.  Its main role is to protect participants.  If 
needed, verification of approval can be obtained either by writing to the Curtin University 
Human Research Ethics Committee, c/- Office of Research and Development, Curtin 
  Endocrinology and Diabetes/ Curtin University 
University, GPO Box U1987, Perth, 6845 or by telephoning 9266 2784 or by emailing 
hrec@curtin.edu.au. If you request any further information, or have any queries you wish to 
be answered, please don’t hesitate to contact Sally Vindedzis on 64775213 or email 
sally.vindedzis@postgrad.curtin.edu.au. Please direct any ethical complaints to the Human 
Research Ethics Committee (Secretary) on phone: 9266 2784 or hrec@curtin.edu.au or in 
writing C/- Office of Research and Development, Curtin University of Technology, GPO 
Box U1987, Perth WA 6845 or Royal Perth Hospital: A/Prof F M Bockxmeer, Chairman of 
the Ethics Committee, phone 92242244.  
 
HOW THE INFORMATION WILL BE HANDLED. 
 
All identifying data will be deleted once your results have been compared. Your name will 
not appear on any document or publication. 
FURTHER INFORMATION 
 


















Symptoms (please tick) 
 
Blood sugar 






  Sweating 
 Hunger 
 Shaking , weakness 
 Irritability 
 Light headedness/Headache 
 Lack of concentration/behaviour change. 
 Numbness around the lips and fingers 
 Other  __________________ 
 None  
 Comment__________________________________ 
10 mins after  Change of symptoms  yes/no 
If blood sugar greater than 3.5  go to Form B  
OR  If blood sugar less than 3.5 treat again and record 
Time Blood 
sugar 
Symptoms (please tick) 
Blood sugar 










 Shaking , weakness 
 Irritability 
 Light headedness/Headache 
 Lack of concentration/behaviour change. 
 Numbness around the lips and fingers 
 Other _____________________ 
10 mins after   Change of symptoms  yes/no 
If blood sugar below 3.5 treat again and record (use another form A) 
                                         OR 
If blood sugar greater than 3.5 go to Diabetic clinic blood test form 
B  
                          
    Signature_________________________ 


















2 hour 30 mins   
3 hours   
3 hour 30 mins   
























2 hour 30 mins   
3 hours   
3 hour 30 mins   





                                               
   
 
This questionnaire forms part of the research being conducted by Sally Vindedzis for her 
PhD project.    Your completed questionnaire indicates your consent to participate and as it is 
anonymous, your answers can’t be identified. 
 
This study forms part of an audit at Royal Perth Hospital and has been approved by the 
Curtin Human Ethics Committee (number HR 86/2010). 
 
If you have any questions about the research, please contact Sally on (64775213) or her 
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Questionnaire on Hypoglycaemia (‘hypos’) or low blood sugar 
Most people with insulin treated diabetes will, at some time have hypoglycaemia (or 
‘hypos’). The symptoms of hypos are different for different people, as is the way 
people treat their hypos. The questionnaire below is designed to ask you about your 
experience of hypos; and is anonymous. We thank you for filling in the questionnaire 
and ask you to place your completed questionnaire in the box marked ‘questionnaire’ 
next to reception. 
1. How many years have you had diabetes?     (please circle) 
0 – 5,     6 – 10,     11 – 20,      21 – 30,     more than 30 
2. Is your diabetes treated with:       insulin injection/insulin pump.   (please 
circle) 
3. Are you:                                           Male/female   (please circle) 
4. Please circle your age range: 
             15 – 25,     26 – 35,     36 – 45,     46 – 55,     56 – 65,     over 66 
5. How many hypos would you have a week? (please circle) 
None,     0 -1,     1 – 2,     2 – 3,     3 – 4,     4 – 5,      more than 5 




 Shaking , weakness 
 Irritability 
 Light headedness/Headache 
 Lack of concentration/behaviour change. 
 Numbness around the lips and fingers 
 Other (please specify) _____________________________________ 
7. What do you first eat or drink to treat a hypo?   -
___________________________ 
8. How much of this do you generally need?         
____________________________ 
9. Do you follow up with anything else?                    yes/no      (please circle) 
10. If yes, what?         ____________________________________ 
 
Thank you for your participation. 
Questionnaire on Hypoglycemia (‘hypos’) or low blood sugar 
Most people with insulin treated diabetes will, at some time have hypoglycemia (or ‘hypos’). 
The symptoms of hypos are different for different people, as is the way people treat their 
hypos. The questionnaire below is designed to ask you about your experience of hypos; and 
is anonymous. We thank you for filling in the questionnaire and ask you to place your 
completed questionnaire in the box marked ‘questionnaire’ next to reception. 
11. How many years have you had diabetes?   
        0 – 5,   6 – 10,   11 – 15,   16 – 20,   21 – 30,   more than 30   (please 
tick) 
2.   Is your diabetes treated with:       
  insulin injection   insulin pump   (please tick) 
3.    Your gender:                                    
 male    female   (please tick) 
4.    Please indicate your age range: 
        15 – 25,     26 – 35,     36 – 45,     46 – 55,     56 – 65,     over 66    
(please tick) 
5.    How many hypos would you have a week?  
 0 -1,     1 – 2,     2 – 3,     3 – 4,     4 – 5,      more than 5   (please tick) 
6.    Do you ever have a repeat hypo within 1 – 2 hours of the first one? 
 yes   no  (please tick) 
7.     If yes, how often would this happen? 
        every time,   often,      sometimes,    rarely,     never   (please tick)          
8.      Do you get warning signs that you are about to have a hypo? 
        every time,   often,      sometimes,    rarely,     never     (please tick)               
9.       What do you first eat or drink to treat a hypo?   ___________________________ 
10.     How much of this do you generally need?         ____________________________ 
11.      Do you follow up with anything else? 
        yes   no   (please tick) 
12.      If yes, what?         ____________________________________ 
 





Questionnaire On Alcohol For People With Type 1 Diabetes 
 
We are asking people on insulin to fill in this short survey to help us assess if we are giving 
out information on alcohol and insulin appropriately. The questionnaire below is anonymous. 
We thank you for filling in the questionnaire and ask you to place your completed 
questionnaire in the box marked ‘questionnaire’ next to reception. 
 
1. How long have you had diabetes? 
  
            ___________________ years 
 
 
2. What types of  insulins do you take and how often do you take them? 
 
Insulin  name: __________________  Taken _______ times a day 
 
Insulin  name: __________________  Taken _______ times a day 
 
Insulin  name: __________________  Taken _______ times a day 
 
 
3. Is it possible for drinks containing alcohol to raise your blood glucose level? 
 
        □   Yes                          □   No 
 
 
4. If yes, when would you expect this to happen? 
       
        ______________________________________________ 
 
 
5.  Is it possible for drinks containing alcohol to lower your blood glucose level? 
 
        □   Yes                          □   No 
 
 
6. If yes, when would you expect this to happen? 
       
        ______________________________________________ 
 
 
7. If yes, after how many standard drinks (approximately) would you expect this to 
happen? (for standard drinks amount see on back) 
 
______________ standard drinks. 
 
Thank you for your participation. If you would like further information on alcohol 


















                                        




























Royal Perth Hospital 
March 2010 
Alcohol and insulin
It is important to understand the way alcohol and insulin 
interact. 
There is an increased risk of hypoglycaemia following alcohol. 
This risk may persist for greater than 12 hours after drinking 
alcohol. 
Alcohol causes the liver to “shut down” its production of glucose. This 
causes a drop in blood glucose 4 - 6 hours (or more) after drinking alcohol. 
The extent of this drop largely depends on the amount of alcohol. Drinking 
more than two standard drinks will cause a significant drop during the night 
and sometimes the next day. 
RECOMMENDATIONS 
1. DRINK MODERATELY - Preferably less than 2 standard drinks (see
below).
2. Have alcohol with a meal or substantial starch containing snack as food
slows down the absorption of alcohol.
3. Have another meal or substantial starch containing snack several hours
afterwards if drinking more than 2 standard drinks.
4. Choose a low sugar drink where possible (dry wine or spirits).
5. Space your drinks using a nonalcoholic beverage such as juice, soda water
or diet soft drink
6. If you drink more than 4 standard drinks in the evening, reduce your bed
time insulin by 25% and you may also need to reduce the next
mornings insulin dose.
7. Check your blood glucose response. During the 24 hours following
excessive alcohol ingestion check your blood glucose on each occasion
before driving or before operating heavy/dangerous machinery
STANDARD DRINKS 
1 small wineglass (100ml) 
1 nip/ measure spirits (30mls) 
1 middy beer or 1 can light beer (375mls)
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